Author: "Barricarte,A" / Topic: medicine.medical_specialty - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Barricarte,A"' showing total 313 results

Start Over Author "Barricarte,A" Topic medicine.medical_specialty

313 results on '"Barricarte,A"'

1. Independent Role of Severe Obesity as a Risk Factor for COVID‐19 Hospitalization: A Spanish Population‐Based Cohort Study

Author: Fresán, Ujué, Guevara, Marcela, Elía, Fernando, Albéniz, Esther, Burgui, Cristina, Castilla, Jesús, Martín, Carmen, Navascués, Ana, Portillo, María Eugenia, Polo, Isabel, Ezpeleta, Carmen, Gorricho, Javier, Ardanaz, Eva, Ascunce, Nieves, Arriazu, Maite, Barricarte, Aurelio, Barriuso, Laura, Casado, Itziar, Díaz, Jorge, Ederra, María, Egüés, Nerea, Garde, Carmen, Gómez‐Ibáñez, Carlos, García Cenoz, Manuel, García, Vega, Iriarte, Nerea, Martínez‐Baz, Iván, Moreno‐Iribas, Conchi, Sayón, Carmen, and Vidán, Juana
Subjects: Adult, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Population, Medicine (miscellaneous), 030209 endocrinology & metabolism, Body Mass Index, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Endocrinology, Risk Factors, Internal medicine, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Poisson regression, Risk factor, Prospective cohort study, education, Pandemics, Aged, education.field_of_study, Nutrition and Dietetics, SARS-CoV-2, business.industry, Incidence, Incidence (epidemiology), COVID-19, Middle Aged, Obesity, Morbid, 3. Good health, Hospitalization, Intensive Care Units, Spain, Relative risk, Cohort, symbols, Female, business, Cohort study
Abstract: Objectives This study analyzed the association between severe obesity and coronavirus disease 2019 (COVID-19) hospitalization and severe disease. Methods The incidence of hospitalization for laboratory-confirmed COVID-19 was evaluated in a prospective population-based cohort of 433,995 persons aged 25 to 79 years in Spain during March and April of 2020. Persons with and without class 3 obesity were compared using Poisson regression to estimate the adjusted relative risk (aRR) from class 3 obesity of COVID-19 hospitalization and of severe disease (intensive care unit admission or death). Differences in the effect by age, sex, and chronic conditions were evaluated. Results Individuals with class 3 obesity had a higher risk of hospitalization (aRR = 2.20, 95% CI: 1.66-2.93) and developing severe COVID-19 (aRR = 2.30, 95% CI: 1.20-4.40). In people younger than 50 years, these effects were more pronounced (aRR = 5.02, 95% CI: 3.19-7.90 and aRR = 13.80, 95% CI: 3.11-61.17, respectively), whereas no significant effects were observed in those aged 65 to 79 years (aRR = 1.22, 95% CI: 0.70-2.12 and aRR = 1.42, 95% CI: 0.52-3.88, respectively). Sex and chronic conditions did not modify the effect of class 3 obesity in any of the outcomes. Conclusions Severe obesity is a relevant risk factor for COVID-19 hospitalization and severity in young adults, having a magnitude similar to that of aging. Tackling the current obesity pandemic could alleviate the impact of chronic and infectious diseases.
Published: 2020

2. Obesity is Associated With Increased Risk of Crohn's disease, but not Ulcerative Colitis:A Pooled Analysis of Five Prospective Cohort Studies

Author: Simon S.M. Chan, Ye Chen, Kevin Casey, Ola Olen, Jonas F. Ludvigsson, Franck Carbonnel, Bas Oldenburg, Marc J. Gunter, Anne Tjønneland, Olof Grip, Paul Lochhead, Andrew T. Chan, Alicia Wolk, Hamed Khalili, Pilar Amian, Aurelio Barricarte, Manuela M. Bergmann, Marie-Christine Boutron-Ruault, Amanda Cross, Andrew R. Hart, Rudolf Kaaks, Tim Key, María Dolores Chirlaque López, null Robert Luben, Giovanna Masala, Jonas Manjer, Anja Olsen, Kim Overvad, Domenico Palli, Elio Riboli, Maria José Sánchez, Rosario Tumino, Roel Vermeulen, W. M. Monique Verschuren, Nick Wareham, Ashwin Ananthakrishnan, Kristin Burke, Emily Walsh Lopes, James Richter, and Apollo - University of Cambridge Repository
Subjects: Adult, medicine.medical_specialty, DEFINe-IBD Investigators, Adolescent, Colitis, Ulcerative/complications, Epidemiology, body mass index, Gastroenterology and Hepatology, Inflammatory bowel disease, Body Mass Index, Young Adult, Waist–hip ratio, Crohn Disease, Risk Factors, Internal medicine, medicine, Gastroenterologi, Humans, Obesity, Prospective Studies, Prospective cohort study, Aged, Aged, 80 and over, Crohn's disease, Gastroenterology & Hepatology, Hepatology, Proportional hazards model, business.industry, Waist-Hip Ratio, Hazard ratio, Gastroenterology, 1103 Clinical Sciences, Middle Aged, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, Crohn Disease/complications, Colitis, Ulcerative, Obesity/complications, business, Body mass index
Abstract: Background and Aims: It is unclear whether obesity is associated with the development of inflammatory bowel disease despite compelling data from basic science studies. We therefore examined the association between obesity and risk of Crohn's disease (CD) and ulcerative colitis (UC). Methods: We conducted pooled analyses of 5 prospective cohorts with validated anthropometric measurements for body mass index (BMI) and waist-hip ratio and other lifestyle factors. Diagnoses of CD and UC were confirmed through medical records or ascertained using validated definitions. We used Cox proportional hazards modeling to calculate pooled multivariable-adjusted HRs (aHRs) and 95% confidence intervals (CIs). Results: Among 601,009 participants (age range, 18-98 years) with 10,110,018 person-years of follow-up, we confirmed 563 incident cases of CD and 1047 incident cases of UC. Obesity (baseline BMI ≥30 kg/m 2) was associated with an increased risk of CD (pooled aHR, 1.34; 95% CI, 1.05-1.71, I 2 = 0%) compared with normal BMI (18.5 to 2). Each 5 kg/m 2 increment in baseline BMI was associated with a 16% increase in risk of CD (pooled aHR, 1.16; 95% CI, 1.05-1.22; I 2 = 0%). Similarly, with each 5 kg/m 2 increment in early adulthood BMI (age, 18-20 years), there was a 22% increase in risk of CD (pooled aHR, 1.22; 95% CI, 1.05-1.40; I 2 = 13.6%). An increase in waist-hip ratio was associated with an increased risk of CD that did not reach statistical significance (pooled aHR across quartiles, 1.08; 95% CI, 0.97-1.19; I 2 = 0%). No associations were observed between measures of obesity and risk of UC. Conclusions: In an adult population, obesity as measured by BMI was associated with an increased risk of older-onset CD but not UC.
Published: 2022

3. Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma

Author: Heinz Freisling, Susana Merino, Aurelio Barricarte, Augustin Scalbert, Domenico Palli, Eleni Peppa, Hanna Nyström, Klas Sjöberg, Magdalena Stepien, Antonia Trichopoulou, Aurora Perez-Cornago, Marina Lopez-Nogueroles, Gianluca Severi, Carlotta Sacerdote, Dragos Ciocan, Tilman Kühn, Elisabete Weiderpass, Cosmin Sebastian Voican, Manuela M. Bergmann, Gabriel Perlemuter, Eugene Jansen, Rudolf Kaaks, Michael F. Leitzmann, Julie A. Schmidt, Catherine Dong, Anna Karakatsani, María José Sánchez, Rosario Tumino, Bodil Ohlsson, H. Bas Bueno-de-Mesquita, Marc J. Gunter, Raul Zamora Ros, Guri Skeie, José Mª Huerta, Heiner Boeing, Agustín Lahoz, Vittorio Krogh, Pilar Amiano, Francesca Mancini, Anne Tjønneland, Marie-Christine Boutron-Ruault, Salvatore Panico, Mazda Jenab, Sofia Christakoudi, Vivian Viallon, Renée T. Fortner, Mårten Werner, Faculté de Médecine Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Kræftens Bekæmpelse, DCS, Deutsches Krebsforschungszentrum, DKFZ, Centre International de Recherche sur le Cancer, CIRC, National Research Council, NRC, University of Maryland School of Public Health, SPH, Medical Research Council, MRC: 1000143, MR/M012190/1, Cancer Research UK, CRUK: 14136, C8221/A29017, World Cancer Research Fund, WCRF, University of Cambridge, Imperial College London, Institut National de la Santé et de la Recherche Médicale, Inserm, Bundesministerium für Bildung und Forschung, BMBF, Cancerfonden, Ministerie van Volksgezondheid, Welzijn en Sport, VWS, Ligue Contre le Cancer, Vetenskapsrådet, VR, Instituto de Salud Carlos III, ISCIII, Deutsche Krebshilfe, Institut National Du Cancer, INCa: 2009‐139, 2014‐1‐RT‐02‐CIRC‐1, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, NIHR Imperial Biomedical Research Centre, BRC, This work was supported in part by the French National Cancer Institute (L'Institut National du Cancer, INCa, grant numbers 2009‐139 and 2014‐1‐RT‐02‐CIRC‐1, PI: M. Jenab) and by internal funds of the IARC. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology—ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC‐Norfolk, C8221/A29017 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford) (United Kingdom). The funding sources had no influence on the design of the study, the collection, analysis and interpretation of data, the writing of the report, or the decision to submit the article for publication. Funding information, and We would like to acknowledge Dr Krasimira Aleksandrova for input on the present manuscript, along with the National Institute for Public Health and the Environment (Bilthoven, The Netherlands), the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands, Department of Public Health Aarhus University (Aarhus, Denmark), University of Cambridge (Cambridge, United Kingdom), for their contributions and ongoing support to the EPIC Study.
Subjects: Adult, Male, Cancer Research, medicine.medical_specialty, obesity, Carcinoma, Hepatocellular, medicine.drug_class, education, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Bile Acids and Salts, Cohort Studies, chemistry.chemical_compound, Internal medicine, medicine, Biomarkers, Tumor, Choline, Humans, Prospective cohort study, Carcinogen, Aged, Cancer prevention, Bile acid, cancer prevention, business.industry, Confounding, Liver Neoplasms, bile acid metabolism, biomarkers, hepatocellular carcinoma, Middle Aged, medicine.disease, Obesity, Oncology, chemistry, Hepatocellular carcinoma, Case-Control Studies, Female, business
Abstract: This is the peer reviewed version of the following article: Stepien et.al (2021). Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma. International Journal of Cancer, which has been published in final form at https://doi.org/10.1002/ijc.33885. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. Bile acids (BAs) play different roles in cancer development. Some are carcinogenic and BA signaling is also involved in various metabolic, inflammatory and immune-related processes. The liver is the primary site of BA synthesis. Liver dysfunction and microbiome compositional changes, such as during hepatocellular carcinoma (HCC) development, may modulate BA metabolism increasing concentration of carcinogenic BAs. Observations from prospective cohorts are sparse. We conducted a study (233 HCC case-control pairs) nested within a large observational prospective cohort with blood samples taken at recruitment when healthy with follow-up over time for later cancer development. A targeted metabolomics method was used to quantify 17 BAs (primary/secondary/tertiary; conjugated/unconjugated) in prediagnostic plasma. Odd ratios (OR) for HCC risk associations were calculated by multivariable conditional logistic regression models. Positive HCC risk associations were observed for the molar sum of all BAs (ORdoubling = 2.30, 95% confidence intervals [CI]: 1.76-3.00), and choline- and taurine-conjugated BAs. Relative concentrations of BAs showed positive HCC risk associations for glycoholic acid and most taurine-conjugated BAs. We observe an association between increased HCC risk and higher levels of major circulating BAs, from several years prior to tumor diagnosis and after multivariable adjustment for confounders and liver functionality. Increase in BA concentration is accompanied by a shift in BA profile toward higher proportions of taurine-conjugated BAs, indicating early alterations of BA metabolism with HCC development. Future studies are needed to assess BA profiles for improved stratification of patients at high HCC risk and to determine whether supplementation with certain BAs may ameliorate liver dysfunction.
Published: 2021

4. Evidence Update on the Relationship between Diet and the Most Common Cancers from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: A Systematic Review

Author: Miguel Rodríguez-Barranco, Dafina Petrova, Antonio Agudo, Ana Ching-López, María Dolores Chirlaque, Esther Molina-Montes, Pilar Amiano, Aurelio Barricarte-Gurrea, Esther Ubago-Guisado, and María José Sánchez
Subjects: vegetables, Oncology, medicine.medical_specialty, Meat, Mediterranean diet, Colorectal cancer, colorectal cancer, fruits, Fruits, meat, Prostate cancer, breast cancer, Breast cancer, Neoplasms, Internal medicine, Vegetables, medicine, Humans, TX341-641, Nutritional Physiological Phenomena, Prospective Studies, Lung cancer, Prospective cohort study, Càncer, Cancer, fish, Nutrition and Dietetics, Cancer prevention, Nutrition. Foods and food supply, alcohol, business.industry, prostate cancer, medicine.disease, European Prospective Investigation into Cancer and Nutrition, Diet, Europe, Alimentació, lung cancer, Fish, Intake, Systematic Review, Alcohol, business, intake, Food Science
Abstract: FundingE.U.-G. is supported by the Programa Operativo Fondo Social Europeo (FSE) de Andalucia (20142020) and Junta de Andalucia (reference DOC_01618)., The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicentre prospective study conducted in 23 centres in 10 European countries. Here we review the findings from EPIC on the relationship between diet-related exposures and incidence or mortality from the four most frequent cancers in the European population: colorectal, breast, lung, and prostate cancer. We conducted a systematic review following PRISMA guidelines and identified 110 high-quality studies based on the EPIC cohort. Fruit and vegetable consumption had a protective effect against colorectal, breast, and lung cancer, whereas only fruit had a protective effect against prostate cancer. A higher consumption of fish and lower consumption of red and processed meat were related with a lower risk of colorectal cancer; and higher consumption of fatty fish with lower risk of breast cancer. Calcium and yogurt intake were found to protect against colorectal and prostate cancer. Alcohol consumption increased the risk for colorectal and breast cancer. Finally, adherence to the Mediterranean diet emerged as a protective factor for colorectal and breast cancer. The EPIC study results are in agreement with the latest evidence from leading authorities on cancer prevention and help to inform public prevention policies and strategies., Programa Operativo Fondo Social Europeo (FSE) de Andalucia (20142020), Junta de Andalucia DOC_01618
Published: 2021

5. Dietary advanced glycation end-products and colorectal cancer risk in the European prospective investigation into cancer and nutrition (EPIC) study

Author: J. Ramón Quirós, Elom K. Aglago, Marie-Christine Boutron-Ruault, Sabina Sieri, Bas Bueno-de-Mesquita, Rosario Tumino, Ingegerd Johansson, Maria Santucci de Magistris, Anne Kirstine Eriksen, Viktoria Knaze, Alicia K Heath, Aurora Perez-Cornago, Pilar Amiano, Anne Tjønneland, Joseph A. Rothwell, Verena Katzke, Elisabete Weiderpass, Casper G. Schalkwijk, Guri Skeie, Matthias B. Schulze, Ana Lucia Mayén, Rudolf Kaaks, Li Jiao, Anna Birukov, Jeroen W.G. Derksen, Jonas Manjer, María Dolores Chirlaque, Fulvio Ricceri, Leila Lujan-Barroso, Veronika Fedirko, Mazda Jenab, Aurelio Barricarte Gurrea, Gianluca Severi, Heinz Freisling, Torkjel M. Sandanger, Domenico Palli, Marc J. Gunter, Inger T. Gram, David J. Hughes, María José Sánchez, Interne Geneeskunde, and RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome
Subjects: Oncology, Glycation End Products, Advanced, Male, Colorectal cancer, Eating, Glycation, Medicine, Advanced glycation end-products, Dietary exposure, Dietary glycation compounds, Adult, Aged, Colorectal Neoplasms, Diet, Diet Surveys, Europe, Female, Humans, Middle Aged, Proportional Hazards Models, Prospective Studies, Risk Assessment, TX341-641, Prospective cohort study, FOODS, Nutrition and Dietetics, Hazard ratio, European Prospective Investigation into Cancer and Nutrition, Näringslära, dietary exposure, Avaluació de l'estat nutricional, Epic study, Nutritional status measurement, SOLUBLE RECEPTOR, medicine.medical_specialty, DATABASE, Glycation End Products, colorectal cancer, ENDPRODUCTS, GUIDE, Article, dietary glycation compounds, advanced glycation end-products, Càncer colorectal, Internal medicine, Cancer och onkologi, Proportional hazards model, business.industry, Nutrition. Foods and food supply, medicine.disease, Confidence interval, Cancer and Oncology, CASEIN, Advanced, 1111 Nutrition and Dietetics, business, 0908 Food Sciences, Food Science
Abstract: This work was funded by the Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund (WCRF) International grant program (WCRF 2015-1391, P.I. Mazda Jenab, International Agency for Research on Cancer). This work was partially financially supported by the Fondation de France (FDF grant no. 00081166 to H. Freisling and FDF grant no. 00089811 to A.-L. Mayen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to thank Bertrand Hemon for the preparation of the databases. The coordination of EPIC is financially supported by the Inter national Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Insti tute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro (AIRC), Compagnia di San Paolo, and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), Instituto de Salud Carlos III (ISCIII), Regional Govern ments of Andalucía, Asturias, the Basque Country, Murcia, and Navarra, and the Catalan Institute of Oncology (ICO) (Spain); Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). We are grateful to all of the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We acknowledge the use of data from the EPIC-Aarhus cohort, PI Kim Overvad. We thank the CERCA Programme/Generalitat de Catalunya for institutional support., Dietary advanced glycation end-products (dAGEs) have been hypothesized to be associated with a higher risk of colorectal cancer (CRC) by promoting inflammation, metabolic dysfunction, and oxidative stress in the colonic epithelium. However, evidence from prospective cohort studies is scarce and inconclusive. We evaluated CRC risk associated with the intake of dAGEs in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Dietary intakes of three major dAGEs: N-epsilon-carboxy-methyllysine (CML), N-epsilon-carboxyethyllysine (CEL), and N-delta-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were estimated in 450,111 participants (median follow-up = 13 years, with 6162 CRC cases) by matching to a detailed published European food composition database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of dAGEs with CRC were computed using multivariable-adjusted Cox regression models. Inverse CRC risk associations were observed for CML (HR comparing extreme quintiles: HRQ5vs.(Q1) = 0.92, 95% CI = 0.85-1.00) and MG-H1 (HRQ5vs.(Q1) = 0.92, 95% CI = 0.85-1.00), but not for CEL (HRQ5vs.(Q1) = 0.97, 95% CI = 0.89-1.05). The associations did not differ by sex or anatomical location of the tumor. Contrary to the initial hypothesis, our findings suggest an inverse association between dAGEs and CRC risk. More research is required to verify these findings and better differentiate the role of dAGEs from that of endogenously produced AGEs and their precursor compounds in CRC development., Wereld Kanker Onderzoek Fonds (WKOF), World Cancer Research Fund (WCRF) International grant program (WCRF) 2015-1391, Fondation de France 00081166- 00089811
Published: 2021

6. Development and validation of circulating CA125 prediction models in postmenopausal women

Author: J. Ramón Quirós, N. Charlotte Onland-Moret, Anna Karakatsani, Marina Kvaskoff, Raina N. Fichorova, Pilar Amiano, Eva Lundin, Louise Hansen, Kathryn L. Terry, Sara Grioni, Kay-Tee Khaw, Leila Lujan-Barroso, Amalia Mattiello, Renée T. Fortner, Agnès Fournier, Linda J. Titus, Rudolf Kaaks, Sandra Colorado-Yohar, Anne Tjønneland, Timothy J. Key, Marc J. Gunter, Aurelio Barricarte, Shelley S. Tworoger, Laure Dossus, Britton Trabert, Naoko Sasamoto, Inger T. Gram, David C. Muller, Hanna Sartor, Bernard Rosner, Allison F. Vitonis, Francesca Mancini, Eleni Peppa, Valentina Fiano, María José Sánchez, Heiner Boeing, Daniel W. Cramer, Ana Babic, Hidemi S. Yamamoto, Rosario Tumino, Nicolas Wentzensen, Domenico Palli, Annika Idahl, Elisabete Weiderpass, Antonia Trichopoulou, Elio Riboli, Sasamoto, Naoko [0000-0002-4526-2181], Tjønneland, Anne [0000-0003-4385-2097], Tumino, Rosario [0000-0003-2666-414X], Apollo - University of Cambridge Repository, [Sasamoto,N, Vitonis,AF, Cramer,DW, Terry,KL] Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, MA, USA. [Babic,A] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [Rosner,BA] Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. [Fortner,RT, Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Yamamoto,H, Fichorova,RN] Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA, USA.[Titus,LJ] Departments of Epidemiology and Pediatrics, Geisel School of Medicine at Dartmouth and Norris Cotton Cancer Center, Hanover, NH, USA. [Tjønneland,A, Hansen,L] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Tjønneland,A] Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [Kvaskoff,M, Fournier,A, Mancini,FR] CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Kvaskoff,M, Mancini,FR] Gustave Roussy, Villejuif, France. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Peppa,E, Karakatsani,A] Hellenic Health Foundation, Athens, Greece. [Trichopoulou,A] WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. [Karakatsani,A] 2nd Pulmonary Medicine Department, School of Medicine, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Haidari, Greece. [Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [Grioni,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. [Mattiello,A] Dipartimento Di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Department, 'Civic - M.P. Arezzo'Hospital, ASP, Ragusa, Italy. [Fiano,V] Unit of Cancer Epidemiology– CeRMS, Department of Medical Sciences, University of Turin, Turin, Italy. [Onland-Moret,NC] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. [Weiderpass,E, Gunter,M, Dossus,L] International Agency for Research on Cancer, Lyon, France. [Gram,IT] Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Lujan-Barroso,L] Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), L’ Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Andalusian School of Public Health (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA). Universidad de Granada, Granada, Spain. [Sánchez,MJ, Colorado-Yohar,S, Barricarte,A, Amiano,P] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Colorado-Yohar,S] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Colorado-Yohar,S] Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia. [Barricarte,A] Navarra Public Health Institute, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Amiano,P] Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain. [Idahl,A] Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden. [Lundin,E] Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. [Sartor,H] Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden. [Sartor,H] Department of Translational Medicine, Lund University, Lund, Sweden. [Khaw,KT] Cancer Epidemiology Unit, University of Cambridge, Cambridge, UK. [Key,TJ] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Muller,D, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Trabert,B, Wentzensen,N] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C, USA. [Tworoger,SS] Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA. [Tworoger,SS, Terry,KL] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Research reported in this publication was supported by U.S. National Institutes of Health under the following award numbers: R01 CA193965 (to K.L. Terry), R01 CA 158119 and R35 CA197605 (to D.W. Cramer), P01 CA087969 (to S.S. Tworoger), UM1 CA186107, R01 CA49449, UM1 CA176726, R01 CA67262, and supported in part by the intramural research program of the U.S. National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten, The Cancer Research Foundation of Northern Sweden (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).
Subjects: Antígeno Ca-125, Oncology, endocrine system diseases, medicine.medical_treatment, Càncer d'ovari, Ovarian neoplasms, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Theoretical [Medical Subject Headings], 0302 clinical medicine, Neoplasms, PROSTATE, 030212 general & internal medicine, CA-125, Early Detection of Cancer, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], 2. Zero hunger, RISK, Reproductive Biology, Biochemical markers, Obstetrics and Gynecology, Early detection, Diseases::Neoplasms [Medical Subject Headings], Middle Aged, Early diagnosis, female genital diseases and pregnancy complications, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Menopause, Postmenopause, Posmenopausia, 030220 oncology & carcinogenesis, Marcadors bioquímics, Biomarker (medicine), Female, Postmenopausal, Life Sciences & Biomedicine, Menopausa, medicine.medical_specialty, Neoplasias ováricas, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosis::Early Detection of Cancer [Medical Subject Headings], BIOMARKERS, CA125, Ovarian cancer, Prediction model, Reproduktionsmedicin och gynekologi, lcsh:Gynecology and obstetrics, Chemicals and Drugs::Biological Factors::Antigens::Antigens, Neoplasm::Antigens, Tumor-Associated, Carbohydrate::CA-125 Antigen [Medical Subject Headings], OVARIAN-CANCER, 03 medical and health sciences, Diagnóstico precoz, Internal medicine, Obstetrics, Gynecology and Reproductive Medicine, medicine, Journal Article, Humans, VDP::Medisinske Fag: 700, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Sexual Development::Climacteric::Menopause::Postmenopause [Medical Subject Headings], lcsh:RG1-991, Aged, Hysterectomy, Science & Technology, business.industry, Research, Case-control study, CANCER SCREENING TRIAL, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Stepwise regression, Models, Theoretical, medicine.disease, VDP::Medical disciplines: 700, Detección precoz del cáncer, Check Tags::Female [Medical Subject Headings], CA-125 Antigen, Hormone therapy, business, Body mass index, LUNG
Abstract: Background Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve its performance as screening biomarker. Methods We developed and validated linear and dichotomous (≥35 U/mL) circulating CA125 prediction models in postmenopausal women without ovarian cancer who participated in one of five large population-based studies: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 26,981), European Prospective Investigation into Cancer and Nutrition (EPIC, n = 861), the Nurses’ Health Studies (NHS/NHSII, n = 81), and the New England Case Control Study (NEC, n = 923). The prediction models were developed using stepwise regression in PLCO and validated in EPIC, NHS/NHSII and NEC. Result The linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset (r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI, smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and 0.80 in validation dataset. Conclusions The linear prediction model explained a small portion of the total variability of CA125, suggesting the need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying healthy women who may have elevated CA125 levels, which may contribute to reducing false positive tests using CA125 as screening biomarker.
Published: 2019

7. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author: Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020
Subjects: Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract: I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
Published: 2021

8. Soft Drink and Juice Consumption and Renal Cell Carcinoma Incidence and Mortality in the European Prospective Investigation into Cancer and Nutrition

Author: Guri Skeie, Leila Lujan-Barroso, Inge Huybrechts, Bernard Srour, Nick P Jayanth, David C. Muller, Vittorio Krogh, Pilar Amiano, Rosario Tumino, Stina Ramne, Matthias B. Schulze, Kim Overvad, Anne Tjønneland, Alberto Catalano, Fabrizio Pasanisi, Mazda Jenab, Aurelio Barricarte Gurrea, Karina Standahl Olsen, Carmen Santiuste, Håkan Axelson, Giovanna Masala, Kristina E.N. Petersen, Elio Riboli, Eleanor L. Watts, Verena Katzke, Joanna L Clasen, Miguel Rodríguez-Barranco, Alicia K Heath, Magritt Brustad, Manuela M. Bergmann, Börje Ljungberg, Elisabete Weiderpass, Cancer Research UK, Heath, A. K., Clasen, J. L., Jayanth, N. P., Jenab, M., Tjonneland, A., Petersen, K. E. N., Overvad, K., Srour, B., Katzke, V., Bergmann, M. M., Schulze, M. B., Masala, G., Krogh, V., Tumino, R., Catalano, A., Pasanisi, F., Brustad, M., Olsen, K. S., Skeie, G., Lujan-Barroso, L., Rodriguez-Barranco, M., Amiano, P., Santiuste, C., Gurrea, A. B., Axelson, H., Ramne, S., Ljungberg, B., Watts, E. L., Huybrechts, I., Weiderpass, E., Riboli, E., and Muller, D. C.
Subjects: Male, 0301 basic medicine, Epidemiology, Carbonated Beverages, urologic and male genital diseases, Carbonated Beverages/adverse effects, Body Mass Index, 0302 clinical medicine, soft drinks, Risk Factors, Renal cell carcinoma, sweetened beverages, Medicine, Prospective Studies, 11 Medical and Health Sciences, Diet Surveys/statistics & numerical data, RISK, Kidney Neoplasms/epidemiology, Incidence, Incidence (epidemiology), kidney cancer, Middle Aged, Kidney Neoplasms, European Prospective Investigation into Cancer and Nutrition, Europe, Fruit and Vegetable Juices, Oncology, 030220 oncology & carcinogenesis, Female, Adult, renal cell carcinoma, medicine.medical_specialty, Diet Surveys, juice, Article, Europe/epidemiology, 03 medical and health sciences, Internal medicine, Humans, Obesity, Risk factor, Carcinoma, Renal Cell, Aged, Carcinoma, Renal Cell/epidemiology, Proportional hazards model, business.industry, Sweetening Agents/adverse effects, Feeding Behavior, Obesity/epidemiology, medicine.disease, Confidence interval, Fruit and Vegetable Juices/adverse effects, 030104 developmental biology, Sweetening Agents, business, Body mass index, Follow-Up Studies
Abstract: Background: Renal cell carcinoma (RCC) accounts for more than 80% of kidney cancers in adults, and obesity is a known risk factor. Regular consumption of sweetened beverages has been linked to obesity and several chronic diseases, including some types of cancer. It is uncertain whether soft drink and juice consumption is associated with risk of RCC. We investigated the associations of soft drink and juice consumption with RCC incidence and mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC). Methods: A total of 389,220 EPIC participants with median age of 52 years at recruitment (1991–2000) were included. Cox regression yielded adjusted HRs and 95% confidence intervals (CI) for RCC incidence and mortality in relation to intakes of juices and total, sugar-sweetened, and artificially sweetened soft drinks. Results: A total of 888 incident RCCs and 356 RCC deaths were identified. In models including adjustment for body mass index and energy intake, there was no higher risk of incident RCC associated with consumption of juices (HR per 100 g/day increment = 1.03; 95% CI, 0.97–1.09), total soft drinks (HR = 1.01; 95% CI, 0.98–1.05), sugar-sweetened soft drinks (HR = 0.99; 95% CI, 0.94–1.05), or artificially sweetened soft drinks (HR = 1.02; 95% CI, 0.96–1.08). In these fully adjusted models, none of the beverages was associated with RCC mortality (HR, 95% CI per 100 g/day increment 1.06, 0.97–1.16; 1.03, 0.98–1.09; 0.97, 0.89–1.07; and 1.06, 0.99–1.14, respectively). Conclusions: Consumption of juices or soft drinks was not associated with RCC incidence or mortality after adjusting for obesity. Impact: Soft drink and juice intakes are unlikely to play an independent role in RCC development or mortality.
Published: 2021

9. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study

Author: Vittorio Simeon, Ana-Lucia Mayén, Anne Tjønneland, Aurora Perez-Cornago, Giovanna Masala, Christina C. Dahm, Sabina Sieri, Elisabete Weiderpass, Heinz Freisling, Paula Jakszyn, Alicia K Heath, Li Jiao, Mazda Jenab, Pilar Amiano, Aurelio Barricarte Gurrea, Theron Johnson, Alessandra Macciotta, David J. Hughes, Anja Olsen, Guri Skeie, Torkjel M. Sandanger, Matthias B. Schulze, Veronika Fedirko, Krasimira Aleksandrova, Rosario Tumino, Verena Katzke, Sandra Colorado-Yohar, Elom K. Aglago, Casper G. Schalkwijk, Bas Bueno-de-Mesquita, María José Sánchez, Marc J. Gunter, Inger T. Gram, Interne Geneeskunde, RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, Aglago, E. K., Schalkwijk, C. G., Freisling, H., Fedirko, V., Hughes, D. J., Jiao, L., Dahm, C. C., Olsen, A., Tjonneland, A., Katzke, V., Johnson, T., Schulze, M. B., Aleksandrova, K., Masala, G., Sieri, S., Simeon, V., Tumino, R., Macciotta, A., Bueno-De-Mesquita, B., Skeie, G., Gram, I. T., Sandanger, T., Jakszyn, P., Sanchez, M. -J., Amiano, P., Colorado-Yohar, S. M., Gurrea, A. B., Perez-Cornago, A., Mayen, A. -L., Weiderpass, E., Gunter, M. J., Heath, A. K., and Jenab, M.
Subjects: 0301 basic medicine, Glycation End Products, Advanced, Male, Ornithine, Cancer Research, STRESS, Colorectal cancer, Gastroenterology, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Glycation, Tandem Mass Spectrometry, Odds Ratio, Medicine, Cancer Biomarkers and Molecular Epidemiology, Imidazoles, General Medicine, Middle Aged, glycotoxin, 030220 oncology & carcinogenesis, METHYLGLYOXAL, Plasma concentration, Cohort, Advanced glycation end-product, Epic study, Female, Colorectal Neoplasms, Adult, SOLUBLE RECEPTOR, EXPRESSION, medicine.medical_specialty, colorectal cancer, 03 medical and health sciences, AGE, FOOD, Internal medicine, Humans, Genetic Predisposition to Disease, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Genetic Association Studies, Aged, business.industry, Lysine, RECOGNITION, advanced glycation end-product, Odds ratio, medicine.disease, Confidence interval, 030104 developmental biology, chemistry, business, Chromatography, Liquid
Abstract: This is a pre-copyedited, author-produced version of an article accepted for publication in Carcinogenesis following peer review. The version of record Aglago, Schalkwijk, Freisling, Fedirko, Hughes, Jiao, Dahm, Olsen, Tjønneland, Katzke, Johnson, Schulze, Aleksandrova, Masala, Sieri, Simeon, Tumino, Macciotta, Bueno-De-Mesquita, Skeie, Gram, Sandanger, Jakszyn, Sánchez, Amiano, Colorado-Yohar, Barricarte, Perez-Cornago, Mayén, Weiderpass, Gunter, Heath, Jenab. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42(5):705-713 is available online at: https://doi.org/10.1093/carcin/bgab026. Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case–control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs—Nε-(carboxy-methyl)lysine (CML), Nε-(carboxy-ethyl)lysine (CEL) and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1)—were measured by ultra-performance liquid chromatography–tandem mass spectrometry in baseline samples collected from 1378 incident primary colorectal cancer cases and 1378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5 versus Q1 = 0.40, 95% CI: 0.27–0.59), MG-H1 (ORQ5 versus Q1 = 0.73, 95% CI: 0.53–1.00) and total AGEs (OR Q5 versus Q1 = 0.52, 95% CI: 0.37–0.73), whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5 versus Q1 = 1.91, 95% CI: 1.31–2.79). The associations observed did not differ by sex, or by tumour anatomical sub-site. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed.
Published: 2021

10. No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition

Author: Salvatore Panico, Nadia García, H. B. Bueno-De-Mesquita, Kim Overvad, Hendriek C. Boshuizen, Timothy J. Key, M. E. Numans, Antonio Berenguer, Rosario Tumino, Khaw K-T., Gabriele Nagel, Carmen Navarro, Boutron-Ruault M-C., Domenico Palli, Elio Riboli, J. Linseisen, Anne Tjønneland, Aurelio Barricarte, A. Olsen, Eiliv Lund, Françoise Clavel-Chapelon, Calogero Saieva, Teresa Norat, G. Del Giudice, Sheila Bingham, Guillem Pera, Henrik Simán, Antonia Trichopoulou, Mazda Jenab, Carlos A. González, Hendrik Bläker, J. R. Quirós, Carlos Martinez, Antonio Agudo, Roger Stenling, P. H. M. Peeters, Carlotta Sacerdote, Pilar Amiano, Pamela Ferrari, Naomi E. Allen, Göran Berglund, Fátima Carneiro, Gabriel Capellá, Franco Berrino, Heiner Boeing, Núria Sala, and Göran Hallmans
Subjects: Male, Oncology, medicine.medical_specialty, Pathology, Genotype, Arylamine N-Acetyltransferase, Epidemiology, Adenocarcinoma, Biology, Glutathione transferase, Gastric adenocarcinoma, Stomach Neoplasms, Internal medicine, medicine, Humans, Stomach cancer, neoplasms, Glutathione Transferase, Polymorphism, Genetic, integumentary system, Cytochrome P-450 CYP2E1, Middle Aged, medicine.disease, digestive system diseases, European Prospective Investigation into Cancer and Nutrition, Europe, Logistic Models, Case-Control Studies, Female, Stomach Adenocarcinoma
Abstract: No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European prospective investigation into cancer and nutrition.
Published: 2021

11. Blood Metal Levels and Amyotrophic Lateral Sclerosis Risk: A Prospective Cohort

Author: Broberg, Karin E., Kippler, Maria J., Veldink, Jan Herman, Van Den Berg, Leonard H., Middleton, Lefkos T., Travis, Ruth C., Bergmann, Manuela M., Mancini, Francesca Romana, Katzke, Verena Andrea, Agudo, Antonio T., Gómez, Jesús Humberto, Rodríguez-Barranco, Miguel A., Trichopoulou, Antonia D., Vermeulen, Roel C.H., Peters, Susan, Broberg, Karin, Gallo, Valentina, Levi, Michael, Kippler, Maria, Vineis, Paolo, Veldink, Jan, Berg, Leonard, Middleton, Lefkos, Travis, Ruth, Bergmann, Manuela, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Elbaz, Alexis, Vlaar, Tim, Mancini, Francesca, Kühn, Tilman, Katzke, Verena, Agudo, Antonio, Goñi, Fernando, Gómez, Jesús‐humberto, Rodríguez‐barranco, Miguel, Merino, Susana, Barricarte, Aurelio, Trichopoulou, Antonia, Jenab, Mazda, Weiderpass, Elisabete, Vermeulen, Roel, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Gustave Roussy (IGR), Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), FOOD‐CT‐2005‐513943 Ministry of National Education and Religious Affairs Cancer Research UK, CRUK Wellcome Trust, WT German Cancer Research Center, DKFZ Department of Health, Australian Government Institut National de la Santé et de la Recherche Médicale, Inserm Kræftens Bekæmpelse, DCS Instituto de Salud Carlos III, ISCIII: C03/09 Stichting Diabetes Onderzoek Nederland British Heart Foundation, BHF Norges Forskningsråd QLK4CT199900927 Stroke Association European Commission, EC Deutsche Krebshilfe World Cancer Research Fund, WCRF Kreftforeningen, NCS Medical Research Council, MRC, The EPIC study is funded by a number of grants, however, no funding source had any role in the preparation of this article. The EPIC study was funded by the Europe against Cancer program of the European Commission (SANCO), Italian Association for Research on Cancer, and Italian National Research Council. In addition, the authors thank the following for their financial support: the Environmental Cancer Risk, Nutrition, and Individual Susceptibility Network of Excellence, operating within the European Union Sixth Framework Program, Priority 5: Food Quality and Safety (FOOD‐CT‐2005‐513943), European Community Fifth Framework Program (grant QLK4CT199900927), ISCIII, Red de Centros RCESP (C03/09), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and Research, Danish Cancer Society, Health Research Fund of the Spanish Ministry of Health, Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia, and Navarra, Cancer Research UK, Medical Research Council, UK, Stroke Association, UK, British Heart Foundation, Department of Health, UK, Food Standards Agency, UK, Wellcome Trust, UK, Greek Ministry of Health, Greek Ministry of Education, Italian Association for Research on Cancer, Italian National Research Council, Dutch Ministry of Public Health, Welfare, and Sports, Netherlands Cancer Registry, LK Research Funds, Dutch Prevention Funds, Zorg Onderzoek Nederland, World Cancer Research Fund, Statistics Netherlands, Swedish Cancer, Swedish Scientific Council, Regional Government of Skåne and Västerbotten, Sweden, Norwegian Cancer Society, Research Council of Norway, French League against Cancer, INSERM, Mutuelle Generale l'Education National, and IGR. The EPIC‐Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC‐UU_12015/1) and Cancer Research UK (C864/A14136)., and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: 0301 basic medicine, Adult, Male, Risk, medicine.medical_specialty, Clinical Neurology, Gastroenterology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, LEAD-EXPOSURE, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Research Articles, POPULATION, Aged, Retrospective Studies, Science & Technology, Neurology & Neurosurgery, business.industry, Amyotrophic Lateral Sclerosis, Neurosciences, 1103 Clinical Sciences, Retrospective cohort study, Odds ratio, Environmental exposure, Environmental Exposure, Mercury, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, 030104 developmental biology, Neurology, Cohort, Population study, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Neurosciences & Neurology, Neurology (clinical), SMOKING, 1109 Neurosciences, business, Life Sciences & Biomedicine, 030217 neurology & neurosurgery, Research Article, Cohort study
Abstract: International audience; Objective: Metals have been suggested as a risk factor for amyotrophic lateral sclerosis (ALS), but only retrospective studies are available to date. We compared metal levels in prospectively collected blood samples from ALS patients and controls, to explore whether metals are associated with ALS mortality. Methods: A nested ALS case–control study was conducted within the prospective EPIC (European Prospective Investigation into Cancer and Nutrition) cohort. Cases were identified through death certificates. We analyzed metal levels in erythrocyte samples obtained at recruitment, as a biomarker for metal exposure from any source. Arsenic, cadmium, copper, lead, manganese, mercury, selenium, and zinc concentrations were measured by inductively coupled plasma–mass spectrometry. To estimate ALS risk, we applied conditional logistic regression models. Results: The study population comprised 107 cases (65% female) and 319 controls matched for age, sex, and study center. Median time between blood collection and ALS death was 8 years (range = 1–15). Comparing the highest with the lowest tertile, cadmium (odds ratio [OR] = 2.04, 95% confidence interval [CI] = 1.08–3.87) and lead (OR = 1.89, 95% CI = 0.97–3.67) concentrations suggest associations with increased ALS risk. Zinc was associated with a decreased risk (OR = 0.50, 95% CI = 0.27–0.94). Associations for cadmium and lead remained when limiting analyses to noncurrent smokers. Interpretation: This is the first study to compare metal levels before disease onset, minimizing reverse causation. The observed associations suggest that cadmium, lead, and zinc may play a role in ALS etiology. Cadmium and lead possibly act as intermediates on the pathway from smoking to ALS. ANN NEUROL 20209999:n/a–n/a.
Published: 2021

12. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021

Author: Mazagatos, Clara, Monge, Susana, Olmedo, Carmen, Vega, Lorena, Gallego, Pilar, Martín-Merino, Elisa, Sierra, María José, Limia, Aurora, Larrauri, Amparo, Viloria, Luis, Malvar Pintos, Alberto, García-Fulgueiras, Ana, Martínez Mateo, Ana, Rivas Pérez, Ana Isabel, Lorusso, Nicola, Alemán Herrera, Araceli, Alonso, Juan Pablo, Barricarte, Aurelio, Salom Castell, Magdalena, Ruiz Sopeña, Cristina, Castrillejo, Daniel, Martínez Ochoa, Eva, Ramos, Julián Mauro, Carbó Malonda, Rosa, Huerta González, Ismael, Arteagoitia Axpe, José Mª, Ordobás, María, and García Hernández., Sara
Subjects: medicine.medical_specialty, LTCF, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Population, 030204 cardiovascular system & hematology, Asymptomatic, 03 medical and health sciences, 0302 clinical medicine, Virology, Pandemic, medicine, Screening method, Humans, 030212 general & internal medicine, RNA, Messenger, education, Pandemics, Aged, education.field_of_study, Surveillance, business.industry, SARS-CoV-2, screening, Vaccination, Public Health, Environmental and Occupational Health, COVID-19, vaccination, Long-Term Care, Hospitalization, Long-term care, Spain, Emergency medicine, surveillance, Screening, medicine.symptom, business, Rapid Communication
Abstract: Residents in long-term care facilities (LTCF) experienced a large morbidity and mortality during the COVID-19 pandemic in Spain and were prioritised for early COVID-19 vaccination. We used the screening method and population-based data sources to obtain estimates of mRNA COVID-19 vaccine effectiveness for elderly LTCF residents. The estimates were 71% (95% CI: 56–82%), 88% (95% CI: 75–95%), and 97% (95% CI: 92-99%), against SARS-CoV-2 infections (symptomatic and asymptomatic), and COVID-19 hospitalisations and deaths, respectively.
Published: 2021

13. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

Author: Ana Osorio, Fiona Bruinsma, Andrew J. Li, Janine Senz, Stacey J. Winham, Michael E. Carney, Deborah J. Thompson, Xifeng Wu, Susan J. Ramus, Alicia A. Tone, Robert P. Edwards, Chu Chen, Daniel D. Buchanan, Rüdiger Klapdor, Diether Lambrechts, Anthony N. Karnezis, Ralf Bützow, Graham G. Giles, Jolanta Kupryjanczyk, James D. Brenton, Pamela J. Thompson, Joseph L. Kelley, Hui Cai, Dylan M. Glubb, Peter Hillemanns, Veronica Wendy Setiawan, Reidun K. Kopperud, Francesmary Modugno, Rodney J. Scott, Karen H. Lu, Andreas du Bois, Weiva Sieh, Clara Bodelon, Katharina Bischof, Sarah E. Ferguson, Ignace Vergote, Todd L. Edwards, Nadeem Siddiqui, Jennifer A. Doherty, Celeste Leigh Pearce, David G. Huntsman, Håkan Olsson, Ailith Ewing, Tjoung-Won Park-Simon, Harvey A. Risch, Taymaa May, Soo Hwang Teo, Elizabeth G. Holliday, Penelope M. Webb, Lukasz Michael Szafron, Alexander Hein, Martin Köbel, Marjorie J. Riggan, Madhuri Koti, Ahmad Alsulimani, Matthias W. Beckmann, Heli Nevanlinna, Domenico Palli, Melissa C. Larson, Emily White, Ingo B. Runnebaum, Robert A. Vierkant, Elza Khusnutdinova, Jolanta Lissowska, Andrew Berchuck, Rosalind Glasspool, Drakoulis Yannoukakos, Alison M. Dunning, Rosario Tumino, Mia M. Gaudet, Alice S. Whittemore, Anna Jakubowska, Marcus Q. Bernardini, Jennifer B. Permuth, Kunle Odunsi, Aleksandra Gentry-Maharaj, Florentia Fostira, Philipp Harter, Rebecca Sutphen, Sandra Orsulic, Beata Spiewankiewicz, Susanne K. Kjaer, Jessica N. McAlpine, Valerie McGuire, Julie M. Cunningham, Jeffrey Killeen, Christine M. Friedenreich, Estrid Høgdall, George Fountzilas, Michelle A.T. Hildebrandt, Katja K.H. Aben, Tomasz Huzarski, Frédéric Amant, Zhaoming Wang, James M. Flanagan, Timothy R. Rebbeck, Joseph H. Rothstein, Clemens Liebrich, Immaculata De Vivo, Linda Titus, Anna deFazio, Jan Gawełko, Irene Konstantopoulou, Adriaan Vanderstichele, Stephen J. Chanock, Jenny Lester, Amanda B. Spurdle, Allan Jensen, Claus Høgdall, Daniela Annibali, Amalia Mattiello, Peter Kraft, Loic Le Marchand, Line Bjørge, Marina Bermisheva, Agnieszka Podgorska, John Attia, Tracy A. O'Mara, Shashikant Lele, Thomas A. Sellers, Bo Gao, Holly R. Harris, Shan Wang-Gohrke, Lingeng Lu, Louise A. Brinton, Alessandra Macciotta, Digna R. Velez Edwards, Peter A. Fasching, Marc T. Goodman, Linda S. Cook, Constance Turman, Jacek Gronwald, Liv Cecilie Vestrheim Thomsen, Matthias Dürst, Kirsten B. Moysich, Usha Menon, Dong Liang, Arif B. Ekici, Bozena Konopka, Aurelio Barricarte, Thilo Dörk, Stefanie Burghaus, Michael Jones, Loren Lipworth, Zhihua Chen, Xiaoqing Chen, Alison Brand, Iain A. McNeish, Tanja Pejovic, Florian Heitz, Beth Y. Karlan, Anthony J. Swerdlow, Anna H. Wu, Obstetrics and Gynaecology, CCA - Cancer biology and immunology, and Amsterdam Reproduction & Development (AR&D)
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, Epidemiology, Quantitative Trait Loci, Genome-wide association study, Biology, Carcinoma, Ovarian Epithelial, Genetic correlation, 03 medical and health sciences, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Uterine cancer, Risk Factors, Internal medicine, medicine, Humans, Genetic association, Ovarian Neoplasms, Endometrial cancer, Cancer, medicine.disease, 3. Good health, Endometrial Neoplasms, 030104 developmental biology, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Human genome, Female, Ovarian cancer, Genome-Wide Association Study
Abstract: Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10−5). We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10−9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10−7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.
Published: 2021

14. A Prospective Diet-Wide Association Study for Risk of Colorectal Cancer in EPIC

Author: Ingegerd Johansson, David S. Lopez, Alicia K Heath, Amanda J. Cross, Anne Tjønneland, J. Ramón Quirós, Melissa A. Merritt, Paula Jakszyn, Bas Bueno-de-Mesquita, Pilar Amiano, Anne Kirstine Eriksen, Manuela M. Bergmann, Marc J. Gunter, Bernard Srour, David C. Muller, Piet A. van den Brandt, Matthias B. Schulze, Salvatore Panico, Claudia Agnoli, Pietro Ferrari, Marco Lukic, José María Huerta, Christina C. Dahm, Therese Haugdahl Nøst, Areti Papadopoulou, Aurelio Barricarte Gurrea, Rosario Tumino, María José Sánchez, Fulvio Ricceri, Nadia Bastide, Paolo Vineis, Ulrika Ericson, Eva Ardanaz, Gianluca Severi, Guri Skeie, Aurora Perez-Cornago, Nikos Papadimitriou, Emmanouil Bouras, Elisabete Weiderpass, Ellio Riboli, Ioanna Tzoulaki, Heiner Boeing, Stina Bodén, Giovanna Masala, Jeroen W.G. Derksen, Jonna Berntsson, Verena Katzke, Elena Critselis, Konstantinos K. Tsilidis, University of Ioannina, Maastricht University [Maastricht], Imperial College London, Biomedical Research Foundation of the Academy of Athens (BRFAA), International Agency for Cancer Research (IACR), German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University of Hawai'i [Honolulu] (UH), The University of Texas Health Science Center at Houston (UTHealth), University of Oxford [Oxford], University of Potsdam, The Arctic University of Norway (UiT), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Umeå University, Università degli studi di Torino = University of Turin (UNITO), Lund University [Lund], Instituto de Salud Carlos III [Madrid] (ISC), Aarhus University [Aarhus], IRCCS Istituto Nazionale dei Tumori [Milano], University of Copenhagen = Københavns Universitet (KU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of Naples Federico II, La Salle [Ramon Llull University], Utrecht University [Utrecht], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Kræftens Bekæmpelse, DCS, Deutsches Krebsforschungszentrum, DKFZ, Centre International de Recherche sur le Cancer, CIRC, International Council of Ophthalmology, ICO, National Research Council, NRC, University of Maryland School of Public Health, SPH, Medical Research Council, MRC: MR/M012190/1, Cancer Research UK, CRUK: C8221/A29017, World Cancer Research Fund, WCRF: WCRF 2014/1180, Institut National de la Santé et de la Recherche Médicale, Inserm, Bundesministerium für Bildung und Forschung, BMBF, Cancerfonden, Ministerie van Volksgezondheid, Welzijn en Sport, VWS, Ligue Contre le Cancer, Vetenskapsrådet, VR, Instituto de Salud Carlos III, ISCIII, Associazione Italiana per la Ricerca sul Cancro, AIRC, Deutsche Krebshilfe, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, Funding This work was supported by the World Cancer Research Fund International Regular Grant Programme (WCRF 2014/1180 to Konstantinos K. Tsilidis). The coordination of EPIC is financially supported by International Agency for Research on Cancer and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the National Institute for Health Research Imperial Biomedical Research Centre. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)?Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology (ICO) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, C8221/A29017 to EPIC-Oxford) and Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization., Funding This work was supported by the World Cancer Research Fund International Regular Grant Programme ( WCRF 2014/1180 to Konstantinos K. Tsilidis). The coordination of EPIC is financially supported by International Agency for Research on Cancer and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the National Institute for Health Research Imperial Biomedical Research Centre . The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer , Institut Gustave Roussy , Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid , German Cancer Research Center ( DKFZ ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research ( BMBF ) (Germany), Dutch Ministry of Public Health , Welfare and Sports ( VWS ), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund ( WCRF ), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)– Instituto de Salud Carlos III ( ISCIII ), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology ( ICO ) (Spain), Swedish Cancer Society , Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Epidemiologie, and RS: GROW - R1 - Prevention
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Riboflavin, colorectal cancer, Lower risk, Cohort Studies, Animal science, beta-Carotene, Risk Factors, Epidemiology, medicine, cohort study, Humans, Prospective Studies, Hepatology, Gastroenterology & Hepatology, business.industry, Hazard ratio, Gastroenterology, food and beverages, 1103 Clinical Sciences, Confidence interval, European Prospective Investigation into Cancer and Nutrition, Diet, epidemiology, nutrition, business, Colorectal Neoplasms, Cohort study
Abstract: Background & Aims: Evidence regarding the association of dietary exposures with colorectal cancer (CRC) risk is not consistent with a few exceptions. Therefore, we conducted a diet-wide association study (DWAS) in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate the associations between several dietary exposures with CRC risk. Methods: The association of 92 food and nutrient intakes with CRC risk was assessed in 386,792 participants, 5069 of whom developed incident CRC. Correction for multiple comparisons was performed using the false discovery rate, and emerging associations were examined in the Netherlands Cohort Study (NLCS). Multiplicative gene-nutrient interactions were also tested in EPIC based on known CRC-associated loci. Results: In EPIC, alcohol, liquor/spirits, wine, beer/cider, soft drinks, and pork were positively associated with CRC, whereas milk, cheese, calcium, phosphorus, magnesium, potassium, riboflavin, vitamin B6, beta carotene, fruit, fiber, nonwhite bread, banana, and total protein intakes were inversely associated. Of these 20 associations, 13 were replicated in the NLCS, for which a meta-analysis was performed, namely alcohol (summary hazard ratio [HR] per 1-SD increment in intake: 1.07; 95% confidence interval [CI], 1.04–1.09), liquor/spirits (HR per 1-SD increment in intake, 1.04; 95% CI, 1.02–1.06), wine (HR per 1-SD increment in intake, 1.04; 95% CI, 1.02–1.07), beer/cider (HR per 1-SD increment in intake, 1.06; 95% CI, 1.04–1.08), milk (HR per 1-SD increment in intake, 0.95; 95% CI, 0.93–0.98), cheese (HR per 1-SD increment in intake, 0.96; 95% CI, 0.94–0.99), calcium (HR per 1-SD increment in intake, 0.93; 95% CI, 0.90–0.95), phosphorus (HR per 1-SD increment in intake, 0.92; 95% CI, 0.90–0.95), magnesium (HR per 1-SD increment in intake, 0.95; 95% CI, 0.92–0.98), potassium (HR per 1-SD increment in intake, 0.96; 95% CI, 0.94–0.99), riboflavin (HR per 1-SD increment in intake, 0.94; 95% CI, 0.92–0.97), beta carotene (HR per 1-SD increment in intake, 0.96; 95% CI, 0.93–0.98), and total protein (HR per 1-SD increment in intake, 0.94; 95% CI, 0.92–0.97). None of the gene-nutrient interactions were significant after adjustment for multiple comparisons. Conclusions: Our findings confirm a positive association for alcohol and an inverse association for dairy products and calcium with CRC risk, and also suggest a lower risk at higher dietary intakes of phosphorus, magnesium, potassium, riboflavin, beta carotene, and total protein.
Published: 2020

15. Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study

Author: Christina C. Dahm, Carlo La Vecchia, Domenico Palli, Salvatore Panico, Nicholas J. Wareham, Amanda J. Cross, Aurelio Barricarte, Jonna Berntsson, Elisabete Weiderpass, Rudolf Kaaks, Mazda Jenab, Anna Karakatsani, Franck Carbonnel, Xiaonan Xue, Heather Ward, Kristin Benjaminsen Borch, Elio Riboli, Marc J. Gunter, Kay-Tee Khaw, Kathryn E. Bradbury, Tilman Kühn, Marina Kvaskoff, Robin Myte, Antonia Trichopoulou, J. Ramón Quirós, Rosario Tumino, Bas Bueno-de-Mesquita, Kim Overvad, Cecilie Kyrø, Sara Grioni, José María Huerta, Francesca Fasanelli, Karin Jirström, Björn Gylling, Leire Gil, Guri Skeie, Neil Murphy, Paula Jakszyn, Marie-Christine Boutron-Ruault, María José Sánchez, Heiner Boeing, Anne Tjønneland, Krasimira Aleksandrova, Petra H.M. Peeters, Joseph A. Rothwell, Wareham, Nicholas [0000-0003-1422-2993], Apollo - University of Cambridge Repository, Murphy, Neil, Ward, Heather A, Jenab, Mazda, Rothwell, Joseph A, Boutron-Ruault, Marie-Christine, Carbonnel, Franck, Kvaskoff, Marina, Kaaks, Rudolf, Kühn, Tilman, Boeing, Heiner, Aleksandrova, Krasimira, Weiderpass, Elisabete, Skeie, Guri, Borch, Kristin Benjaminsen, Tjønneland, Anne, Kyrø, Cecilie, Overvad, Kim, Dahm, Christina C, Jakszyn, Paula, Sánchez, Maria-Jose, Gil, Leire, Huerta, José M, Barricarte, Aurelio, Quirós, J Ramón, Khaw, Kay-Tee, Wareham, Nick, Bradbury, Kathryn E, Trichopoulou, Antonia, La Vecchia, Carlo, Karakatsani, Anna, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Fasanelli, Francesca, Panico, Salvatore, Bueno-de-Mesquita, Ba, Peeters, Petra H, Gylling, Björn, Myte, Robin, Jirström, Karin, Berntsson, Jonna, Xue, Xiaonan, Riboli, Elio, Cross, Amanda J, Gunter, Marc J, Department of Medical and Clinical Genetics, Faculty of Medicine, and Imperial College Trust
Subjects: Oncology, Male, Risk Factors, Colorectal cancer, EPIC, Anatomic Subsite, HEIGHT, 0302 clinical medicine, Prospective Studies, 2. Zero hunger, Incidence, Hazard ratio, Smoking, Gastroenterology, Colonoscopy, Proximal Colon, Middle Aged, C-REACTIVE PROTEIN, TIME, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Multinational corporation, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, Menopausal hormone therapy, Colorectal Neoplasms, Life Sciences & Biomedicine, Cohort study, Adult, medicine.medical_specialty, Alcohol Drinking, Colon, 3122 Cancers, anatomical subsite, Gastroenterology and Hepatology, 03 medical and health sciences, Internal medicine, REGRESSION, Journal Article, medicine, Gastroenterologi, Humans, VDP::Medisinske Fag: 700, Distal Colon, Exercise, Life Style, RECTAL-CANCER, METAANALYSIS, Colorectal Cancer, Cancer och onkologi, Science & Technology, Gastroenterology & Hepatology, Hepatology, business.industry, Risk Factor, Rectum, Cancer, 1103 Clinical Sciences, medicine.disease, VDP::Medical disciplines: 700, PHYSICAL-ACTIVITY, 3121 General medicine, internal medicine and other clinical medicine, Cancer and Oncology, Heterogeneity, business, Follow-Up Studies
Abstract: Background & Aims - Colorectal cancer located at different anatomical subsites may have distinct etiologies and risk factors. Previous studies that have examined this hypothesis have yielded inconsistent results, possibly because most studies have been of insufficient size to identify heterogeneous associations with precision. Methods - In the European Prospective Investigation into Cancer and Nutrition study, we used multivariable joint Cox proportional hazards models, which accounted for tumors at different anatomical sites (proximal colon, distal colon, and rectum) as competing risks, to examine the relationships between 14 established/suspected lifestyle, anthropometric, and reproductive/menstrual risk factors with colorectal cancer risk. Heterogeneity across sites was tested using Wald tests. Results - After a median of 14.9 years of follow-up of 521,330 men and women, 6291 colorectal cancer cases occurred. Physical activity was related inversely to proximal colon and distal colon cancer, but not to rectal cancer (P heterogeneity = .03). Height was associated positively with proximal and distal colon cancer only, but not rectal cancer (P heterogeneity = .0001). For men, but not women, heterogeneous relationships were observed for body mass index (P heterogeneity = .008) and waist circumference (P heterogeneity = .03), with weaker positive associations found for rectal cancer, compared with proximal and distal colon cancer. Current smoking was associated with a greater risk of rectal and proximal colon cancer, but not distal colon cancer (P heterogeneity = .05). No heterogeneity by anatomical site was found for alcohol consumption, diabetes, nonsteroidal anti-inflammatory drug use, and reproductive/menstrual factors. Conclusions - The relationships between physical activity, anthropometry, and smoking with colorectal cancer risk differed by subsite, supporting the hypothesis that tumors in different anatomical regions may have distinct etiologies.
Published: 2019

16. Association between anthropometry and lifestyle factors and risk of B cell lymphoma: an exposome wide analysis

Author: Anne Tjønneland, Claudia Agnoli, Pietro Ferrari, Pilar Amiano, Bas Bueno-de-Mesquita, Miguel Rodríguez-Barranco, Alexandra Nieters, Aurelio Barricarte, Roel Vermeulen, Elisabete Weiderpass, Giovanna Masala, José María Huerta, Marta Solans, Delphine Casabonne, Federico Canzian, Caroline Besson, Florentin Späth, Gianluca Severi, Carlotta Sacerdote, James McKay, Catalina Bonet, Sabine Naudin, Fatemeh Saberi Hosnijeh, Sofia Christakoudi, Heinz Freisling, Rosario Tumino, Kristin Benjaminsen Borch, Rudolf Kaaks, Matthias B. Schulze, Yolanda Benavente, Anja Olsen, Charlotta Rylander, Anika Knuppel, Marie Christine Boutron Ruault, Mats Jerkeman, Immunology, Centre international de Recherche sur le Cancer (CIRC), Institut Gustave Roussy (IGR), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 179 2017SGR1085 Kræftens Bekæmpelse, DCS German Cancer Research Center, DKFZ Centre International de Recherche sur le Cancer, CIRC Wellcome Trust, WT: 205212/Z/16/Z National Research Council, NRC Medical Research Council, MRC: MR/M012190/1 Cancer Research UK, CRUK: 14136, C570/A11692, C570/A16491 World Cancer Research Fund, WCRF European Commission, EC Institut National de la Santé et de la Recherche Médicale, Inserm Bundesministerium für Bildung und Forschung, BMBF: 01EO1303 Cancerfonden Ministerie van Volksgezondheid, Welzijn en Sport, VWS Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR Ligue Contre le Cancer Vetenskapsrådet, VR NordForsk Associazione Italiana per la Ricerca sul Cancro, AIRC Deutsche Krebshilfe Institut Gustave-Roussy Mutuelle Générale de l'Education Nationale, MGEN European Regional Development Fund, ERDF: ERC2009‐AdG 232997, PI13/00061, PI13/01162, PI14/01219, PI17/01280 Hellenic Health Foundation, HHF, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support, Grant/Award Number: 2017SGR1085, Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy), Cancer Research UK, Grant/Award Numbers: 14136 (to EPIC‐Norfolk), C570/A11692, C570/A16491, Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), (Spain), Danish Cancer Society (Denmark), TRANSCAN/Dutch Cancer Society, Grant/Award Number: 179, NOVEL consortium, Dutch Ministry of Public Health, Welfare and Sports (VWS), Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), European Commission (DG‐SANCO), Federal Ministry of Education and Research (BMBF), German Cancer Aid, German Cancer Research Center (DKFZ), German Federal Ministry of Education and Research, Grant/Award Number: BMBF 01EO1303, German Institute of Human Nutrition Potsdam‐Rehbruecke, Nuthetal (Germany), Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale (France), International Agency for Research on Cancer, Ligue Natinale Contre le Cancer, LK Research Funds, Medical Research Council, Grant/Award Numbers: 1000143 (to EPIC‐Norfolk), MR/M012190/1 (to EPIC‐Oxford), Mutuelle Generale de l'Education Nationale, Netherlands Cancer Registry (NKR), Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Spanish Ministry of Economy and Competitiveness ‐ Carlos III Institute of Health cofunded by FEDER funds/European Regional Develpment Fund (ERDF) ‐ a way to build Europe, Grant/Award Numbers: PI13/00061 (to Granada), PI13/01162 (to EPIC‐Murcia), PI17/01280, PI14/01219 (to Barcelona), Statistics Netherlands (The Netherlands), Grant/Award Number: Grant number: ERC2009‐AdG 232997, Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Vasterbotten (Sweden), the Hellenic Health Foundation (Greece), Wellcome Trust, Grant/Award Number: 205212/Z/16/Z, and World Cancer Research Fund (WCRF) Funding information
Subjects: Oncology, Male, Limfomes, Cancer Research, Lymphoma, Follicular lymphoma, Cohort Studies, 0302 clinical medicine, Risk Factors, Prospective Studies, Càncer, Prospective cohort study, B-cell lymphoma, Cancer, 2. Zero hunger, wide association study, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, Anthropometry, exposome wide association study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Plasma cell neoplasm, Middle Aged, exposome‐, CANCER, 3. Good health, European Prospective Investigation into Cancer and Nutrition, exposome&#8208, MEDITERRANEAN DIET, 030220 oncology & carcinogenesis, OBESITY, Lymphomas, Female, SMOKING, NON-HODGKIN-LYMPHOMA, Life Sciences & Biomedicine, Cancer Epidemiology, prospective study, NATIONAL-HEALTH, medicine.medical_specialty, Inverse Association, lifestyle, Lymphoma, B-Cell, [SDV.CAN]Life Sciences [q-bio]/Cancer, lymphoma, exposome‐wide association study, exposome, DIETARY-FAT, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, VALIDITY, Life Style, Cancer och onkologi, Science & Technology, Proportional hazards model, business.industry, medicine.disease, exposome-wide association study, PHYSICAL-ACTIVITY, PROSPECTIVE COHORT, Cancer and Oncology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business
Abstract: To better understand the role of individual and lifestyle factors in human disease, an exposome‐wide association study was performed to investigate within a single‐study anthropometry measures and lifestyle factors previously associated with B‐cell lymphoma (BCL). Within the European Prospective Investigation into Cancer and nutrition study, 2402 incident BCL cases were diagnosed from 475 426 participants that were followed‐up on average 14 years. Standard and penalized Cox regression models as well as principal component analysis (PCA) were used to evaluate 84 exposures in relation to BCL risk. Standard and penalized Cox regression models showed a positive association between anthropometric measures and BCL and multiple myeloma/plasma cell neoplasm (MM). The penalized Cox models additionally showed the association between several exposures from categories of physical activity, smoking status, medical history, socioeconomic position, diet and BCL and/or the subtypes. PCAs confirmed the individual associations but also showed additional observations. The PC5 including anthropometry, was positively associated with BCL, diffuse large B‐cell lymphoma (DLBCL) and MM. There was a significant positive association between consumption of sugar and confectionary (PC11) and follicular lymphoma risk, and an inverse association between fish and shellfish and Vitamin D (PC15) and DLBCL risk. The PC1 including features of the Mediterranean diet and diet with lower inflammatory score showed an inverse association with BCL risk, while the PC7, including dairy, was positively associated with BCL and DLBCL risk. Physical activity (PC10) was positively associated with DLBCL risk among women. This study provided informative insights on the etiology of BCL., What's new? The “exposome” includes all non‐genetic exposures (e.g. diet, viral, environmental, etc.), with the goal of understanding how those exposures may affect an individual's health. In this study, the authors used a technique called “EWAS” (exposome‐wide association study) to identify multiple factors that are associated with B‐cell lymphoma (BCL) risk. Their results confirm both previously reported risk factors and protective factors. In addition, they identify several previously unknown associations. These new insights, gained via the analysis of multiple exposures, suggest that traditional single‐factor approaches may be suboptimal compared with an EWAS approach.
Published: 2020

17. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers

Author: Clara Bodelon, Anna H. Wu, V. Wendy Setiawan, Jenny Lester, Adriaan Vanderstichele, Daniela Annibali, Michael E. Carney, Jennifer A. Doherty, Shashikant Lele, Jacek Gronwald, Matthias W. Beckmann, George Fountzilas, Christine M. Friedenreich, Heli Nevanlinna, Immaculata De Vivo, Jolanta Lissowska, Soo Hwang Teo, Ahmad Alsulimani, Daniel D. Buchanan, Rosalind Glasspool, Domenico Palli, Madhuri Koti, Katja K.H. Aben, Tanja Pejovic, Linda S. Cook, Line Bjørge, Mia M. Gaudet, Anna Jakubowska, Tomasz Huzarski, Florian Heitz, Beth Y. Karlan, Andreas du Bois, Linda J. Titus, Joseph L. Kelley, Andrew Berchuck, Aleksandra Gentry-Maharaj, Florentia Fostira, Weiva Sieh, Anthony J. Swerdlow, Celeste Leigh Pearce, Constance Turman, Zhaoming Wang, Ignace Vergote, Dylan M. Glubb, Peter Hillemanns, Chu Chen, Tjoung-Won Park-Simon, Andrew J. Li, Susanne K. Kjaer, Jan Gawełko, Stephen J. Chanock, Tracy A. O'Mara, Elizabeth G. Holliday, Jessica N. McAlpine, Ailith Ewing, Amalia Mattiello, Pamela J. Thompson, Xifeng Wu, Alicia A. Tone, Ana Osorio, Fiona Bruinsma, Digna R. Velez Edwards, Janine Senz, Francesmary Modugno, Michael Jones, Sandra Orsulic, Xiaoqing Chen, Todd L. Edwards, Aurelio Barricarte, Hui Cai, Loren Lipworth, David G. Huntsman, Zhihua Chen, Alison M. Dunning, Julie M. Cunningham, Rosario Tumino, Melissa C. Larson, Ralf Bützow, Alison Brand, Allan Jensen, Marina Bermisheva, Reidun K. Kopperud, Beata Spiewankiewicz, Timothy R. Rebbeck, Bozena Konopka, Matthias Dürst, Thomas A. Sellers, Penelope M. Webb, Claus Høgdall, Anthony N. Karnezis, Håkan Olsson, Liv Cecilie Vestrheim Thomsen, Rodney J. Scott, Iain A. McNeish, Arif B. Ekici, Valerie McGuire, Lukasz Szafron, Harvey A. Risch, Bo Gao, Louise A. Brinton, Alessandra Macciotta, Anna deFazio, Rüdiger Klapdor, Graham G. Giles, Usha Menon, Marc T. Goodman, Robert P. Edwards, Robert A. Vierkant, Dong Liang, Shan Wang-Gohrke, Lingeng Lu, Kirsten B. Moysich, Holly R. Harris, Deborah J. Thompson, Jennifer B. Permuth, Alexander Hein, Thilo Dörk, Elza Khusnutdinova, Stefanie Burghaus, Irene Konstantopoulou, Stacey J. Winham, Susan J. Ramus, Agnieszka Podgorska, Rebecca Sutphen, Michelle A.T. Hildebrandt, Jolanta Kupryjanczyk, Ingo B. Runnebaum, James D. Brenton, Karen H. Lu, Katharina Bischof, Nadeem Siddiqui, Drakoulis Yannoukakos, Estrid Høgdall, John Attia, Clemens Liebrich, Loic Le Marchand, Emily White, Amanda B. Spurdle, Peter Kraft, Alice S. Whittemore, Kunle Odunsi, Sarah E. Ferguson, Taymaa May, Marjorie J. Riggan, Philipp Harter, Jeffrey Killeen, James M. Flanagan, Frédéric Amant, Marcus Q. Bernardini, Joseph H. Rothstein, Martin Köbel, Peter A. Fasching, and Diether Lambrechts
Subjects: Oncology, 0303 health sciences, medicine.medical_specialty, business.industry, Endometrial cancer, Genome-wide association study, medicine.disease, Genetic correlation, 3. Good health, 03 medical and health sciences, Serous fluid, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Epidemiology, medicine, Epithelial ovarian cancer, business, Clear cell, 030304 developmental biology, Genetic association
Abstract: Accumulating evidence suggests a relationship between endometrial cancer and epithelial ovarian cancer. For example, endometrial cancer and epithelial ovarian cancer share epidemiological risk factors and molecular features observed across histotypes are held in common (e.g. serous, endometrioid and clear cell). Independent genome-wide association studies (GWAS) for endometrial cancer and epithelial ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. Using GWAS summary statistics, we explored the shared genetic etiology between endometrial cancer and epithelial ovarian cancer. Genetic correlation analysis using LD Score regression revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10−5). To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e. inverse-variance meta-analysis, co-localization, and M-values), and performed analyses by stratified by subtype. We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10−9). In addition, four novel regions at 7p22.2, 7q22.1, 9p12 and 11q13.3 were identified at a sub-genome wide threshold (P < 5 × 10−7). Integration with promoter-associated HiChIP chromatin loops from immortalized endometrium and epithelial ovarian cell lines, and expression quantitative trait loci (eQTL) data highlighted candidate target genes for further investigation.
Published: 2020
Full Text: View/download PDF

18. Serum levels of hsa‐miR‐16‐5p , hsa‐miR‐29a‐3p , hsa‐miR‐150‐5p , hsa‐miR‐155‐5p and hsa‐miR ‐ 223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Author: Heiner Boeing, María Arestin, Aurelio Barricarte, Delphine Casabonne, Elio Riboli, Roel Vermeulen, Carlo La Vecchia, Alexandra Nieters, Federico Canzian, Julie A. Schmidt, Matthias B. Schulze, María Armesto, Rosario Tumino, Yolanda Benavente, Rudolf Kaaks, Salvatore Panico, María José Sánchez, Anna Karakatsani, Pilar Amiano, Caroline Besson, Marc J. Gunter, Giovanna Masala, Carlotta Sacerdote, María Dolores Chirlaque, Silvia de Sanjosé, Valeria Pala, Anne Tjønneland, Charles H. Lawrie, Antonia Trichopoulou, Elisabete Weiderpass, Eric J. Duell, Fatemeh Saberi Hosnijeh, Anja Olsen, Vittorio Perduca, Julia Seifert, Francesca Mancini, Laura Costas, CIBER de Epidemiología y Salud Pública (CIBERESP), Catalan Institute of Oncology (ICO-IDIBELL), Facultat de Medicina [Barcelona], Centre Hospitalier de Versailles André Mignot (CHV), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Gustave Roussy (IGR), Épidémiologie des radiations, épidémiologie clinique des cancers et survie (U1018 (Équipe 3) ), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Unit of Nutrition, Environment, and Cancer, Catalan Institute of Oncology, Department of Community Medicine, Faculty of Health Sciences, The Arctic University of Norway (UiT), Cancer Risk Factors and LifeStyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department of Cancer Epidemiology, Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS), Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan], WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens]-University of Athens Medical School [Athens], Hellenic Health Foundation, Department of Clinical Sciences and Community Health [Milan, Italy], Università degli Studi di Milano [Milano] (UNIMI), Civile - M.P.Arezzo Hospital, Nutrition and Metabolism Section, International Agency for Research on Cancer, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, CPO Piemonte, Department of Epidemiology, German Institute of Human Nutrition (DIfE), German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Danish Cancer Society Research Center, Danish Cancer Society, Division of Environmental Epidemiology, Utrecht University [Utrecht]-Institute of Risk Assessment Sciences, Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, Freiburg, Germany, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, and Immunology
Subjects: Oncology, Male, DOWN-REGULATION, Cancer Research, PROGNOSIS, Chronic lymphocytic leukemia, ACTIVATION, 0302 clinical medicine, mir-223, Odds Ratio, Prospective Studies, Prospective cohort study, ComputingMilieux_MISCELLANEOUS, Area under the curve, Middle Aged, MIR-155, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Up-Regulation, Europe, DIFFERENTIATION, INFECTIONS, 030220 oncology & carcinogenesis, embryonic structures, Monoclonal B-cell lymphocytosis, Female, B-CELL LYMPHOCYTOSIS, Life Sciences & Biomedicine, prospective study, EXPRESSION, medicine.medical_specialty, MICRORNA SIGNATURE, miR-155, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, medicine, Biomarkers, Tumor, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Liquid biopsy, Science & Technology, business.industry, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, body regions, circulating miRNA, MicroRNAs, Case-Control Studies, chronic lymphocytic leukemia, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, serum, CLL
Abstract: Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25–p75: 7–13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18–1.72), 1.64 (1.31–2.04) and 1.75 (1.31–2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve
Published: 2020

19. Plasma polyphenols associated with lower high-sensitivity C-reactive protein concentrations:a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Author: Harms, L.M., Scalbert, A., Zamora-Ros, R., Rinaldi, S., Jenab, M., Murphy, N., Achaintre, D., Tjønneland, A., Olsen, A., Overvad, K., Romana Mancini, F., Mahamat-Saleh, Y., Boutron-Ruault, M.-C., Kühn, T., Katzke, V., Trichopoulou, A., Martimianaki, G., Karakatsani, A., Palli, D., Panico, S., Sieri, S., Tumino, R., Sacerdote, C., Bueno-De-Mesquita, B., Vermeulen, R.C.H., Weiderpass, E., Nøst, T.H., Lasheras, C., Rodríguez-Barranco, M., Huerta, J.M., Barricarte, A., Dorronsoro, M., Hultdin, J., Gunter, M., Riboli, E., Aleksandrova, K., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), PI13/00061, PI13/01162 RD06/0020 6236 KrÃ¦ftens BekÃ¦mpelse, DCS Deutsches Krebsforschungszentrum, DKFZ Centre International de Recherche sur le Cancer, CIRC College of Environmental Science and Forestry, State University of New York, ESF National Research Council, NRC Medical Research Council, MRC: CP15/00100, MR/M012190/1 Cancer Research UK, CRUK: C8221/A19170 World Cancer Research Fund, WCRF: ERC-2009-AdG 232997 European Commission, EC Institut National de la SantÃ© et de la Recherche MÃ©dicale, Inserm Bundesministerium fÃ¼r Bildung und Forschung, BMBF Cancerfonden Ministerie van Volksgezondheid, Welzijn en Sport, VWS Ligue Contre le Cancer VetenskapsrÃ¥det, VR Instituto de Salud Carlos III, ISCIII NordForsk European Social Fund, ESF Associazione Italiana per la Ricerca sul Cancro, AIRC Deutsche Krebshilfe Mutuelle GÃ©nÃ©rale de l'Education Nationale, MGEN, The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK). R. Z.-R. is supported by the ‘Miguel Servet’ programme (CP15/00100) from the Institute of Health Carlos III and the European Social Fund (ESF).
Subjects: Male, 0301 basic medicine, Medicine (miscellaneous), Gastroenterology, Cohort Studies, chronic diseases, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Neoplasms, Caffeic acid, Medicine, Malalties cròniques, odds ratio, Prospective Studies, Prospective cohort study, Nutrition and Dietetics, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, biology, food and beverages, Full Papers, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Näringslära, Europe, hormone replacement therapy, Polifenols, Cohort, Female, standard deviation, Human and Clinical Nutrition, Cohort study, Adult, Plasma measurements, medicine.medical_specialty, 030209 endocrinology & metabolism, body mass index, Diet Surveys, C-reactive protein, 03 medical and health sciences, Internal medicine, Humans, polyphenols, Aged, Inflammation, 030109 nutrition & dietetics, business.industry, Daidzein, Polyphenols, Diet, cardiovascular diseases, Cross-Sectional Studies, Nutrition Assessment, chemistry, confidence interval, Polyphenol, plasma measurements, inflammation, Chronic diseases, randomized controlled trial, biology.protein, high-sensitivity C-reactive protein, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Biomarkers
Abstract: Experimental studies have reported on the anti-inflammatory properties of polyphenols. However, results from epidemiological investigations have been inconsistent and especially studies using biomarkers for assessment of polyphenol intake have been scant. We aimed to characterise the association between plasma concentrations of thirty-five polyphenol compounds and low-grade systemic inflammation state as measured by high-sensitivity C-reactive protein (hsCRP). A cross-sectional data analysis was performed based on 315 participants in the European Prospective Investigation into Cancer and Nutrition cohort with available measurements of plasma polyphenols and hsCRP. In logistic regression analysis, the OR and 95 % CI of elevated serum hsCRP (>3 mg/l) were calculated within quartiles and per standard deviation higher level of plasma polyphenol concentrations. In a multivariable-adjusted model, the sum of plasma concentrations of all polyphenols measured (per standard deviation) was associated with 29 (95 % CI 50, 1) % lower odds of elevated hsCRP. In the class of flavonoids, daidzein was inversely associated with elevated hsCRP (OR 0 center dot 66, 95 % CI 0 center dot 46, 0 center dot 96). Among phenolic acids, statistically significant associations were observed for 3,5-dihydroxyphenylpropionic acid (OR 0 center dot 58, 95 % CI 0 center dot 39, 0 center dot 86), 3,4-dihydroxyphenylpropionic acid (OR 0 center dot 63, 95 % CI 0 center dot 46, 0 center dot 87), ferulic acid (OR 0 center dot 65, 95 % CI 0 center dot 44, 0 center dot 96) and caffeic acid (OR 0 center dot 69, 95 % CI 0 center dot 51, 0 center dot 93). The odds of elevated hsCRP were significantly reduced for hydroxytyrosol (OR 0 center dot 67, 95 % CI 0 center dot 48, 0 center dot 93). The present study showed that polyphenol biomarkers are associated with lower odds of elevated hsCRP. Whether diet rich in bioactive polyphenol compounds could be an effective strategy to prevent or modulate deleterious health effects of inflammation should be addressed by further well-powered longitudinal studies.
Published: 2020

20. Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition

Author: Elisabete Weiderpass, Kim Overvad, Giovanna Masala, Guy Fagherazzi, Rudolf Kaaks, Daniel Redondo-Sánchez, Sabina Rinaldi, Ulrica Ericson, Dagfinn Aune, Pilar Amiano, Therese Haugdahl Nøst, Antonia Trichopoulou, Rosario Tumino, Paula Jakszyn, Neil Murphy, Elio Riboli, Tilman Kühn, Francesca Mancini, Heinz Freisling, Bas Bueno-de-Mesquita, Marie-Christine Boutron-Ruault, Maria Santucci de Magistris, Inge Huybrechts, Marc J. Gunter, Carlotta Sacerdote, Nathalie Kliemann, Christina C. Dahm, Vivian Viallon, Vittorio Krogh, Lena Maria Nilsson, Isabel Drake, Anne M. May, Heiner Boeing, Matthias B. Schulze, Carlo La Vecchia, Anne Tjønneland, Anna Karakatsani, Aurelio Barricarte Gurrea, Konstantinos K. Tsilidis, María Dolores Chirlaque, José Ramón Quirós, Centre international de Recherche sur le Cancer (CIRC), Université de Paris-Saclay [Villejuif], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Deutsche Krebshilfe Cancer Research UK, CRUK: C8221/A19170, 14136, C570/A16491 Ligue Contre le Cancer Bundesministerium für Bildung und Forschung, BMBF Bundesministerium für Bildung und Forschung, BMBF Institut National de la Santé et de la Recherche Médicale, Inserm Kræftens Bekæmpelse, DCS Research Councils UK, RCUK Health and Medical Research Fund, HMRF: FIS Zorginstituut Nederland, ZIN PI13/01162, PI13/00061 World Cancer Research Fund, WCRF: ERC‐2009‐AdG 232997 Associazione Italiana per la Ricerca sul Cancro, AIRC National Research Council, NRC Ecumenical Project for International Cooperation, EPIC Institut National de la Santé et de la Recherche Médicale, Inserm European Commission, EU Centre International de Recherche sur le Cancer, CIRC Norway Deutsches Krebsforschungszentrum, DKFZ: DKFZ World Cancer Research Fund, WCRF Cancerfonden NordForsk Medical Research Council, MRC: MR/M012190/1, 1000143, The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to thank Mr Bertrand Hemon for his support in preparing the databases and Dr Joseph Rothwell for his support in creating the figures. The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM, France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF, Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), ERC‐2009‐AdG 232997 and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS) of the Spanish Ministry of Health (FIS, PI13/00061 to Granada, PI13/01162 to EPIC‐Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra and the Catalan Institute of Oncology (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC‐Norfolk, C570/A16491 and C8221/A19170 to EPIC‐Oxford), Medical Research Council (1000143 to EPIC‐Norfolk, MR/M012190/1 to EPIC‐Oxford, and United Kingdom).
Subjects: Oncology, Adult, Male, metabolic disorder, Cancer Research, medicine.medical_specialty, obesity, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Humans, cancer, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Prospective Studies, Risk factor, Càncer, Nutrició, Aged, Cancer, Nutrition, Sex Characteristics, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Metabolic disorder, Middle Aged, medicine.disease, Obesity, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Nutrition Assessment, 030220 oncology & carcinogenesis, Basal metabolic rate, basal metabolic rate, Female, Basal Metabolism, business
Abstract: Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer risk. Therefore, we investigated the association of predicted BMR with incidence of 13 obesity-related cancers in the European Prospective Investigation into Cancer and Nutrition (EPIC). BMR at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR and cancer risk were investigated using multivariable Cox proportional hazards regression models. A total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been linked with obesity. However, among normal weight participants, higher BMR was associated with elevated risks of esophageal adenocarcinoma (hazard ratio per 1-standard deviation change in BMR [HR 1-SD]: 2.46; 95% CI 1.20; 5.03) and distal colon cancer (HR 1-SD: 1.33; 95% CI 1.001; 1.77) among men and with proximal colon (HR 1-SD: 1.16; 95% CI 1.01; 1.35), pancreatic (HR 1-SD: 1.37; 95% CI 1.13; 1.66), thyroid (HR 1-SD: 1.65; 95% CI 1.33; 2.05), postmenopausal breast (HR 1-SD: 1.17; 95% CI 1.11; 1.22) and endometrial (HR 1-SD: 1.20; 95% CI 1.03; 1.40) cancers in women. These results indicate that higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer types, and may be a useful predictor of cancer risk independent of body fatness.
Published: 2020

21. Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: AProspective Study in the EPIC Cohort

Author: Aurora Perez-Cornago, Veronica Sciannameo, Salvatore Panico, Domenico Palli, Pilar Amiano, Marit Waaseth, Tilman Kühn, Kay-Tee Khaw, Tanja Stocks, Fredrik Liedberg, Lambertus A. Kiemeney, Carla H. van Gils, Anne Tjønneland, Neil Murphy, María José Sánchez, Leila Lujan-Barroso, Christel Häggström, Amanda J. Cross, Heiner Boeing, Bas Bueno-de-Mesquita, Raul Zamora-Ros, Nina Roswall, Marc J. Gunter, Renée T. Fortner, Inger T. Gram, Kim Overvad, Vittorio Krogh, Börje Ljungberg, Amalia Mattiello, Eric J. Duell, Saverio Caini, Antonia Trichopoulou, Elisabete Weiderpass, Virginia Menéndez, Iris Cervenka, Rosario Tumino, Carmen Santiuste, Agnès Fournier, Edoardo Botteri, Aurelio Barricarte, Eleni Peppa, Eiliv Lund, Marina Kvaskoff, N. Charlotte Onland-Moret, and Anna Karakatsani
Subjects: 0301 basic medicine, Oncology, Epidemiology, IMPACT, THERAPY, 0302 clinical medicine, Pregnancy, Risk Factors, Prospective Studies, Child, Prospective cohort study, Reproductive History, 11 Medical and Health Sciences, Bladder cancer, WOMEN, ASSOCIATION, European Prospective Investigation into Cancer and Nutrition, Menstruation, ESTROGEN, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Cohort, Female, SMOKING, Developed country, EXPRESSION, medicine.medical_specialty, Adolescent, Hormone Replacement Therapy, Càncer de bufeta, DIET, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Humans, Menstrual Cycle, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, Proportional hazards model, business.industry, medicine.disease, Hormones, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, 030104 developmental biology, BLADDER-CANCER RISK, SEX-HORMONES, business, Hormone, Menstruació
Abstract: Background: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk. Methods: We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non–muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models. Results: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 = 0.48; 0.25–0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03–1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non–muscle-invasive urothelial carcinoma risk was observed. Conclusions: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk. Impact: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.
Published: 2020

22. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort

Author: Agnès Fournier, Eva Lundin, N. Charlotte Onland-Moret, Louise Hansen, Elisavet Valanou, Marina Kvaskoff, Leire Gil, Inger T. Gram, Rosario Tumino, Marc J. Gunter, Annika Idahl, Rudolf Kaaks, Noemi Bender, Eric J. Duell, María José Sánchez, Carlotta Sacerdote, Kristian Riesbeck, Sandra González Maldonado, Claudia Agnoli, Anne Tjønneland, Charlotte Le Cornet, Renée T. Fortner, Laure Dossus, Marie-Christine Boutron-Ruault, Elisabete Weiderpass, Antonia Trichopoulou, Amalia Mattiello, José Ramón Quirós, Aurelio Barricarte, Maria Dolores Chirlaque, Tim Waterboer, Eleni Peppa, Domenico Palli, Jenny Brändstedt, Kay-Tee Khaw, Aurora Perez-Cornago, Heiner Boeing, Umeå University, Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, Danish Cancer Society Research Center, Copenhagen, Denmark, parent, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Hellenic Health Foundation, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy, University of Naples Federico II, Civile - M.P.Arezzo Hospital, Center for Cancer Prevention (CPO-Piemonte), Universiteit Utrecht, Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway, Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France. Electronic address: steliarova@iarc.fr., Catalan Institute of Oncology (ICO-IDIBELL), Hospitales Universitarios de Granada/Universidad de Granada, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIB-Arrixaca [Murcia, Spain], Universidad de Murcia, Public Health Institute of Navarra, Pamplona, Spain, and CIBER Epidemiología y Salud Pública (CIBERESP), IdiSNA, Navarra Institute for Health Research, Public Health Division of Gipuzkoa, Institute BIO Donostia-Health Department, Skane University Hospital [Lund], Department of Translational Medicine [Malmö, Sweden] (Clinical Microbiology), Lund University [Lund, Sweden], University of Cambridge [UK] (CAM), University of Oxford [Oxford], Ministerie van Volksgezondheid, Welzijn en Sport, VWS Deutsche Krebshilfe Cancer Research UK, CRUK: C8221/A19170, C570/A16491 VetenskapsrÃ¥det, VR Ministerie van Volksgezondheid, Welzijn en Sport, VWS Ligue Contre le Cancer Bundesministerium fÃ¼r Bildung und Forschung, BMBF Bundesministerium fÃ¼r Bildung und Forschung, BMBF Institut National de la Santé et de la Recherche Médicale, Inserm KrÃ¦ftens BekÃ¦mpelse, DCS CAN 2016/545 German Cancer Research Center, DKFZ National Research Council, NRC Cancer Research Foundation in Northern Sweden European Commission, EC Centre International de Recherche sur le Cancer, IARC RD06/0020 German Cancer Research Center, DKFZ Cancerfonden PI13/01162, PI13/00061 World Cancer Research Fund, WCRF: ERC-2009-AdG 232997 NordForsk Associazione Italiana per la Ricerca sul Cancro, AIRC Medical Research Council, MRC: MR/M012190/1, This work was supported by grants from The Cancer Research Foundation in Northern Sweden and The County Council of V?sterbotten, Sweden, and the German Cancer Research Center. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Additional funding received from the Anna and Edwin Berger Foundation (K.R.), Malm? Hospital Cancer Foundation (K.R.), Cancerfonden (CAN 2016/545 to K.R.).
Subjects: Oncology, Cancer Research, endocrine system diseases, Càncer d'ovari, Chlamydia trachomatis, Mycoplasma genitalium, Carcinoma, Ovarian Epithelial, medicine.disease_cause, Serology, 0302 clinical medicine, Risk Factors, Pelvic inflammatory disease, Prospective Studies, human papillomavirus, Aged, 80 and over, Ovarian Neoplasms, Sexually transmitted diseases, Human papillomavirus 16, Chlamydia, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, biology, Public Health, Global Health, Social Medicine and Epidemiology, Middle Aged, female genital diseases and pregnancy complications, 3. Good health, Serous fluid, ovarian cancer, 030220 oncology & carcinogenesis, Female, Malalties de transmissió sexual, Adult, Risk, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Ovarian cancer, Internal medicine, medicine, Humans, Neoplastic transformation, Aged, business.industry, Papillomavirus Infections, Chlamydia Infections, biology.organism_classification, medicine.disease, herpes simplex virus, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, Relative risk, Case-Control Studies, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, Biomarkers
Abstract: International audience; A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
Published: 2020

23. Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition

Author: Aurelio Barricarte, Tilman Kühn, Nikos Papadimitriou, Rosario Tumino, Elio Riboli, Lena Maria Nilsson, Dimitrios Trichopoulos, Dagfinn Aune, Bas Bueno-de-Mesquita, Kim Overvad, Ruth C. Travis, Nerea Larrañaga, Bodil Hammer Bech, Peter Wallström, Antonia Trichopoulou, Christina Bamia, Maria Luisa Redondo, Heiner Boeing, Valerie Cayssials, Rudolf Kaaks, Carlotta Sacerdote, Anne Tjønneland, Ioanna Tzoulaki, Neil Murphy, Anna Karakatsani, Aurora Perez-Cornago, Rikard Landberg, Anastasia Kotanidou, Cecilie Kyrø, Sara Grioni, Pagona Lagiou, Saverio Caini, David S. Lopez, Heinz Freisling, Maria Dolores Chirlaque, Amanda J. Cross, Kay-Tee Khaw, Isabel Drake, Timothy J. Key, Konstantinos K. Tsilidis, Domenico Palli, Marc J. Gunter, David C. Muller, Abhijit Sen, Malene Outzen, Manuela M. Bergmann, and María José Sánchez
Subjects: Cancer Research, medicine.medical_specialty, business.industry, Proportional hazards model, Incidence (epidemiology), Hazard ratio, Cancer, medicine.disease, European Prospective Investigation into Cancer and Nutrition, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, Epidemiology, medicine, business, Cohort study
Abstract: The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
Published: 2018

24. Interaction between cardiovascular risk factors and body mass index and 10-year incidence of cardiovascular disease, cancer death, and overall mortality

Author: Miquel Quesada, Fernando Rigo, Fresco Investigators, Jesús Berjón, José Miguel Baena-Díez, Manel García-Lareo, María Grau, María Barroso, Aurelio Barricarte, David Lora-Pablos, Diana Gavrila, Rafel Ramos, Guillem Frontera, Agustín Gómez de la Cámara, Eduardo Mayoral, María Jesús Guembe, Alejandro Marín-Ibañez, Antonio Segura, José María García, María José Tormo-Díaz, Albert Goday, Josep Basora, José Lapetra, María José Medrano, Jaume Marrugat, J.J. Cabré, and Conchi Moreno-Iribas
Subjects: Adult, Male, medicine.medical_specialty, Epidemiology, Disease, 030204 cardiovascular system & hematology, Overweight, Body Mass Index, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Cor -- Malalties, Risk Factors, Neoplasms, Cause of Death, Internal medicine, Mortalitat, medicine, Humans, Longitudinal Studies, Obesity, 030212 general & internal medicine, Mortality, Càncer, Epidemiologia, Body mass index, Aged, Tumors, Cause of death, Malalties cardiovasculars, business.industry, Incidence, Hazard ratio, Public Health, Environmental and Occupational Health, Cancer, Middle Aged, Cardiovascular disease, medicine.disease, Cardiovascular diseases, Cardiovascular Diseases, Spain, Obesitat, Female, medicine.symptom, business
Abstract: The effect of above-normal body mass index (BMI) on health outcomes is controversial because it is difficult to distinguish from the effect due to BMI-associated cardiovascular risk factors. The objective was to analyze the impact on 10-year incidence of cardiovascular disease, cancer deaths and overall mortality of the interaction between cardiovascular risk factors and BMI. We conducted a pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35-79years old at basal examination. Body mass index was measured at baseline being the outcome measures ten-year cardiovascular disease, cancer and overall mortality. Multivariable analyses were adjusted for potential confounders, considering the significant interactions with cardiovascular risk factors. We included 54,446 individuals (46.5% with overweight and 27.8% with obesity). After considering the significant interactions, the 10-year risk of cardiovascular disease was significantly increased in women with overweight and obesity [Hazard Ratio=2.34 (95% confidence interval: 1.19-4.61) and 5.65 (1.54-20.73), respectively]. Overweight and obesity significantly increased the risk of cancer death in women [3.98 (1.53-10.37) and 11.61 (1.93-69.72)]. Finally, obese men had an increased risk of cancer death and overall mortality [1.62 (1.03-2.54) and 1.34 (1.01-1.76), respectively]. In conclusion, overweight and obesity significantly increased the risk of cancer death and of fatal and non-fatal cardiovascular disease in women; whereas obese men had a significantly higher risk of death for all causes and for cancer. Cardiovascular risk factors may act as effect modifiers in these associations.
Published: 2018

25. Pre-diagnostic copper and zinc biomarkers and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort

Author: Magdalena Czuban, Verena Katzke, Hendrik B. Bueno-de-Mesquita, Domenico Palli, Kim Overvad, Lutz Schomburg, Christina Bamia, Tilman Kühn, Francesca Mancini, Amanda J. Cross, Behany van Guelpen, Heinz Freisling, Nicholas J. Wareham, José María Huerta, Kay-Tee Khaw, Alessio Naccarati, David J. Hughes, Mazda Jenab, María José Sánchez, Magdalena Stepien, Kathryn E. Bradbury, Petra H.M. Peeters, Rosario Tumino, Sabina Sieri, Khalid Iqbal, Anja Olsen, Anne Tjønneland, Susana Merino, Aurelio Barricarte, Isabelle Savoye, Antonia Trichopoulou, Philippos Orfanos, Elisabete Weiderpass, Miren Dorronsoro, Niels-Peter Becker, Heiner Boeing, Stina Bodén, Salvatore Panico, Paula Jakszyn, Marie-Christine Boutron-Ruault, Stepien, Magdalena, Jenab, Mazda, Freisling, Heinz, Becker, Niels peter, Czuban, Magdalena, Tjã¸nneland, Anne, Olsen, Anja, Overvad, Kim, Boutron ruault, Marie christine, Mancini, Francesca Romana, Savoye, Isabelle, Katzke, Verena, Kã¼hn, Tilman, Boeing, Heiner, Iqbal, Khalid, Trichopoulou, Antonia, Bamia, Christina, Orfanos, Philippo, Palli, Domenico, Sieri, Sabina, Tumino, Rosario, Naccarati, Alessio, Panico, Salvatore, Bueno de mesquita, H. B., Peeters, Petra H., Weiderpass, Elisabete, Merino, Susana, Jakszyn, Paula, Sanchez, Maria jose, Dorronsoro, Miren, Huerta, Josã© Marãa, Barricarte, Aurelio, Boden, Stina, Van Guelpen, Behany, Wareham, Nick, Khaw, Kay tee, Bradbury, Kathryn E., Cross, Amanda J., Schomburg, Lutz, Hughes, David J., Wareham, Nicholas [0000-0003-1422-2993], Khaw, Kay-Tee [0000-0002-8802-2903], and Apollo - University of Cambridge Repository
Subjects: 0301 basic medicine, Oncology, Male, Cancer Research, Colorectal cancer, diagnosis, Colorectal Neoplasm, SERUM, 0302 clinical medicine, Risk Factors, follow-up, Medicine, Prospective Studies, Prospective cohort study, General Medicine, Middle Aged, Micronutrient, European Prospective Investigation into Cancer and Nutrition, Zinc, 030220 oncology & carcinogenesis, Cohort, Female, Case-Control Studie, Colorectal Neoplasms, Life Sciences & Biomedicine, HUMAN PHYSIOLOGY, biological markers, Human, medicine.medical_specialty, European Continental Ancestry Group, colorectal cancer, HEME IRON, White People, 03 medical and health sciences, RATIO, Breast cancer, nutrition in cancer, DIAGNOSTIC-VALUE, Internal medicine, SELENIUM STATUS, TRACE-ELEMENTS, Journal Article, Biomarkers, Tumor, BREAST-CANCER, Humans, Oncology & Carcinogenesis, RECTAL-CANCER, Aged, Science & Technology, copper measurement, business.industry, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, Risk Factor, Case-control study, Oxidative Stre, Odds ratio, medicine.disease, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, Prospective Studie, Oxidative Stress, 030104 developmental biology, Case-Control Studies, Immunology, business, 1112 Oncology And Carcinogenesis, Copper
Abstract: Adequate intake of copper and zinc, two essential micronutrients, are important for antioxidant functions. Their imbalance may have implications for development of diseases like colorectal cancer (CRC), where oxidative stress is thought to be etiologically involved. As evidence from prospective epidemiologic studies is lacking, we conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to investigate the association between circulating levels of copper and zinc, and their calculated ratio, with risk of CRC development. Copper and zinc levels were measured by reflection X-ray fluorescence spectrometer in 966 cases and 966 matched controls. Multivariable adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression and are presented for the fifth versus first quintile. Higher circulating concentration of copper was associated with a raised CRC risk (OR = 1.50; 95% CI: 1.06, 2.13; P-trend = 0.02) whereas an inverse association with cancer risk was observed for higher zinc levels (OR = 0.65; 95% CI: 0.43, 0.97; P-trend = 0.07). Consequently, the ratio of copper/zinc was positively associated with CRC (OR = 1.70; 95% CI: 1.20, 2.40; P-trend = 0.0005). In subgroup analyses by follow-up time, the associations remained statistically significant only in those diagnosed within 2 years of blood collection. In conclusion, these data suggest that copper or copper levels in relation to zinc (copper to zinc ratio) become imbalanced in the process of CRC development. Mechanistic studies into the underlying mechanisms of regulation and action are required to further examine a possible role for higher copper and copper/zinc ratio levels in CRC development and progression.
Published: 2018
Full Text: View/download PDF

26. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort

Author: J. R. Quirós, Weimin Ye, Aurelio Barricarte, Petra H.M. Peeters, Isabelle Romieu, M-D Chirlaque, Hendrik B. Bueno-de-Mesquita, Verena Katzke, K. T. Khaw, Marc J. Gunter, Timothy J. Key, Paolo Vineis, Franck Carbonnel, Bertrand Hémon, H. Boeing, M. C. Boutron-Ruault, Claudia Agnoli, Rudolf Kaaks, Aurora Perez-Cornago, Eric J. Duell, D. Palli, Anne Laure Renault, M-J Sanchez, Salvatore Panico, Pilar Amiano, Marco Matejcic, R. Tumino, Sahar Yammine, Veronique Chajes, Miquel Porta, Tilman Kühn, Carlotta Sacerdote, Vinciane Rebours, Pekka Keski-Rahkonen, Antonia Trichopoulou, Elisabete Weiderpass, Fabienne Lesueur, Carine Biessy, Elio Riboli, Kuanrong Li, Noura Mebirouk, Matejcic, M, Lesueur, F, Biessy, C, Renault, A L, Mebirouk, N, Yammine, S, Keski-Rahkonen, P, Li, K, Hémon, B, Weiderpass, E, Rebours, V, Boutron-Ruault, M C, Carbonnel, F, Kaaks, R, Katzke, V, Kuhn, T, Boeing, H, Trichopoulou, A, Palli, D, Agnoli, C, Panico, S, Tumino, R, Sacerdote, LAURA LEA, Quirós, J R, Duell, E J, Porta, M, Sánchez, M J, Chirlaque, M D, Barricarte, A, Amiano, P, Ye, W, Peeters, P H, Khaw, K T, Perez-Cornago, A, Key, T J, Bueno-de-Mesquita, H B, Riboli, E, Vineis, P, Romieu, I, Gunter, M J, and Chajès, V
Subjects: Male, 0301 basic medicine, FOOD-INTAKE, Cancer Research, pancreatic cancer, Gastroenterology, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Phospholipids, ASSOCIATIONS, chemistry.chemical_classification, INDUCTION, Incidence, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Europe, Oncology, 030220 oncology & carcinogenesis, Cohort, F344 RATS, biomarker, GROWTH, NUTRITION, Female, Heptadecanoic acid, HEALTH, Docosapentaenoic acid, Life Sciences & Biomedicine, Polyunsaturated fatty acid, Adult, Risk, medicine.medical_specialty, CARCINOMA, plasma phospholipids, Lower risk, fatty acids, OVARIAN-CANCER, DIET, 03 medical and health sciences, Pancreatic cancer, Internal medicine, medicine, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, tobacco smoking, Aged, Science & Technology, 030109 nutrition & dietetics, business.industry, plasma phospholipid, biomarkers, Odds ratio, medicine.disease, Pancreatic Neoplasms, chemistry, Case-Control Studies, fatty acid, business
Abstract: There are both limited and conflicting data on the role of dietary fat and specific fatty acids in the development of pancreatic cancer. In this study, we investigated the association between plasma phospholipid fatty acids and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The fatty acid composition was measured by gas chromatography in plasma samples collected at recruitment from 375 incident pancreatic cancer cases and 375 matched controls. Associations of specific fatty acids with pancreatic cancer risk were evaluated using multivariable conditional logistic regression models with adjustment for established pancreatic cancer risk factors. Statistically significant inverse associations were found between pancreatic cancer incidence and levels of heptadecanoic acid (ORT3-T1 [odds ratio for highest versus lowest tertile] =0.63; 95%CI[confidence interval]=0.41-0.98; Ptrend =0.036), n-3 polyunsaturated α-linolenic acid (ORT3-T1 =0.60; 95%CI=0.39-0.92; Ptrend =0.02) and docosapentaenoic acid (ORT3-T1 =0.52; 95%CI=0.32-0.85; Ptrend =0.008). Industrial trans-fatty acids were positively associated with pancreatic cancer risk among men (ORT3-T1 =3.00; 95%CI=1.13-7.99; Ptrend =0.029), while conjugated linoleic acids were inversely related to pancreatic cancer among women only (ORT3-T1 =0.37; 95%CI=0.17-0.81; Ptrend =0.008). Among current smokers, the long-chain n-6/n-3 polyunsaturated fatty acids ratio was positively associated with pancreatic cancer risk (ORT3-T1 =3.40; 95%CI=1.39-8.34; Ptrend =0.007). Results were robust to a range of sensitivity analyses. Our findings suggest that higher circulating levels of saturated fatty acids with an odd number of carbon atoms and n-3 polyunsaturated fatty acids may be related to lower risk of pancreatic cancer. The influence of some fatty acids on the development of pancreatic cancer may be sex-specific and modulated by smoking. This article is protected by copyright. All rights reserved.
Published: 2018

27. Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition

Author: Oskar Hemmingsson, Renée T. Fortner, Marit B. Veierød, Catalina Bonet, Marc J. Gunter, Marina Kvaskoff, Sabina Rinaldi, Susana Merino, Aurelio Barricarte, Kim Overvad, Heiner Boeing, Domenico Palli, Dagfinn Aune, Nerea Larrañaga, Timothy J. Key, José María Huerta, H. Bas Bueno-de-Mesquita, Yahya Mahamat-Saleh, Rudolf Kaaks, Iris Cervenka, Konstantinos K. Tsilidis, Kay-Tee Khaw, Alexander J. Stratigos, Sarah Tipper, Ingrid Ljuslinder, Petra H.M. Peeters, Rosario Tumino, Jytte Halkjær, Salvatore Panico, Ruth C. Travis, Fabrice Bonnet, Paul N. Appleby, Giuseppe Matullo, Carlo La Vecchia, Sara Grioni, Nicholas J. Wareham, Elio Riboli, Reza Ghiasvand, Tanja Stocks, Elena Molina, Kathryn E. Bradbury, Naomi E. Allen, Karolin Isaksson, Antonia Trichopoulou, Elisabete Weiderpass, Anne Tjønneland, Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Faculty of Medicine, World Cancer Research Fund International, Bradbury, Kathryn E, Appleby, Paul N, Tipper, Sarah J, Travis, Ruth C, Allen, Naomi E, Kvaskoff, Marina, Overvad, Kim, Tjønneland, Anne, Halkjaer, Jytte, Cervenka, Iri, Mahamat-Saleh, Yahya, Bonnet, Fabrice, Kaaks, Rudolf, Fortner, Renée T, Boeing, Heiner, Trichopoulou, Antonia, La Vecchia, Carlo, Stratigos, Alexander J, Palli, Domenico, Grioni, Sara, Matullo, Giuseppe, Panico, Salvatore, Tumino, Rosario, Peeters, Petra H, Bueno-de-Mesquita, H Ba, Ghiasvand, Reza, Veierød, Marit B, Weiderpass, Elisabete, Bonet, Catalina, Molina, Elena, Huerta, José M, Larrañaga, Nerea, Barricarte, Aurelio, Merino, Susana, Isaksson, Karolin, Stocks, Tanja, Ljuslinder, Ingrid, Hemmingsson, Oskar, Wareham, Nick, Khaw, Kay-Tee, Gunter, Marc J, Rinaldi, Sabina, Tsilidis, Konstantinos K, Aune, Dagfinn, Riboli, Elio, Key, Timothy J, Bradbury, Kathryn E [0000-0003-3345-7333], Kvaskoff, Marina [0000-0002-4557-3772], La Vecchia, Carlo [0000-0003-1441-897X], Palli, Domenico [0000-0002-5558-2437], Matullo, Giuseppe [0000-0003-0674-7757], Veierød, Marit B [0000-0002-2083-2758], Ljuslinder, Ingrid [0000-0002-5046-1820], Rinaldi, Sabina [0000-0002-6846-1204], and Apollo - University of Cambridge Repository
Subjects: Oncology, Male, Cancer Research, CUTANEOUS MELANOMA, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, Insulina, Odds Ratio, Insulin, Prospective cohort study, Càncer, Breast Neoplasms/etiology, INDEX, Cancer, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, Melanoma, Melanoma/etiology, insulin-like growth factor I, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, IGF-I, Europe, Insulin-Like Growth Factor I/metabolism, 030220 oncology & carcinogenesis, Cohort, biomarker, Female, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, 3122 Cancers, Nutritional Status, Breast Neoplasms, 03 medical and health sciences, Internal medicine, medicine, Journal Article, melanoma, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Nutrició, METAANALYSIS, Nutrition, Aged, Science & Technology, Nutritional Status/physiology, business.industry, Kirurgi, Case-control study, Prostatic Neoplasms, Odds ratio, medicine.disease, Confidence interval, prospective studies, Prostatic Neoplasms/etiology, Case-Control Studies, Cutaneous melanoma, CELLS, EPIC, height, Surgery, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business
Abstract: Source at https://doi.org/10.1002/ijc.31854. Insulin‐like growth factor‐I (IGF‐I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF‐I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF‐I concentrations and melanoma risk. A nested case–control study of 1,221 melanoma cases and 1,221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF‐I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF‐I concentration and melanoma risk (OR for highest vs lowest fifth = 0.93 [95% confidence interval [CI]: 0.71 to 1.22]). There was no significant heterogeneity in the association between IGF‐I concentrations and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF‐I measured in adulthood and the risk of melanoma.
Published: 2018

28. Prediction of acute myeloid leukaemia risk in healthy individuals

Author: Aurelio Barricarte, Claire Hardy, Kristian M. Bowles, Abigail Britten, Mattias Johansson, Sabina Sieri, Kay-Tee Khaw, Sagi Abelson, Philip A. Beer, Stanley W.K. Ng, Matthieu Foll, Lee Timms, Diana Hoult, Salvatore Panico, Shabina Hayat, Elena Salamanca-Fernández, Paul M. Krzyzanowski, Rosario Tumino, Noam Barda, José María Huerta, Lawrence E. Heisler, Jean C.Y. Wang, Inigo Martincorena, Mark D. Minden, Robert Luben, John E. Dick, Trevor J. Pugh, Sam Behjati, Anna Karakatsani, Philip Awadalla, Carlo La Vecchia, Zhen Zhao, Ruth C. Travis, Iulia Cirlan, Omer Weissbrod, Giovanna Masala, Heiner Boeing, Rui Costa, Elio Riboli, Nicholas J. Wareham, Calli Latimer, Philip C. Zuzarte, David T. Jones, Ting Ting Wang, J. Ramón Quirós, Grace Collord, Peter J. Campbell, Roel Vermeulen, Yogi Sundaravadanam, Elli Papaemmanuil, Antonia Trichopoulou, Ran D. Balicer, James McKay, Alwin Krämer, Jessica Miller, Keiran Raine, Jenna Eagles, Paolo Vineis, Netta Mendelson Cohen, Silvia Polidoro, Scott V. Bratman, Amos Tanay, Moritz Gerstung, George S. Vassiliou, Paul Brennan, Eran Segal, Karen Ng, Rudolf Kaaks, Núria Sala, David Soave, Faridah Mbabaali, Danielle Pasternack, Liran I. Shlush, John Douglas Mcpherson, Elisabeth Niemeyer, One Health Chemisch, dIRAS RA-2, Abelson, Sagi, Collord, Grace, Ng, Stanley W K, Weissbrod, Omer, Mendelson Cohen, Netta, Niemeyer, Elisabeth, Barda, Noam, Zuzarte, Philip C, Heisler, Lawrence, Sundaravadanam, Yogi, Luben, Robert, Hayat, Shabina, Wang, Ting Ting, Zhao, Zhen, Cirlan, Iulia, Pugh, Trevor J, Soave, David, Ng, Karen, Latimer, Calli, Hardy, Claire, Raine, Keiran, Jones, David, Hoult, Diana, Britten, Abigail, Mcpherson, John D, Johansson, Mattia, Mbabaali, Faridah, Eagles, Jenna, Miller, Jessica K, Pasternack, Danielle, Timms, Lee, Krzyzanowski, Paul, Awadalla, Philip, Costa, Rui, Segal, Eran, Bratman, Scott V, Beer, Philip, Behjati, Sam, Martincorena, Inigo, Wang, Jean C Y, Bowles, Kristian M, Quirós, J Ramón, Karakatsani, Anna, La Vecchia, Carlo, Trichopoulou, Antonia, Salamanca-Fernández, Elena, Huerta, José M, Barricarte, Aurelio, Travis, Ruth C, Tumino, Rosario, Masala, Giovanna, Boeing, Heiner, Panico, Salvatore, Kaaks, Rudolf, Krämer, Alwin, Sieri, Sabina, Riboli, Elio, Vineis, Paolo, Foll, Matthieu, Mckay, Jame, Polidoro, Silvia, Sala, Núria, Khaw, Kay-Tee, Vermeulen, Roel, Campbell, Peter J, Papaemmanuil, Elli, Minden, Mark D, Tanay, Amo, Balicer, Ran D, Wareham, Nicholas J, Gerstung, Moritz, Dick, John E, Brennan, Paul, Vassiliou, George S, Shlush, Liran I, Italian Institute for Genomic Medicine IIGM, Collord, Grace [0000-0003-1924-4411], Luben, Robert [0000-0002-5088-6343], Khaw, Kay-Tee [0000-0002-8802-2903], Wareham, Nicholas [0000-0003-1422-2993], Vassiliou, George [0000-0003-4337-8022], and Apollo - University of Cambridge Repository
Subjects: 0301 basic medicine, Oncology, Myeloid, Male, 0302 clinical medicine, Models, hemic and lymphatic diseases, Prevalence, 2.1 Biological and endogenous factors, Electronic Health Records, Aetiology, Cells, Cultured, Cancer, Pediatric, screening and diagnosis, Multidisciplinary, Leukemia, Incidence (epidemiology), Age Factors, CLONAL HEMATOPOIESIS, Hematology, Middle Aged, CANCER, 3. Good health, Multidisciplinary Sciences, Haematopoiesis, Detection, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Myeloid leukemia, Health, 030220 oncology & carcinogenesis, Cohort, Disease Progression, Science & Technology - Other Topics, Female, Adult, medicine.medical_specialty, Pediatric Cancer, Childhood Leukemia, General Science & Technology, Leucèmia mieloide, MODELS, Acute, Risk Assessment, CLASSIFICATION, Article, 03 medical and health sciences, Rare Diseases, Genetic, Cancer stem cell, Internal medicine, MD Multidisciplinary, medicine, Genetics, Mortalitat, Humans, Genetic Predisposition to Disease, Progenitor cell, Mortality, neoplasms, Aged, Science & Technology, Models, Genetic, business.industry, Prevention, SOMATIC MUTATIONS, medicine.disease, EVOLUTION, Hematopoiesis, 4.1 Discovery and preclinical testing of markers and technologies, 030104 developmental biology, Good Health and Well Being, Mutagenesis, Mutation, PATTERNS, Bone marrow, business
Abstract: The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure(1). The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion(2,3). However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH)(4-8). Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age- and gender-matched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.
Published: 2018

29. A Prospective Evaluation of Plasma Polyphenol Levels and Colon Cancer Risk

Author: Aurelio Barricarte, Marc J. Gunter, Amanda J. Cross, Eleni Peppa, H. B. Bueno-De-Mesquita, Cecilie Kyrø, Augustin Scalbert, J. Ramón Quirós, Isabelle Savoye, José María Huerta, Tilman Kühn, Heiner Boeing, Marie-Christine Boutron-Ruault, Ingegerd Johansson, Salvatore Panico, Martin Rutegård, Carlotta Sacerdote, Kim Overvad, Kostas Tsilidis, Rosario Tumino, Neil Murphy, Raul Zamora-Ros, Anne Tjønneland, Mazda Jenab, Heinz Freisling, Hwayoung Noh, Aurora Perez-Cornago, María José Sánchez, Franck Carbonnel, Antonia Trichopoulou, David Achaintre, Paolo Vineis, Jone M. Altzibar, Kathryn E. Bradbury, Krasimira Aleksandrova, Sara Grioni, Petra H.M. Peeters, Rudolf Kaaks, Anna Karakatsani, Domenico Palli, Kay-Tee Khaw, Murphy, Neil, Achaintre, David, Zamora-Ros, Raul, Jenab, Mazda, Boutron-Ruault, Marie-Christine, Carbonnel, Franck, Savoye, Isabelle, Kaaks, Rudolf, Kühn, Tilman, Boeing, Heiner, Aleksandrova, Krasimira, Tjønneland, Anne, Kyrø, Cecilie, Overvad, Kim, Quirós, J Ramón, Sánchez, Maria-Jose, Altzibar, Jone M, María Huerta, José, Barricarte, Aurelio, Khaw, Kay-Tee, Bradbury, Kathryn E, Perez-Cornago, Aurora, Trichopoulou, Antonia, Karakatsani, Anna, Peppa, Eleni, Palli, Domenico, Grioni, Sara, Tumino, Rosario, Sacerdote, Carlotta, Panico, Salvatore, Bueno-de-Mesquita, H B A, Peeters, Petra H, Rutegård, Martin, Johansson, Ingegerd, Freisling, Heinz, Noh, Hwayoung, Cross, Amanda J, Vineis, Paolo, Tsilidis, Kosta, Gunter, Marc J, and Scalbert, Augustin
Subjects: 0301 basic medicine, Oncology, Male, Cancer Research, Colorectal cancer, Prospective evaluation, COLORECTAL-CANCER, Body Mass Index, EPIC COHORT, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, nested case-control study, Risk Factors, Prospective Studies, Biochemical markers, food and beverages, Biological activity, Equol, Middle Aged, Prognosis, PROSTATE-CANCER, Estudi de casos, colon cancer, 030220 oncology & carcinogenesis, Polifenols, Colonic Neoplasms, Marcadors bioquímics, biomarker, NUTRITION, Female, Life Sciences & Biomedicine, EQUOL, Cancer Epidemiology, FLAVONOID INTAKE, medicine.medical_specialty, ESTROGEN-RECEPTOR-BETA, PHENOL-EXPLORER DATABASE, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Càncer colorectal, Internal medicine, SYSTEMATIC ANALYSIS, medicine, Biomarkers, Tumor, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, METAANALYSIS, Estrogen receptor beta, polyphenols, Cancer och onkologi, Science & Technology, business.industry, biomarkers, nested case–control study, medicine.disease, digestive system diseases, 030104 developmental biology, chemistry, Polyphenol, Case-Control Studies, Cancer and Oncology, Nested case-control study, Case studies, business, EPIC, Follow-Up Studies
Abstract: Polyphenols have been shown to exert biological activity in experimental models of colon cancer; however, human data linking specific polyphenols to colon cancer is limited. We assessed the relationship between pre‐diagnostic plasma polyphenols and colon cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Using high pressure liquid chromatography coupled to tandem mass spectrometry, we measured concentrations of 35 polyphenols in plasma from 809 incident colon cancer cases and 809 matched controls. We used multivariable adjusted conditional logistic regression models that included established colon cancer risk factors. The false discovery rate (q values) was computed to control for multiple comparisons. All statistical tests were two‐sided. After false discovery rate correction and in continuous log2‐transformed multivariable models, equol (odds ratio [OR] per log2‐value, 0.86, 95% confidence interval [95% CI] = 0.79–0.93; q value = 0.01) and homovanillic acid (OR per log2‐value, 1.46, 95% CI = 1.16–1.84; q value = 0.02) were associated with colon cancer risk. Comparing extreme fifths, equol concentrations were inversely associated with colon cancer risk (OR = 0.61, 95% CI = 0.41–0.91, p trend = 0.003), while homovanillic acid concentrations were positively associated with colon cancer development (OR = 1.72, 95% CI = 1.17–2.53, p trend, What's new? Polyphenols are antioxidants abundant in food, and some polyphenols have demonstrated an anti‐cancer effect. Here, the authors looked for an association between polyphenols and colon cancer risk by conducting a nested case–control analysis within the EPIC cohort. Rather than employing questionnaires that rely on participant memories of their diet, this study directly measured 35 polyphenols in plasma samples and compared them with colon cancer risk. Only 2 chemicals showed any association. Concentrations of equol, which is metabolized from soy foods, were inversely associated with colon cancer risk. Higher levels of homovanillic acid, on the other hand, were associated with increased risk.
Published: 2018

30. Prospective analysis of circulating metabolites and endometrial cancer risk

Author: Alicia K Heath, Eirini Kouloura, Pilar Amiano, Joseph A. Rothwell, Marta Crous-Bou, Konstantinos K. Tsilidis, Melissa A. Merritt, Julie A. Schmidt, Lucie Lécuyer, María José Sánchez, Rosario Tumino, Domenico Palli, Hector C. Keun, Marc J. Gunter, Roel Vermeulen, Matthias B. Schulze, Inger T. Gram, Laure Dossus, Amalia Mattiello, Aurelio Barricarte Gurrea, Sandra Colorado-Yohar, Therese Haugdahl Nøst, Ruth C. Travis, Gianluca Severi, Carlotta Sacerdote, Claudia Agnoli, Naomi E. Allen, Elisabete Weiderpass, Alexandros P. Siskos, Carine Biessy, Vivian Viallon, Renée T. Fortner, Rudolf Kaaks, Niki Dimou, Sofia Christakoudi, Sabina Rinaldi, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, International Agency for Cancer Research (IACR), Imperial College London, European Food Safety Authority (EFSA), University of Hawai'i [Honolulu] (UH), Nuffield Department of Population Health [Oxford], University of Oxford [Oxford], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University Hospital of North Norway [Tromsø] (UNN), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University of Potsdam, Harvard T.H. Chan School of Public Health, University of Granada [Granada], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute for Cancer Research, Prevention and Clinical Network (ISPRO), IRCCS Istituto Nazionale dei Tumori [Milano], Provincial Health Authority (ASP 7) [Ragusa, Italy], University Hospital Città della Salute e della Scienza di Torino, University of Naples Federico II, Utrecht University [Utrecht], Kræftens Bekæmpelse, DCS, Deutsches Krebsforschungszentrum, DKFZ, Centre International de Recherche sur le Cancer, CIRC, Academy of Pharmaceutical Sciences, APS, National Research Council, NRC, Imperial Experimental Cancer Medicine Centre, ECMC, University of Maryland School of Public Health, SPH, Medical Research Council, MRC: MR/M012190/1, Cancer Research UK, CRUK: C19335/A21351, C8221/ A29017, World Cancer Research Fund, WCRF, Institut National de la Santé et de la Recherche Médicale, Inserm, Bundesministerium für Bildung und Forschung, BMBF, Cancerfonden, Ministerie van Volksgezondheid, Welzijn en Sport, VWS, Ligue Contre le Cancer, Vetenskapsrådet, VR, Instituto de Salud Carlos III, ISCIII, Associazione Italiana per la Ricerca sul Cancro, AIRC, Deutsche Krebshilfe, Institut Gustave-Roussy, Mutuelle Générale de l'Education Nationale, MGEN, NIHR Imperial Biomedical Research Centre, BRC, This work was supported by Cancer Research UK (CRUK) (grant number C19335/A21351, to MJG and HK).The metabolomics infrastructure in the Division of Cancer, Imperial College London is supported by the Imperial College Experimental Cancer Medicine Centre, the Imperial College Cancer Research UK Centre and the NIHR Imperial Biomedical Research Centre (APS & HK). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G?n?rale de l'Education Nationale, Institut National de la Sant? et de la Recherche M?dicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc?a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Sk?ne and V?sterbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford). (United Kingdom)., The metabolomics infrastructure in the Division of Cancer, Imperial College London is supported by the Imperial College Experimental Cancer Medicine Centre , the Imperial College Cancer Research UK Centre and the NIHR Imperial Biomedical Research Centre (APS & HK). The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics , School of Public Health , Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC) . The national cohorts are supported by: Danish Cancer Society (Denmark), Ligue Contre le Cancer , Institut Gustave Roussy , Mutuelle Générale de l'Education Nationale , Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds , Dutch Prevention Funds , Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) , Statistics Netherlands (The Netherlands), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII) , Regional Governments of Andalucía, Asturias , Basque Country, Murcia and Navarra , and the Catalan Institute of Oncology - ICO (Spain), Swedish Cancer Society , Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK ( 14136 to EPIC-Norfolk, C8221/ A29017 to EPIC-Oxford), Medical Research Council ( 1000143 to EPIC-Norfolk, This work was supported by Cancer Research UK (CRUK) (grant number C19335/A21351 , to MJG and HK)., University of Oxford, University of Naples Federico II = Università degli studi di Napoli Federico II, Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino, Universidad de Granada = University of Granada (UGR), University of Potsdam = Universität Potsdam, HAL UVSQ, Équipe, Cancer Research UK, and Imperial College Healthcare NHS Trust- BRC Funding
Subjects: 0301 basic medicine, Trastorns del metabolisme, [SDV]Life Sciences [q-bio], BMI, body mass index, NIST, National Institute of Standards and Technology, Body Mass Index, Serine, 0302 clinical medicine, Endometrial cancer, Risk Factors, WC, waist circumference, LC-MS/MS, liquid chromatography-tandem mass spectrometry, Prospective Studies, 2. Zero hunger, SPHINGOMYELIN, Endometrial Neoplasms/blood, Sphingomyelins/blood, Obstetrics & Gynecology, Obstetrics and Gynecology, C0, free carnitine, Middle Aged, Lipids, MHT, menopausal hormone therapy, AMINO-ACID, Sphingomyelins, 3. Good health, European Prospective Investigation into Cancer and Nutrition, [SDV] Life Sciences [q-bio], Disorders of metabolism, Oncology, 030220 oncology & carcinogenesis, Obesitat, Amino acids, Tumor/blood, NUTRITION, Female, ULOQ, upper limit of quantification, Life Sciences & Biomedicine, medicine.medical_specialty, Carnitine/blood, medicine.drug_class, MODELS, Glycine, LLOQ, lower limit of quantification, Glycine/blood, Malignancy, Article, 03 medical and health sciences, Carnitine, Internal medicine, Biomarkers, Tumor, medicine, Humans, Metabolomics, 1112 Oncology and Carcinogenesis, Serine/blood, Oncology & Carcinogenesis, Obesity, Aged, SRM, standard reference material, Science & Technology, LOD, limit of detection, SM, sphingomyelin, EPIC, European Prospective Investigation into Cancer and Nutrition, business.industry, IARC, International Agency for Research on Cancer, PROFILES, Odds ratio, medicine.disease, SYNTHASES, Sphingolipid, Endometrial Neoplasms, BODY-MASS INDEX, CI, confidence interval, OR, odds ratio, 030104 developmental biology, Endocrinology, Càncer d'endometri, Estrogen, Biomarkers, Tumor/blood, Case-Control Studies, 1114 Paediatrics and Reproductive Medicine, SD, standard deviation, business, CVs, coefficients of variation, Body mass index, Biomarkers
Abstract: This work was supported by Cancer Research UK (CRUK) (grant number C19335/A21351, to MJG and HK) . The metabolomics infrastructure in the Division of Cancer, Imperial College London is supported by the Imperial College Experimental Can-cer Medicine Centre, the This work was supported by Cancer Research UK (CRUK) (grant number C19335/A21351, to MJG and HK) . The metabolomics infrastructure in the Division of Cancer, Imperial College London is supported by the Imperial College Experimental Can-cer Medicine Centre, the Imperial College Cancer Research UK Centre and the NIHR Imperial Biomedical Research Centre (APS & HK) . The co-ordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Im-perial Biomedical Research Centre (BRC) . The national cohorts are sup-ported by: Danish Cancer Society (Denmark) ; Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France) ; German Cancer Aid, German Cancer Research Center (DKFZ) , German Institute of Human Nutrition PotsdamRehbruecke (DIfE) , Federal Ministry of Education and Research (BMBF) (Germany) ; Associazione Italiana per la Ricerca sul CancroAIRCItaly, Compagnia di SanPaolo and National Research Council (Italy) ; Dutch Ministry of Public Health, Welfare and Sports (VWS) , Netherlands Can-cer Registry (NKR) , LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland) , World Cancer Research Fund (WCRF) , Statistics Netherlands (The Netherlands) ; Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII) , Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology-ICO (Spain) ; Swedish Cancer Society, Swedish Research Council and County Councils of Skkne and Vasterbotten (Sweden) ; Cancer Research UK (14136 to EPICNorfolk; C8221/A29017 to EPICOxford) , Medical Research Council (1000143 to EPICNorfolk; MR/M012190/1 to EPICOxford) . (United Kingdom) ., Background. Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from853 case-control pairs fromthe European Prospective Investigation into Cancer and Nutrition (EPIC). Methods. A total of 129metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed. Results. After adjustment for body mass index, sphingomyelin [SM] C18:0was positively (OR1SD: 1.18,95%CI: 1.05–1.33), and glycine, serine, and free carnitine (C0) were inversely (OR1SD: 0.89, 95% CI: 0.80–0.99; OR1SD: 0.89, 95% CI: 0.79–1.00 and OR1SD: 0.91, 95% CI: 0.81–1.00, respectively) associated with endometrial cancer risk. Serine, C0 and two sphingomyelins were selected by the lasso method in >90% of the bootstrap samples. The ratio of esterified to free carnitine (OR1SD: 1.14, 95% CI: 1.02–1.28) and that of short chain to free acylcarnitines (OR1SD: 1.12, 95% CI: 1.00–1.25) were positively associated with endometrial cancer risk. Further adjustment for C-peptide or other endometrial cancer risk factors only minimally altered the results. Conclusion. These findings suggest that variation in levels of glycine, serine, SMC18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention., Cancer Research UK C19335/A21351, Imperial College Experimental Cancer Medicine Centre Imperial College Cancer Research UK Centre, NIHR Imperial Biomedical Research Centre, World Health Organization, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Danish Cancer Society, Ligue Contre le Cancer (France) Institut Gustave Roussy (France) Mutuelle Generale de l'Education Nationale (France), Institut National de la Sante et de la Recherche Medicale (Inserm), Deutsche Krebshilfe, German Cancer Research Center (DKFZ) (Germany) German Institute of Human Nutrition PotsdamRehbruecke (DIfE) (Germany), Federal Ministry of Education & Research (BMBF), Fondazione AIRC per la ricerca sul cancro Compagnia di San Paolo Consiglio Nazionale delle Ricerche (CNR), Netherlands Government Netherlands Government, World Cancer Research Fund International (WCRF), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII) (Spain), Junta de Andalucia, Regional Government of Asturias (Spain), Regional Government of Basque Country (Spain), Regional Government of Murcia (Spain), Regional Government of Navarra (Spain), Catalan Institute of Oncology-ICO (Spain), Swedish Cancer Society, Swedish Research Council, County Council of Skkne (Sweden), County Council of Vasterbotten (Sweden), Cancer Research UK 14136 C8221/A29017, UK Research & Innovation (UKRI), Medical Research Council UK (MRC) 1000143 MR/M012190/1
Published: 2021

31. Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations

Author: Rosario Tumino, Jody van den Ouweland, Kathryn E. Bradbury, Petra H.M. Peeters, Martin Almquist, Fränzel J.B. Van Duijnhoven, Anja Olsen, Giuseppe Matullo, Miren Dorronsoro, Heinz Freisling, Mazda Jenab, Weimin Ye, Eivind Ness-Jensen, Elio Riboli, Maria Dolores Chirlaque, Jonas Manjer, Marina Kvaskoff, Veronika Fedirko, Verena Katzke, H. Bas Bueno-de-Mesquita, Dagfinn Aune, Marie-Christine Boutron-Ruault, Claudia Agnoli, Mireia Obón-Santacana, Frida Renström, Elisabete Weiderpass, Claire Cadeau, Teresa Norat, Cristina Lasheras, Kay-Tee Khaw, Maria Kritikou, Salvatore Panico, Henk J. van Kranen, Karina Standahl Olsen, Nicholas J. Wareham, Anouk Halfweeg, Arnulf Langhammer, María José Sánchez, Heiner Boeing, Kim Overvad, Anne Tjønneland, Domenico Palli, Antonia Trichopoulou, Ellen Kampman, Neil Murphy, Magritt Brustad, Aurelio Barricarte, Kristian Hveem, Eric J. Duell, Peter D. Siersema, Anastasia Kotanidou, and Tilman Kühn
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, 25-Hydroxyvitamin D 2, Vitamin D and neurology, Prospective cohort study, 2. Zero hunger, business.industry, Case-control study, 3. Good health, European Prospective Investigation into Cancer and Nutrition, 030104 developmental biology, Endocrinology, Oncology, chemistry, 030220 oncology & carcinogenesis, Nested case-control study, Calcifediol, business, Body mass index
Abstract: Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer (PC). However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and PC incidence in European populations. We conducted a pooled nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trondelag Health Study's second survey (HUNT2) cohorts. In total, 738 primary incident PC cases (EPIC n = 626; HUNT2 n = 112; median follow-up = 6.9 years) were matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smoking habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). Compared with a reference category of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42-1.20); 0.94 (0.72-1.22); 1.12 (0.82-1.53) and 1.26 (0.79-2.01) for clinically pre-defined categories of ≤25; >25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with PC risk (p for trend = 0.23). Although these findings among participants from the largest combination of European cohort studies to date show increasing effect estimates of PC risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant.
Published: 2017

32. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts

Author: Elisabete Weiderpass, Eva Lundin, Shelley S. Tworoger, Naomi E. Allen, Louise A. Brinton, Aurelio Barricarte, Ruth C. Travis, Annika Idahl, Helena Schock, Seungyoun Jung, Roni T. Falk, Kala Visvanathan, Melissa A. Merritt, Sabina Rinaldi, Yu-Tang Gao, Kathy J. Helzlsouer, Joanne F. Dorgan, Antonia Trichopoulou, Carlotta Sacerdote, Laura Baglietto, Vittorio Krogh, Renée T. Fortner, Patrick M. Sluss, Paul N. Staats, Alan A. Arslan, Brian L. Egleston, Xiao-Ou Shu, N. Charlotte Onland-Moret, Rudolph Kaaks, Anne Zeleniuch-Jacquotte, and Anne Tjønneland
Subjects: 0301 basic medicine, Oncology, endocrine system, Cancer Research, medicine.medical_specialty, endocrine system diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Young adult, Ovarian reserve, biology, business.industry, Case-control study, Anti-Müllerian hormone, Odds ratio, medicine.disease, female genital diseases and pregnancy complications, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Adenocarcinoma, Ovarian cancer, business, Cohort study
Abstract: Animal and experimental data suggest that anti-Mullerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
Published: 2017

33. Hepcidin levels and gastric cancer risk in the EPIC-EurGast study

Author: Núria Aranda, Bodil Ohlsson, Francesca Fasanelli, Heiner Boeing, Antonio Agudo, Ana Fonseca-Nunes, Fulvio Ricceri, Rosario Tumino, Domenico Palli, Aurora Perez-Cornago, Mazda Jenab, Petra H.M. Peeters, Elisabete Weiderpass, Emilio Sánchez-Cantalejo, José María Huerta, Leila Lujan-Barroso, Rudolf Kaaks, Miren Dorronsoro, H. Bas Bueno-de-Mesquita, Monica Tous, Tilman Kühn, Anja Olsen, Kim Overvad, Kay-Tee Khaw, José Maria Quirós, Klas Sjöberg, Amanda J. Cross, Marc J. Gunter, Antonia Trichopoulou, Vittorio Krogh, Anne Tjønneland, Aurelio Barricarte, Effie Vasilopoulou, Eleni Peppa, Amalia Mattiello, Victoria Arija, and Paula Jakszyn
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Hepcidin, hemic and lymphatic diseases, Internal medicine, medicine, Stomach cancer, biology, business.industry, Stomach, Confounding, nutritional and metabolic diseases, Cancer, Odds ratio, medicine.disease, European Prospective Investigation into Cancer and Nutrition, Ferritin, 030104 developmental biology, Endocrinology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, biology.protein, business
Abstract: Hepcidin is the main regulator of iron homeostasis and dysregulation of proteins involved in iron metabolism has been associated with tumorogenesis. However, to date, no epidemiological study has researched the association between hepcidin levels and gastric cancer risk. To further investigate the relationship between hepcidin levels and gastric cancer risk, we conducted a nested case-control study (EURGAST) within the multicentric European Prospective Investigation into Cancer and Nutrition study. The study included 456 primary incident gastric adenocarcinoma cases and 900 matched controls that occurred during an average of 11 years of follow-up. We measured serum levels of hepcidin-25, iron, ferritin, transferrin and C-reactive protein. Odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of gastric cancer by hepcidin levels were estimated from multivariable conditional logistic regression models. Mediation effect of the ferritin levels on the hepcidin-gastric cancer pathway was also evaluated. After adjusting for relevant confounders, we observed a statistically significant inverse association between gastric cancer and hepcidin levels (OR 5 ng/l = 0.96, 95% CI = 0.93–0.99). No differences were found by tumor localization or histological type. In mediation analysis, we found that the direct effect of hepcidin only represents a nonsignificant 38% (95% CI: −69%, 91%). In summary, these data suggest that the inverse association of hepcidin levels and gastric cancer risk was mostly accounted by ferritin levels. Further investigation including repeated measures of hepcidin is needed to clarify their role in gastric carcinogenesis.
Published: 2017

34. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort

Author: R. Tumino, Marco Matejcic, J. R. Quirós, Anne Zeleniuch-Jacquotte, Marc J. Gunter, Björn Gylling, Elisabete Weiderpass, Pagona Lagiou, Genevieve Buckland, Salvatore Panico, Flavie Perrier, C. Ricci, Renée T. Fortner, Fulvio Ricceri, Pilar Amiano, Inge Huybrechts, Veronique Chajes, Mathilde His, Claire Cadeau, Petra H.M. Peeters, Isabelle Romieu, M-D Chirlaque, Timothy J. Key, Vassiliki Benetou, Antonia Trichopoulou, David G. Cox, Elio Riboli, M. C. Boutron-Ruault, Rudolf Kaaks, Sabina Sieri, D. Palli, María José Sánchez, Aurelio Barricarte, Carine Biessy, H. Bas Bueno-de-Mesquita, J. D. De Batlle, H. Boeing, C. H. van Gils, and Guri Skeie
Subjects: 0301 basic medicine, Oncology, Gynecology, Cancer Research, medicine.medical_specialty, business.industry, Follow up studies, Case-control study, EPIC, medicine.disease, 03 medical and health sciences, B vitamins, 030104 developmental biology, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, Epidemiology, Cohort, medicine, Vitamin B12, business
Abstract: Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vit ...
Published: 2017

35. Physical activity, mediating factors and risk of colon cancer:insights into adiposity and circulating biomarkers from the EPIC cohort

Author: Catalina Bonet, Antonia Trichopoulou, Dagmar Drogan, Tilman Kühn, Elisabete Weiderpass, Dagfinn Aune, Pagona Lagiou, Elio Riboli, Kim Overvad, Rosario Tumino, Kay-Tee Khaw, Miren Dorronsoro, María José Sánchez, A. M. May, Marion Carayol, Elissavet Valanou, Christina C. Dahm, Kristin Benjaminsen Borch, Christina Bamia, Marie Christine Bouton-Ruault, Krasimira Aleksandrova, Tobias Pischon, Patrik Wennberg, Aurelio Barricarte, Rudolf Kaaks, Heather Ward, Sunday Oluwafemi Oyeyemi, Nada Assi, Eleni Peppa, Domenico Palli, Bethany Van Guelpen, Mazda Jenab, Anne Tjønneland, Jonna K. van Vulpen, Timothy J. Key, Sabina Rinaldi, Heiner Boeing, Paula Jakszyn, Heinz Freisling, Carmen Navarro, Salvatore Panico, Carlo La Vecchia, J. Ramón Quirós, Claudia Agnoli, Nicholas J. Wareham, Bas Bueno-de-Mesquita, Carlotta Sacerdote, Michael F. Leitzmann, Imperial College Trust, Aleksandrova, Krasimira, Jenab, Mazda, Leitzmann, Michael, Bueno de mesquita, Ba, Kaaks, Rudolf, Trichopoulou, Antonia, Bamia, Christina, Lagiou, Pagona, Rinaldi, Sabina, Freisling, Heinz, Carayol, Marion, Pischon, Tobia, Drogan, Dagmar, Weiderpass, Elisabete, Jakszyn, Paula, Overvad, Kim, Dahm, Christina C, Tjønneland, Anne, Bouton ruault, Marie christine, Kühn, Tilman, Peppa, Eleni, Valanou, Elissavet, La Vecchia, Carlo, Palli, Domenico, Panico, Salvatore, Sacerdote, Carlotta, Agnoli, Claudia, Tumino, Rosario, May, Anne, Van Vulpen, Jonna, Benjaminsen Borch, Kristin, Oluwafemi Oyeyemi, Sunday, Quirós, J. Ramón, Bonet, Catalina, Sánchez, María josé, Dorronsoro, Miren, Navarro, Carmen, Barricarte, Aurelio, Van Guelpen, Bethany, Wennberg, Patrik, Key, Timothy J, Khaw, Kay tee, Wareham, Nichola, Assi, Nada, Ward, Heather A, Aune, Dagfinn, Riboli, Elio, and Boeing, Heiner
Subjects: Oncology, Male, SOLUBLE LEPTIN RECEPTOR, Colorectal cancer, Epidemiology, physical activity, law.invention, Body Mass Index, COLORECTAL-CANCER, 0302 clinical medicine, Randomized controlled trial, Weight loss, law, Risk Factors, 030212 general & internal medicine, Prospective Studies, Vitamin D, VITAMIN-D, Public, Environmental & Occupational Health, METABOLIC SYNDROME, adiposity, Leptin, 0104 Statistics, General Medicine, Middle Aged, SERUM-LEVELS, Europe, NUTRITION COHORT, 1117 Public Health And Health Services, colon cancer, 030220 oncology & carcinogenesis, Cohort, Colonic Neoplasms, biomarker, Female, medicine.symptom, Waist Circumference, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, WEIGHT-LOSS, CONTROLLED-TRIAL, Article, 03 medical and health sciences, Internal medicine, medicine, Vitamin D and neurology, Journal Article, Humans, mediating factors, Exercise, METAANALYSIS, Aged, Science & Technology, RECTAL CANCERS, business.industry, Physical activity, biomarkers, medicine.disease, Logistic Models, Case-Control Studies, Metabolic syndrome, business
Abstract: Background: There is convincing evidence that high physical activity lowers the risk of colon cancer; however, the underlying biological mechanisms remain largely unknown. We aimed to determine the extent to which body fatness and biomarkers of various biologically plausible pathways account for the association between physical activity and colon cancer.Methods: We conducted a nested case-control study in a cohort of 519 978 men and women aged 25 to 70 years followed from 1992 to 2003. A total of 713 incident colon cancer cases were matched, using risk-set sampling, to 713 controls on age, sex, study centre, fasting status and hormonal therapy use. The amount of total physical activity during the past year was expressed in metabolic equivalent of task [MET]-h/week. Anthropometric measurements and blood samples were collected at study baseline.Results: High physical activity was associated with a lower risk of colon cancer: relative risk ≥91 MET-h/week vs Conclusions: Promoting physical activity, particularly outdoors, and maintaining metabolic health and adequate vitamin D levels could represent a promising strategy for colon cancer prevention.
Published: 2017

36. A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study

Author: Kim Overvad, Rosario Tumino, Isabel Drake, Pietro Ferrari, Anna Karakatsani, Fulvio Ricceri, Antonio Agudo, Piet A. van den Brandt, Milan Geybels, María José Sánchez, Paolo Vineis, Tilman Kühn, Timothy J. Key, Aurelio Barricarte Gurrea, Chirag J. Patel, Georgia Martimianaki, Elio Riboli, Bas Bueno-de-Mesquita, David S. Lopez, Nerea Larrañaga, Marc J. Gunter, David C. Muller, Vittorio Krogh, Kay-Tee Khaw, José Ramón Quirós, Domenico Palli, Antonia Trichopoulou, Ioanna Tzoulaki, Nikos Papadimitriou, Renée T. Fortner, Pär Stattin, Elisabete Weiderpass, Carmen Santiuste, Ingegerd Johansson, Konstantinos K. Tsilidis, Anne Tjønneland, Heiner Boeing, Dorthe Furstrand Lauritzen, Anders Bjartell, Aurora Perez-Cornago, Elin Thysell, World Cancer Research Fund International, Epidemiologie, RS: GROW - R1 - Prevention, RS: CAPHRI - R5 - Optimising Patient Care, Tsilidis, Konstantinos K [0000-0002-8452-8472], Apollo - University of Cambridge Repository, and Tsilidis, Konstantinos K. [0000-0002-8452-8472]
Subjects: Male, Oncology, Epidemiology, Medicine (miscellaneous), Cohort Studies, Prostate cancer, 0302 clinical medicine, Risk Factors, Medicine, Prospective Studies, 030212 general & internal medicine, INDEX, Netherlands, Nutrition and Dietetics, Hazard ratio, Original Contribution, European Prospective Investigation into Cancer and Nutrition, Europe, Näringslära, 030220 oncology & carcinogenesis, Cohort, Cohort study, Life Sciences & Biomedicine, medicine.medical_specialty, Diet, Nutrition, QUESTIONNAIRE, OVARIAN-CANCER, CALCIUM, DIET, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, CARBOHYDRATE, Humans, Science & Technology, Nutrition & Dietetics, business.industry, SCALE PROSPECTIVE COHORT, Prostatic Neoplasms, Nutrients, medicine.disease, Confidence interval, PRODUCTS, PHYSICAL-ACTIVITY, 1111 Nutrition and Dietetics, business, Body mass index, Genome-Wide Association Study
Abstract: Funder: Centre International de Recherche sur le Cancer; doi: http://dx.doi.org/10.13039/100008700, Purpose: The evidence from the literature regarding the association of dietary factors and risk of prostate cancer is inconclusive. Methods: A nutrient-wide association study was conducted to systematically and comprehensively evaluate the associations between 92 foods or nutrients and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cox proportional hazard regression models adjusted for total energy intake, smoking status, body mass index, physical activity, diabetes and education were used to estimate hazard ratios and 95% confidence intervals for standardized dietary intakes. As in genome-wide association studies, correction for multiple comparisons was applied using the false discovery rate (FDR < 5%) method and suggested results were replicated in an independent cohort, the Netherlands Cohort Study (NLCS). Results: A total of 5916 and 3842 incident cases of prostate cancer were diagnosed during a mean follow-up of 14 and 20 years in EPIC and NLCS, respectively. None of the dietary factors was associated with the risk of total prostate cancer in EPIC (minimum FDR-corrected P, 0.37). Null associations were also observed by disease stage, grade and fatality, except for positive associations observed for intake of dry cakes/biscuits with low-grade and butter with aggressive prostate cancer, respectively, out of which the intake of dry cakes/biscuits was replicated in the NLCS. Conclusions: Our findings provide little support for an association for the majority of the 92 examined dietary factors and risk of prostate cancer. The association of dry cakes/biscuits with low-grade prostate cancer warrants further replication given the scarcity in the literature.
Published: 2019

37. Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults

Author: M. C. Boutron-Ruault, Christina C. Dahm, Casper G. Schalkwijk, J. H. Gómez-Gómez, Stina Ramne, Salvatore Panico, Francesca Mancini, Karl-Heinz Wagner, Jytte Halkjær, Antonio Agudo, Rosario Tumino, Fulvio Ricceri, Kim Overvad, Ingegerd Johansson, J. R. Quirós, Emily Sonestedt, Tammy Y.N. Tong, Giovanna Masala, Mazda Jenab, Annemieke M.W. Spijkerman, Anne Tjønneland, Dagfinn Aune, Reynalda Cordova, Elom K. Aglago, A. L. Mayen-Chacon, Daniel Redondo-Sanchez, Anders Esberg, Aurelio Barricarte, Charlotta Rylander, Pilar Amiano, Kristin Benjaminsen Borch, Heiner Boeing, Tilman Kühn, Marc J. Gunter, Matthias B. Schulze, Anna Karakatsani, Vittorio Krogh, Verena Katzke, Heinz Freisling, Guri Skeie, Guy Fagherazzi, Viktoria Knaze, Antonia Trichopoulou, Elisabete Weiderpass, Petra Rust, Paschalis Thriskos, Vivian Viallon, Kostas Tsilidis, Jan Freark de Boer, RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, and Interne Geneeskunde
Subjects: Glycation End Products, Advanced, 0301 basic medicine, Medicine (miscellaneous), DISEASE, 0302 clinical medicine, Tandem Mass Spectrometry, Glycation, PARTICIPANTS, Prospective Studies, RISK, Nutrition and Dietetics, Dietary intake, Weight change, food and beverages, Dietary advanced glycation end products, CANCER, Europe, OBESITY, Adults, Obesity, Life Sciences & Biomedicine, Adult, COUNTRIES, medicine.medical_specialty, 030209 endocrinology & metabolism, Body weight, ENDPRODUCTS, 03 medical and health sciences, Insulin resistance, FOOD, Internal medicine, medicine, Humans, VALIDITY, 030109 nutrition & dietetics, Science & Technology, Nutrition & Dietetics, business.industry, Body Weight, fungi, Cancer, CONSUMPTION, NUTRITION&DIETETICS, medicine.disease, Diet, Endocrinology, 1111 Nutrition and Dietetics, business, Chromatography, Liquid
Abstract: Purpose:Advanced glycation end products (AGEs) can be formed in foods by the reaction of reducing sugars with proteins, and have been shown to induce insulin resistance and obesity in experimental studies. We examined the association between dietary AGEs intake and changes in body weight in adults over an average of 5years of follow-up. Methods:A total of 255,170 participants aged 25–70years were recruited in ten European countries (1992–2000) in the PANACEA study (Physical Activity, Nutrition, Alcohol, Cessation of smoking, Eating out of home in relation to Anthropometry), a sub-cohort of the EPIC (European Prospective Investigation into Cancer and Nutrition). Body weight was measured at recruitment and self-reported between 2 and 11years later depending on the study center. A reference database for AGEs was used containing UPLC–MS/MS-measured Nε-(carboxymethyl)-lysine (CML), Nε-(1-carboxyethyl)-lysine (CEL), and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) in 200 common European foods. This reference database was matched to foods and decomposed recipes obtained from country-specific validated dietary questionnaires in EPIC and intake levels of CEL, CML, and MG-H1 were estimated. Associations between dietary AGEs intake and body weight change were estimated separately for each of the three AGEs using multilevel mixed linear regression models with center as random effect and dietary AGEs intake and relevant confounders as fixed effects. Results:A one-SD increment in CEL intake was associated with 0.111kg (95% CI 0.087–0.135) additional weight gain over 5years. The corresponding additional weight gain for CML and MG-H1 was 0.065kg (0.041–0.089) and 0.034kg (0.012, 0.057), respectively. The top six food groups contributing to AGEs intake, with varying proportions across the AGEs, were cereals/cereal products, meat/processed meat, cakes/biscuits, dairy, sugar and confectionary, and fish/shellfish. Conclusion:In this study of European adults, higher intakes of AGEs were associated with marginally greater weight gain over an average of 5years of follow-up.
Published: 2019

38. Association of circulating Vitamin D with colorectal cancer depends on Vitamin D-binding protein isoforms: A pooled, nested, case-control study

Author: W. Dana Flanders, Tilman Kühn, Anne Tjønneland, Kana Wu, Roberd M. Bostick, Yahya Mahamat-Saleh, Marjorie L. McCullough, Aurelio Barricarte Gurrea, Konstantinos K. Tsilidis, Antonia Trichopoulou, Johan Hultdin, Bas Bueno-de-Mesquita, Mingyang Song, Elisabete Weiderpass, Edward Giovannucci, David C. Gibbs, Magritt Brustad, Marc J. Gunter, Veronika Fedirko, Mazda Jenab, Aurora Perez-Cornago, Caroline Y. Um, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and Institut Gustave Roussy (IGR)
Subjects: Vitamin, 25-HYDROXYVITAMIN D, D SUPPLEMENTATION, Cancer Research, medicine.medical_specialty, Vitamin D-binding protein, [SDV]Life Sciences [q-bio], Lower risk, Gastroenterology, CALCIUM, Article, vitamin D deficiency, SERUM, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, D-RECEPTOR, GENETIC-VARIANTS, GC-GLOBULIN, Internal medicine, Vitamin D and neurology, Medicine, GENOME-WIDE ASSOCIATION, 030304 developmental biology, RISK, 0303 health sciences, Cancer och onkologi, Science & Technology, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, business.industry, Odds ratio, medicine.disease, PREVENTION, Confidence interval, 3. Good health, Oncology, chemistry, 030220 oncology & carcinogenesis, Cancer and Oncology, Nested case-control study, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, Life Sciences & Biomedicine
Abstract: Background Higher circulating 25-hydroxyvitamin-D [25(OH)D] concentrations are consistently inversely associated with colorectal cancer (CRC) risk in observational studies. However, it is unknown whether this association depends on the functional GC-rs4588*A (Thr436Lys) variant encoding the vitamin D–binding protein-2 (DBP2) isoform, which may affect vitamin D status and bioavailability. Methods We analyzed data from 1710 incident CRC cases and 1649 incidence-density–matched controls nested within three prospective cohorts of mostly Caucasians. Study-specific incidence rate ratios (RRs) for associations of prediagnostic, season-standardized 25(OH)D concentrations according to DBP2 isoform with CRC were estimated using multivariable unconditional logistic regression and were pooled using fixed-effects models. All statistical significance tests were two-sided. Results The odds of having 25(OH)D concentrations less than 50 nmol/L (considered insufficient by the Institute of Medicine) were 43% higher for each DBP2-encoding variant (rs4588*A) inherited (per DBP2 odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.27 to 1.62, Ptrend = 1.2 × 10−8). The association of 25(OH)D concentrations with CRC risk differed by DBP2: 25(OH)D concentrations considered sufficient (≥ 50 nmol/L), relative to deficient ( Conclusions Our results suggest that the 25(OH)D-CRC association may differ by DBP isoform, and those with a DBP2-encoding genotype linked to vitamin D insufficiency may particularly benefit from adequate 25(OH)D for CRC prevention.
Published: 2019

39. Reproductive and lifestyle factors and circulating sRANKL and OPG concentrations in women:Results from the EPIC cohort

Author: Elisabete Weiderpass, Inger T. Gram, Jiaxi Yang, Renée T. Fortner, Theron Johnson, Amalia Mattiello, Anna Karakatsani, Elissavet Valanou, Kim Overvad, Marc J. Gunter, Antonia Trichopoulou, Agnès Fournier, Dafina Petrova, Giovanna Masala, Marina Kvaskoff, Aurelio Barricarte, Rudolf Kaaks, Ruth C. Travis, Danja Sarink, Carla H. van Gils, Carmen Santiuste, Jenny Chang-Claude, Carlotta Sacerdote, Leila Lujan-Barroso, Claudia Agnoli, J. Ramón Quirós, Guri Skeie, Anja Olsen, Heiner Boeing, Sofia Christakoudi, Francesca Mancini, Anne Tjønneland, Laure Dossus, Pilar Amiano, and Rosario Tumino
Subjects: 0301 basic medicine, musculoskeletal diseases, medicine.medical_specialty, Cross-sectional study, Epidemiology, medicine.medical_treatment, Physiology, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Osteoprotegerin, medicine, Humans, Contraception Behavior, Life Style, Reproductive History, 11 Medical and Health Sciences, business.industry, Estrogen Replacement Therapy, RANK Ligand, Age Factors, Middle Aged, medicine.disease, European Prospective Investigation into Cancer and Nutrition, Postmenopause, 030104 developmental biology, Cross-Sectional Studies, Premenopause, Oncology, 030220 oncology & carcinogenesis, Cohort, Female, Hormone therapy, business, Body mass index, Biomarkers
Abstract: Background: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women. Methods: This study includes 2,016 controls [n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case–control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors. Results: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women (Ptrend ≤ 0.03) and higher OPG concentrations in all women (Ptrend ≤ 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG (Ptrend ≤ 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking (P ≤ 0.01). sRANKL concentrations were higher among women with higher BMI (Ptrend ≤ 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations. Conclusions: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. Impact: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors.
Published: 2019

40. Gallstones and incident colorectal cancer in a large pan-European cohort study

Author: Anne Tjønneland, Kim Overvad, Giovanna Masala, Marc J. Gunter, Antonia Trichopoulou, Raul Zamora-Ros, Heather Ward, Pagona Lagiou, Susana Merino, Elisabete Weiderpass, Marie-Christine Boutron-Ruault, Heinz Freisling, Rosario Tumino, Aurelio Barricarte, Dagfinn Aune, Carla H. van Gils, Gianluca Severi, Elom K. Aglago, Roel Vermeulen, Heiner Boeing, Hanna Nyström, Bas Bueno-de-Mesquita, Franck Carbonnel, Rudolf Kaaks, Amanda J. Cross, María Dolores Chirlaque, Neil Murphy, Mazda Jenab, Elio Riboli, Tilman Kühn, Martin Rutegård, Aurora Perez-Cornago, Christina Bamia, Michael F. Leitzmann, Miguel Rodríguez-Barranco, Sara Grioni, Miren Dorronsoro, Amalia Mattiello, Anja Olsen, Carlotta Sacerdote, Imperial College Trust, One Health Chemisch, and dIRAS RA-2
Subjects: Adult, Male, medicine.medical_specialty, Cancer Research, CHOLECYSTECTOMY, Population, colorectal cancer, Gallstones, DISEASE, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Journal Article, Medicine, Humans, 1112 Oncology and Carcinogenesis, Registries, Oncology & Carcinogenesis, Risk factor, education, Prospective cohort study, POPULATION, Proportional Hazards Models, RISK, education.field_of_study, Science & Technology, business.industry, Incidence, Hazard ratio, ASSOCIATION, cohort, Middle Aged, medicine.disease, European Prospective Investigation into Cancer and Nutrition, Europe, Oncology, 030220 oncology & carcinogenesis, Cohort, SERUM BILIRUBIN, Female, business, Colorectal Neoplasms, EPIC, Life Sciences & Biomedicine, Cohort study
Abstract: Gallstones, a common gastrointestinal condition, can lead to several digestive complications and can result in inflammation. Risk factors for gallstones include obesity, diabetes, smoking and physical inactivity, all of which are known risk factors for colorectal cancer (CRC), as is inflammation. However, it is unclear whether gallstones are a risk factor for CRC. We examined the association between history of gallstones and CRC in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, a prospective cohort of over half a million participants from ten European countries. History of gallstones was assessed at baseline using a self-reported questionnaire. The analytic cohort included 334,986 participants; a history of gallstones was reported by 3,917 men and 19,836 women, and incident CRC was diagnosed among 1,832 men and 2,178 women (mean follow-up: 13.6 years). Hazard ratios (HR) and 95% confidence intervals (CI) for the association between gallstones and CRC were estimated using Cox proportional hazards regression models, stratified by sex, study centre, and age at recruitment. The models were adjusted for body mass index, diabetes, alcohol intake, and physical activity. A positive, marginally significant association was detected between gallstones and CRC among women in multivariable analyses (HR=1.14, 95%CI 0.99-1.31, p=0.077). The relationship between gallstones and CRC among men was inverse but not significant (HR=0.81, 95%CI 0.63-1.04, p=0.10). Additional adjustment for details of reproductive history or waist circumference yielded minimal changes to the observed associations. Further research is required to confirm the nature of the association between gallstones and CRC by sex. This article is protected by copyright. All rights reserved.
Published: 2019

41. Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study

Author: Domenico Palli, Mazda Jenab, Susana Merino, Elio Riboli, Aurelio Barricarte, Salvatore Panico, Heinz Freisling, Aurora Perez-Cornago, Agustín Lahoz, Francesca Mancini, Alicia K Heath, Augustin Scalbert, Maria J. Sánchez, Carlotta Sacerdote, Carla H. van Gils, Sandra González Maldonado, Solomon A Sowah, Sandra Colorado-Yohar, Marta Roca, Magdalena Stepien, Kay-Tee Khaw, Paula Jakszyn, Paschalis Thriskos, Tilman Kühn, Neil Murphy, Marc J. Gunter, Disorn Sookthai, Claudia Agnoli, Marina Lopez-Nogueroles, Gianluca Severi, Marie-Christine Boutron-Ruault, Antonia Trichopoulou, Sabina Rinaldi, Anika Hüsing, Anna Karakatsani, Bas Bueno-de-Mesquita, Amanda J. Cross, Heiner Boeing, Theron Johnson, Rudolf Kaaks, Antje Damms-Machado, Julie A. Schmidt, Rosario Tumino, and Veronika Fedirko
Subjects: Male, Cancer Research, diagnosis, Gastroenterology, Cohort Studies, chemistry.chemical_compound, taurodeoxycholic acid, 0302 clinical medicine, metabolites, 0303 health sciences, Bile acid, Articles, Middle Aged, European Prospective Investigation into Cancer and Nutrition, colon cancer, Oncology, Glycodeoxycholic acid, glycocholic acid, 030220 oncology & carcinogenesis, Colonic Neoplasms, Female, Taurodeoxycholic acid, Corrigendum, carcinogenesis, Adult, Risk, medicine.medical_specialty, medicine.drug_class, Glycocholic acid, Taurochenodeoxycholic acid, colorectal cancer, taurocholic acid, digestive system, Bile Acids and Salts, 03 medical and health sciences, nutrition in cancer, glycochenodeoxycholic acid, Internal medicine, tandem mass spectrometry, taurochenodeoxycholic acid, medicine, Glycochenodeoxycholic acid, Journal Article, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, plasma, 030304 developmental biology, Aged, bile acids, glycodeoxycholic acid, colon, business.industry, Taurocholic acid, digestive system diseases, chemistry, Spain, Case-Control Studies, business
Abstract: Background Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans. Methods Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations. Results Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk. Conclusions This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
Published: 2019

42. Vitamin D-Related Genes, Blood Vitamin D Levels and Colorectal Cancer Risk in Western European Populations

Author: Aleksandrova Krasimira, Hannah B. Mandle, Sophia Harlid, Alicia K Heath, Konstantinos K. Tsilidis, Dimitris Thanos, Wanzhe Zhu, Elisabete Weiderpass, Dagfinn Aune, Anne Tjønneland, Björn Gylling, Mazda Jenab, Marie-Christine Boutron-Ruault, Heinz Freisling, Guri Skeie, Sandra Colorado-Yohar, Pilar Amiano, Aurora Perez-Cornago, María José Sánchez, Theron Johnson, Marc J. Gunter, Bas Bueno-de-Mesquita, Veronika Fedirko, Vittorio Krogh, Ramón Quirós, Pietro Ferrari, Carlotta Sacerdote, Elio Riboli, Isabelle Romieu, Afshan Siddiq, Peter D. Siersema, Neil Murphy, Vittorio Perduca, Antonia Trichopoulou, Franck Carbonnel, Aurelio Barricarte, Fränzel J.B. Van Duijnhoven, Anja Olsen, Periklis Makrythanasis, David J. Hughes, Tilman Kühn, Salvatore Panico, Núria Sala, International Agency for Cancer Research (IACR), Department of Epidemiology and Biostatistics, Imperial College London-Faculty of Medicine-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Nutrition and Metabolism Section, International Agency for Research on Cancer, Centre International de Recherche contre le Cancer (CIRC), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Danish Cancer Society, Danish Cancer Society Research Center, Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Deutsches Krebsforschungszentrum, WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens]-University of Athens Medical School [Athens], University of Geneva, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), CPO Piemonte, Department of Community Medicine, Faculty of Health Sciences, The Arctic University of Norway (UiT), Catalan Institute of Oncology, CIBER de Epidemiología y Salud Pública (CIBERESP), Andalusian School of Public Health [Granada], Nuffield Department of Population Health - Cancer Epidemiology Unit, University of Oxford [Oxford], and School of Public Health - Department of Epidemiology and Biostatistics
Subjects: 0301 basic medicine, Male, Nutrition and Disease, Colorectal cancer, vitamin D, Calcitriol receptor, chemistry.chemical_compound, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Polymorphism (computer science), Risk Factors, Transforming Growth Factor beta, Voeding en Ziekte, Nutritional Physiological Phenomena, Prospective Studies, Vitamin D, ComputingMilieux_MISCELLANEOUS, Nutrition and Dietetics, Incidence, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Näringslära, Europe, 030220 oncology & carcinogenesis, Female, lcsh:Nutrition. Foods and food supply, Signal Transduction, Vitamin, medicine.medical_specialty, Vitamina D, lcsh:TX341-641, [SDV.CAN]Life Sciences [q-bio]/Cancer, Single-nucleotide polymorphism, Biology, Polymorphism, Single Nucleotide, Article, Colorectal neoplasms, 03 medical and health sciences, single nucleotide polymorphism (SNP), Càncer colorectal, Single nucleotide polymorphism (SNP), Internal medicine, medicine, Vitamin D and neurology, Humans, VDP::Medisinske Fag: 700, Genetic Predisposition to Disease, Aged, Cancer och onkologi, colorectal neoplasms, medicine.disease, VDP::Medical disciplines: 700, 030104 developmental biology, Endocrinology, chemistry, Cancer and Oncology, Case-Control Studies, incidence, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Calcifediol, Food Science
Abstract: Higher circulating 25-hydroxyvitamin D levels (25(OH)D) have been found to be associated with lower risk for colorectal cancer (CRC) in prospective studies. Whether this association is modified by genetic variation in genes related to vitamin D metabolism and action has not been well studied in humans. We investigated 1307 functional and tagging single-nucleotide polymorphisms (SNPs, individually, and by gene/pathway) in 86 vitamin D-related genes in 1420 incident CRC cases matched to controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We also evaluated the association between these SNPs and circulating 25(OH)D in a subset of controls. We confirmed previously reported CRC risk associations between SNPs in the VDR, GC, and CYP27B1 genes. We also identified additional associations with 25(OH)D, as well as CRC risk, and several potentially novel SNPs in genes related to vitamin D transport and action (LRP2, CUBN, NCOA7, and HDAC9). However, none of these SNPs were statistically significant after Benjamini&ndash, Hochberg (BH) multiple testing correction. When assessed by a priori defined functional pathways, tumor growth factor &beta, (TGF&beta, ) signaling was associated with CRC risk (P &le, 0.001), with most statistically significant genes being SMAD7 (PBH = 0.008) and SMAD3 (PBH = 0.008), and 18 SNPs in the vitamin D receptor (VDR) binding sites (P = 0.036). The 25(OH)D-gene pathway analysis suggested that genetic variants in the genes related to VDR complex formation and transcriptional activity are associated with CRC depending on 25(OH)D levels (interaction P = 0.041). Additional studies in large populations and consortia, especially with measured circulating 25(OH)D, are needed to confirm our findings.
Published: 2019

43. Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium

Author: Aimée R. Kreimer, Roger L. Milne, William J. Blot, Alan Hildesheim, Carlotta Sacerdote, Eivind Ness-Jensen, Hilde Langseth, Lesley F. Tinker, Demetrius Albanes, Roel Vermeulen, Aurelio Barricarte, Gypsyamber D'Souza, Graham G. Giles, Wen-Yi Huang, Aida Ferreiro-Iglesias, Wei Zheng, Hilary A. Robbins, Stephanie J. Weinstein, Lea Schroeder, Giske Ursin, Anne Tjønneland, Neal D. Freedman, Michael Pawlita, Kala Visvanathan, Mattias Johansson, Judith Hoffman-Bolton, Mari Nygård, Kristian Hveem, Betty J. May, Elisabete Weiderpass, Qiuyin Cai, Ilir Agalliu, Antonia Trichopoulou, Nicolas F. Schlecht, Paul Brennan, Tim Waterboer, Nicole Brenner, Noemi Bender, Sylvia Smoller, Rudolf Kaaks, Department of Medical and Clinical Genetics, Faculty of Medicine, and University of Helsinki
Subjects: 0301 basic medicine, Male, Time Factors, Carcinogenesis, Epidemiology, Antibodies, Viral, Serology, 0302 clinical medicine, DESIGN, OPCSCC, Prospective Studies, Prospective cohort study, RISK, education.field_of_study, Human papillomavirus 16, biology, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, Hematology, Middle Aged, CANCER, 3. Good health, Oropharyngeal Neoplasms, Oncology, Seroconversion, 030220 oncology & carcinogenesis, Cohort, Female, Antibody, HPVC3, Adult, medicine.medical_specialty, 3122 Cancers, Population, 03 medical and health sciences, Internal medicine, medicine, Humans, COHORT, HEAD, education, Aged, business.industry, Squamous Cell Carcinoma of Head and Neck, HUMAN-PAPILLOMAVIRUS, Papillomavirus Infections, Case-control study, Cancer, Oncogene Proteins, Viral, Original Articles, medicine.disease, Repressor Proteins, 030104 developmental biology, Case-Control Studies, biology.protein, oropharyngeal squamous cell carcinoma, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, Follow-Up Studies
Abstract: Background Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown. Patients and methods We formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was 11.4 years (IQR = 6–11 years, range = 0–40 years). Antibodies against HPV16-E6 were measured by multiplex serology (GST fusion protein based Luminex assay). Results HPV16-E6 seropositivity was present in 0.4% of controls (22/5814; 95% CI 0.2% to 0.6%) and 26.2% (195/743; 95% CI 23.1% to 29.6%) of OPSCC cases. HPV16-E6 seropositivity increased the odds of OPSCC 98.2-fold (95% CI 62.1–155.4) in whites and 17.2-fold (95% CI 1.7–170.5) in blacks. Seropositivity in cases was more frequent in recent calendar periods, ranging from 21.9% pre-1996 to 68.4% in 2005 onwards, in those with blood collection near diagnosis (lead time 30 years (N = 24), 20–30 years (N = 148), 10–20 years (N = 228), and
Published: 2019

44. Predicting circulating CA125 levels among healthy premenopausal women

Author: Marc J. Gunter, Agnès Fournier, Kim Overvad, David C. Muller, Eva Lundin, Hanna Sartor, Marina Kvaskoff, Louise Hansen, Domenico Palli, Renée T. Fortner, Rudolf Kaaks, J. Ramón Quirós, Miren Dorronsoro, Antonia Trichopoulou, Miguel Rodríguez-Barranco, Shelley S. Tworoger, N. Charlotte Onland-Moret, Chiara Grasso, Kathryn L. Terry, Naoko Sasamoto, Anna Karakatsani, Raina N. Fichorova, Ana Babic, Hidemi S. Yamamoto, Valeria Pala, Annika Idahl, Elisabete Weiderpass, Elio Riboli, Heiner Boeing, Daniel W. Cramer, Amalia Mattiello, Rosario Tumino, Aurelio Barricarte, Allison F. Vitonis, Eleni Peppa, Sandra Colorado-Yohar, Kay-Tee Khaw, Anne Tjønneland, Laure Dossus, Francesca Mancini, Bernard Rosner, Leila Lujan-Barroso, Timothy J. Key, and Imperial College Trust
Subjects: 0301 basic medicine, Oncology, endocrine system diseases, Epidemiology, Càncer d'ovari, Ovarian cancer screening, CA-125 LEVELS, 0302 clinical medicine, Prostate, REPRODUCIBILITY, PROSTATE, Medicine, Prospective Studies, 11 Medical and Health Sciences, Early Detection of Cancer, Public, Environmental & Occupational Health, Ovarian Neoplasms, Middle Aged, Prognosis, female genital diseases and pregnancy complications, Cancer antigen, prediction model, medicine.anatomical_structure, ovarian cancer, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, Menopause, Life Sciences & Biomedicine, Menopausa, Adult, medicine.medical_specialty, MODELS, Article, 03 medical and health sciences, CA125, OVARIAN-CANCER RISK, Internal medicine, Humans, VALIDITY, Nutrició, Nutrition, Science & Technology, premenopausal, business.industry, MORTALITY, screening, Membrane Proteins, 030104 developmental biology, Premenopause, CA-125 Antigen, Case-Control Studies, Women's Health, business, LUNG, Follow-Up Studies
Abstract: Background: Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. Methods: We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥35 U/mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Results: The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC (r = 0.22) and in EPIC (r = 0.22). The dichotomous CA125 prediction model included age, tubal ligation, endometriosis, prior personal cancer diagnosis, family history of ovarian cancer, number of miscarriages, menstrual phase at blood draw, and smoking status with AUC of 0.83. The abridged dichotomous model (including age, number of miscarriages, menstrual phase at blood draw, and smoking status) showed similar AUCs in NEC (0.73) and in EPIC (0.78). Conclusions: We identified a combination of factors associated with CA125 levels in premenopausal women. Impact: Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.
Published: 2019

45. Mediation analysis of the alcohol‐postmenopausal breast cancer relationship by sex hormones in the EPIC Cohort

Author: Anne Tjønneland, Georgia Martimianaki, Laure Dossus, Vivian Viallon, Iris Cervenka, H. Bas Bueno de Mesquita, Rosario Tumino, Marina Kvaskoff, Merete Ellingjord-Dale, Susana Merino, Anna Karakatsani, Kim Overvad, Manuela M. Bergmann, Sabina Rinaldi, Kostas Tsilidis, María José Sánchez Pérez, Pilar Amiano Etxezarreta, Rudolf Kaaks, Elio Riboli, Sara Grioni, Catalina Bonet, Agnès Fournier, Domenico Palli, Maria Dolores Chirlaque, Nada Assi, Sofia Christakoudi, Antonia Trichopoulou, Fulvio Ricceri, Marc J. Gunter, S. Ghazaleh Dashti, Renée Turzanski-Fortner, Charlotte Onland-Moret, Carla H. van Gils, Heiner Boeing, Salvatore Panico, Pietro Ferrari, Timothy J. Key, Aurelio Barricarte Gurrea, and Commission of the European Communities
Subjects: Cancer Research, 0302 clinical medicine, Sex hormone-binding globulin, Breast cancer, Sex Hormone-Binding Globulin, hormonal signature, Testosterone, Sex hormones, Prospective Studies, Hormones sexuals, biology, Estradiol, alcohol, Incidence, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Postmenopause, Oncology, Drinking of alcoholic beverages, 030220 oncology & carcinogenesis, breast cancer, EPIC, mediation analysis, sex steroids, Aged, Alcohol Drinking, Breast Neoplasms, Case-Control Studies, Female, Humans, Consum d'alcohol, medicine.medical_specialty, medicine.drug_class, Article, Càncer de mama, 03 medical and health sciences, Internal medicine, medicine, Journal Article, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, business.industry, Case-control study, Odds ratio, medicine.disease, Endocrinology, Estrogen, biology.protein, business, Hormone
Abstract: Alcohol consumption is associated with higher risk of breast cancer (BC); however, the biological mechanisms underlying this association are not fully elucidated, particularly the extent to which this relationship is mediated by sex hormone levels. Circulating concentrations of estradiol, testosterone, their free fractions and sex-hormone binding globulin (SHBG), were examined in 430 incident BC cases and 645 matched controls among alcohol-consuming postmenopausal women nested within the European Prospective Investigation into Cancer and Nutrition. Mediation analysis was applied to assess whether individual hormone levels mediated the relationship between alcohol intake and BC risk. An alcohol-related hormonal signature, obtained by Partial Least Square (PLS) regression, was evaluated as a potential mediator. Total (TE), natural direct (NDE) and natural indirect effects (NIE) were estimated. Alcohol intake was positively associated with overall BC risk and specifically with estrogen receptor positive tumours with respectively TE=1.17(95%CI: 1.01,1.35) and 1.36(1.08,1.70) for a 1-SD deviation increase of intake. There was no evidence of mediation by sex steroids or SHBG separately except for a weak indirect effect through free estradiol where NIE=1.03(1.00,1.06). However, an alcohol-related hormonal signature negatively associated with SHBG and positively with estradiol and testosterone, was associated with BC risk (OR=1.25 (1.07,1.47)) for a 1-SD higher PLS score, and had a statistically significant NIE accounting for a mediated proportion of 24%. There was limited evidence of mediation of the alcohol-BC association by individual sex hormones. However, a hormonal signature, reflecting lower levels of SHBG and higher levels of sex steroids, mediated a substantial proportion of the association. This article is protected by copyright. All rights reserved.
Published: 2019

46. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

Author: Pilar Amiano, Marta Solans, Anne Katrine Bolvig, Heinz Freisling, José María Huerta, Roel Vermeulen, Christina C. Dahm, Caroline Besson, Yahya Mahamat-Saleh, Pietro Ferrari, Christina Bamia, Genevieve Buckland, Salvatore Panico, Antonio Agudo, Delphine Casabonne, Yolanda Benavente, Aurelio Barricarte, Hwayoung Noh, Guri Skeie, Silvia de Sanjosé, Rudolf Kaaks, Claudia Agnoli, Kim Overvad, Eleni Peppa, Cristina Lasheras, Antonia Trichopoulou, Heiner Boeing, Tilman Kühn, Ulrika Ericson, Sabine Naudin, Elisabete Weiderpass, Lena Maria Nilsson, Giovanna Masala, Marc Saez, Alexandra Nieters, Marie-Christine Boutron-Ruault, Florentin Späth, Carlotta Sacerdote, Miguel Rodríguez-Barranco, Mats Jerkeman, Elio Riboli, Julie A. Schmidt, Rosario Tumino, Paolo Vineis, Anne Tjønneland, Fatemeh Saberi Hosnijeh, One Health Chemisch, dIRAS RA-2, Immunology, and Imperial College Trust
Subjects: Oncology, Male, Cancer Research, Limfomes, RATIONALE, Diet, Mediterranean, Dieta mediterrània, Cohort Studies, 0302 clinical medicine, hemic and lymphatic diseases, Prospective cohort study, Càncer, FRUITS, Diet -- Mediterranean Region, Cancer, risk, Not Otherwise Specified, Hazard ratio, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Europe, 030220 oncology & carcinogenesis, Female, Lymphomas, NON-HODGKIN-LYMPHOMA, Life Sciences & Biomedicine, NEOPLASMS, Cohort study, medicine.medical_specialty, lymphoma, Lower risk, MALIGNANCIES, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Mediterranean diet, medicine, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Nutrició, VEGETABLES, METAANALYSIS, Proportional Hazards Models, Nutrition, Science & Technology, Proportional hazards model, business.industry, CYTOKINES, CONSUMPTION, medicine.disease, prospective studies, Lymphoma, PATTERNS, business
Abstract: European Commission (DG‐SANCO). International Agency for Research on Cancer. Spanish Ministry of Economy and Competitiveness ‐ Carlos III Institute of Health cofunded by FEDER funds/European Regional Develpment Fund (ERDF) ‐ a way to build Europe. Grant Numbers: PI13/00061 (to Granada), PI13/01162 (to EPIC‐Murcia, Regional Governments of Andalucıa, Asturias, Basque Country, Murcia and Navarra), PI17/01280 and PI14/01219 (to Barcelona). Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP, Spain), Solans, M., Benavente, Y., Saez, M., Agudo, A., Naudin, S., Hosnijeh, F.S., Noh, H., Freisling, H., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M.-C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Rodríguez-Barranco, M., Amiano, P., Huerta, J.M., Barricarte, A., Schmidt, J.A., Vineis, P., Riboli, E., Trichopoulou, A., Bamia, C., Peppa, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Panico, S., Skeie, G., Weiderpass, E., Jerkeman, M., Ericson, U., Späth, F., Nilsson, L.M., Dahm, C.C., Overvad, K., Bolvig, A.K., Tjønneland, A., de Sanjose, S., Buckland, G., Vermeulen, R., Nieters, A., Casabonne, D.
Published: 2019

47. Plasma phospholipid long-chain n-3 polyunsaturated fatty acids and body weight change

Author: Giovanna Tagliabue, Ingegerd Johansson, José María Huerta, Domenico Palli, Anne Tjønneland, Petra H.M. Peeters, Aurelio Barricarte, Anne M. May, Göran Hallmans, Francesca L. Crowe, Madlen Schütze, Daphne L. van der A, Françoise Clavel-Chapelon, Birgit Teucher, George Makrygiannis, Thorkild I. A. Sørensen, Jonas Manjer, Isabelle Romieu, Laudina Rodríguez, H. B. Bueno-de-Mesquita, Veronique Chajes, Kim Overvad, Guy Fagherazzi, Nadia Slimani, Karen Margrete Due, Nicholas J. Wareham, Dimosthenis Zylis, Heiner Boeing, Pilar Amiano, Kay-Tee Khaw, Claus Dethlefsen, Amalia Mattiello, Marianne Uhre Jakobsen, Rudolf Kaaks, Jytte Halkjær, Marie-Christine Boutron-Ruault, Elisabet Wirfält, Esther Molina-Montes, Noémie Travier, Elio Riboli, Antonia Trichopoulou, [Jakobsen,MU] Department of Clinical Epidemiology. [Jakobsen,MU, Dethlefsen,C, Due,KM, Overvad,K] Department of Cardiology, Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg. [Jakobsen,MU, Overvad,K] Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark. [Slimani,N, Chajès,V, Romieu,I] Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. [May,AM, Peeter,PHM] Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht. [May,AM, van der A,DL, Bueno-de-Mesquita,HB] National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Sørensen,TIA] Institute of Preventive Medicine, Copenhagen University Hospital. [Halkjær,J, Tjønneland,A] The Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark. [Clavel-Chapelon,F, Boutron-Ruault,M, Fagherazzi,G] Inserm, Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy. Paris South University, Villejuif, France. [Teucher,B, Kaaks,R] German Cancer Research Center, Department of Cancer Epidemiology, Heidelberg. [Boeing,H, Schütze,M, Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Zylis,D] WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School. [Trichopoulou,A, Zylis,D, Makrygiannis,G] Hellenic Health Foundation, Athens, Greece. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence. [Mattiello,A] Department of Clinical and Experimental Medicine, Federico II University, Naples. [Tagliabue,G] Cancer Registry and Environmental Epidemiology Division, National Cancer Institute, Milan, Italy. [Bueno-de-Mesquita,HB] Department of Gastroenterology and Hepatology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands. [Rodríguez,L] Public Health and Participation Directorate, Health and Health Care Services Council, Asturias. [Travier,N] Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, IDIBELL, Barcelona. [Molina-Montes,E] Andalusian School of Public Health, Granada. [Molina-Montes,E, Huerta,JM, Barricarte,A, Amiano,P] CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, Murcia. [Barricarte,A] Public Health Institute of Navarra, Pamplona. [Amiano,P] Public Health Division of Gipuzkoa, Basque Government, Spain. [Manjer,J] Department of Surgery, Skåne University Hospital Malmö, Lund University. [Wirfält,E] Department of Clinical Sciences in Malmö/Nutrition Epidemiology, Lund University, Malmö. [Johansson,I] Department of Odontology, Umeå University. [Hallmans,G] Department of Public Health and Clinical Medicine, Umeå University, Nutritional Research, Umeå, Sweden. [Khaw,K] Clinical Gerontology Unit, Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge. [Wareham, NJ] MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge. [Crowe,F] Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford. [Riboli,E, Peeters, PHM] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK., This work is part of the project Physical Activity, Nutrition, Alcohol, Cessation of Smoking, Eating out of Home and Obesity (PANACEA), which is supported by the European Union in the framework of the Public Health Programmme (Contract 2005328). The work was further supported by the European Commission: Public Health and Consumer Protection Directorate 1993–2004, Research Directorate-General 2005, Ligue contre le Cancer, Société 3M, Mutuelle Générale de l’Education Nationale, Institut National de la Santé de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center, Federal Ministry of Education and Research (Germany), Danish Cancer Society (Denmark), ISCIII (RETICC RD06/0020) of the Spanish Ministry of Health, the participating regional governments and institutions (Spain), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, The Wellcome Trust (UK), Greek Ministry of Health, Greek Ministry of Education, Hellenic Ministry of Health, Stavros Niarchos Foundation, and the Hellenic Health Foundation (Greece), Italian Association for Research on Cancer, National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports, Dutch Ministry of Health, Dutch Prevention Funds, LK Research Funds, Dutch Zorg Onderzoek Nederland (ZON), World Cancer Research Fund (WCRF) (The Netherlands), and and Swedish Cancer Society, Swedish Scientific Council, Regional Government of Skane and Västerbotten (Sweden). This work is also part of the project Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome (HEPADIP, www.hepadip.org), which is supported by the European Commission as an Integrated Project under the 6th Framework Programme (Contract LSHM-CT-2005-018734) and part of the research program of the Danish Obesity Research Centre (DanORC, www.danorc.dk), which is supported by the Danish Council for Strategic Research (Contract 2101-06-0005).
Subjects: Male, Health (social science), 030309 nutrition & dietetics, Obesidad, Ácidos grasos omega-3, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], chemistry.chemical_compound, 0302 clinical medicine, Estudios prospectivos, Fosfolípidos, Modelos lineales, Prospective Studies, Masculino, Prospective cohort study, Phospholipids, chemistry.chemical_classification, 0303 health sciences, education.field_of_study, Weight change, Femenino, Middle Aged, n-3 fatty acids, Humanos, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Female, Original Article, lipids (amino acids, peptides, and proteins), Cohort study, Polyunsaturated fatty acid, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Population, Phospholipid, Check Tags::Male [Medical Subject Headings], 030209 endocrinology & metabolism, 03 medical and health sciences, Chemicals and Drugs::Lipids::Fats::Dietary Fats::Dietary Fats, Unsaturated::Fatty Acids, Omega-3 [Medical Subject Headings], Physiology (medical), Internal medicine, Fatty Acids, Omega-3, Omega-3 fatty acids, medicine, Humans, Obesity, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Linear Models [Medical Subject Headings], Chemicals and Drugs::Lipids::Phospholipids [Medical Subject Headings], education, Mediana edad, business.industry, Body Weight, Peso corporal, Body weight, Confidence interval, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Endocrinology, Check Tags::Female [Medical Subject Headings], chemistry, Linear Models, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings], sense organs, business
Abstract: Journal Article; Research Support, Non-U.S. Gov't; OBJECTIVE We investigated the association between the proportion of long-chain n-3 polyunsaturated fatty acids (PUFA) in plasma phospholipids from blood samples drawn at enrollment and subsequent change in body weight. Sex, age, and BMI were considered as potential effect modifiers. METHOD A total of 1,998 women and men participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) were followed for a median of 4.9 years. The associations between the proportion of plasma phospholipid long-chain n-3 PUFA and change in weight were investigated using mixed-effect linear regression. RESULTS The proportion of long-chain n-3 PUFA was not associated with change in weight. Among all participants, the 1-year weight change was -0.7 g per 1% point higher long-chain n-3 PUFA level (95% confidence interval: -20.7 to 19.3). The results when stratified by sex, age, or BMI groups were not systematically different. CONCLUSION The results of this study suggest that the proportion of long-chain n-3 PUFA in plasma phospholipids is not associated with subsequent change in body weight within the range of exposure in the general population. Yes
Published: 2016

48. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis

Author: Baena-Díez, Jose Miguel, Peñafiel, Judit, Subirana, Isaac, Ramos, Rafel, Elosua, Roberto, Marín-Ibañez, Alejandro, Guembe, María Jesús, Rigo, Fernando, Tormo-Díaz, María José, Moreno-Iribas, Conchi, Cabré, Joan Josep, Segura, Antonio, García-Lareo, Manel, Gómez de la Cámara, Agustín, Lapetra, José, Quesada, Miquel, Marrugat, Jaume, Medrano, Maria José, Berjón, Jesús, Frontera, Guiem, Gavrila, Diana, Barricarte, Aurelio, Basora, Josep, García, Jose María, Pavone, Natalia C, Lora-Pablos, David, Mayoral, Eduardo, Franch, Josep, Mata, Manel, Castell, Conxa, Frances, Albert, Grau, María, FRESCO Investigators, [Miguel Baena-Diez, Jose] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Penafiel, Judit] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Subirana, Isaac] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Elosua, Roberto] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Marrugat, Jaume] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Grau, Maria] Hosp del Mar, Med Res Inst, REGICOR Study Grp Cardiovasc Epidemiol & Genet, Barcelona, Spain, [Miguel Baena-Diez, Jose] Catalan Inst Hlth, Primary Care Ctr La Marina, Barcelona, Spain, [Garcia-Lareo, Manel] Catalan Inst Hlth, Primary Care Ctr La Marina, Barcelona, Spain, [Pavone, Natalia C.] Catalan Inst Hlth, Primary Care Ctr La Marina, Barcelona, Spain, [Miguel Baena-Diez, Jose] Catalan Inst Hlth, Primary Hlth Care Res Inst Jordi Gol, Barcelona, Spain, [Garcia-Lareo, Manel] Catalan Inst Hlth, Primary Hlth Care Res Inst Jordi Gol, Barcelona, Spain, [Pavone, Natalia C.] Catalan Inst Hlth, Primary Hlth Care Res Inst Jordi Gol, Barcelona, Spain, [Miguel Baena-Diez, Jose] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Subirana, Isaac] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Gomez de la Carnara, Agustin] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Gavrila, Diana] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Barricarte, Aurelio] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Lora-Pablos, David] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain, [Ramos, Rafel] Catalan Inst Hlth, Family Med Res Unit, Girona, Spain, [Jose Tormo-Diaz, Maria] Catalan Inst Hlth, Family Med Res Unit, Girona, Spain, [Quesada, Miguel] Catalan Inst Hlth, Family Med Res Unit, Girona, Spain, [Ramos, Rafel] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Girona, Spain, [Jose Tormo-Diaz, Maria] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Girona, Spain, [Quesada, Miguel] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Girona, Spain, [Ramos, Rafel] Univ Girona, Girona, Spain, [Marin-Ibanez, Alejandro] San Jose Norte Hlth Ctr, Zaragoza, Spain, [Jesus Guembe, Maria] Navarra Govt, Dept Hlth, Vasc Risk Navarra Res Grp, Pamplona, Spain, [Berjon, Jesus] Navarra Govt, Dept Hlth, Vasc Risk Navarra Res Grp, Pamplona, Spain, [Jesus Guembe, Maria] Navarra Govt, Dept Hlth, Knowledge Planning Evaluat & Management, Navarra, Spain, [Rigo, Fernando] Cardiovasc Grp Balear Isl, Palma De Mallorca, Spain, [Frontera, Guiem] Cardiovasc Grp Balear Isl, Palma De Mallorca, Spain, [Jose Tormo-Diaz, Maria] Murcian Hlth Dept, Murcia, Spain, [Jose Tormo-Diaz, Maria] Univ Murcia, Murcia, Spain, [Jose Tormo-Diaz, Maria] Murcian Inst Biomed Res, Murcia, Spain, [Moreno-Iribas, Conchi] Navarre Publ Hlth Inst, Pamplona, Spain, [Barricarte, Aurelio] Navarre Publ Hlth Inst, Pamplona, Spain, [Moreno-Iribas, Conchi] Res Network Hlth Serv Chron Dis, Pamplona, Spain, [Moreno-Iribas, Conchi] Navarra Hlth Res Inst, Pamplona, Spain, [Berjon, Jesus] Navarra Hlth Res Inst, Pamplona, Spain, [Barricarte, Aurelio] Navarra Hlth Res Inst, Pamplona, Spain, [Josep Cabre, Joan] Catalan Inst Hlth, Primary Care Ctr Sant Pere Ctr, Reus, Spain, [Josep Cabre, Joan] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Reus, Spain, [Segura, Antonio] Castille La Mancha Government, Dept Hlth & Social Affairs, Hlth Sci Inst, Talavera De La Reina, Spain, [Maria Garcia, Jose] Castille La Mancha Government, Dept Hlth & Social Affairs, Hlth Sci Inst, Talavera De La Reina, Spain, [Gomez de la Carnara, Agustin] Hosp 12 Octubre Res Inst, Clin Res Dept, Madrid, Spain, [Lora-Pablos, David] Hosp 12 Octubre Res Inst, Clin Res Dept, Madrid, Spain, [Lapetra, Jose] Consortium Biomed Res Obes & Nutr, Madrid, Spain, [Mayora, Eduardo] Consortium Biomed Res Obes & Nutr, Madrid, Spain, [Lapetra, Jose] Primary Care Ctr San Pablo, Dept Family Med, Primary Care Div, Seville, Spain, [Jose Medrano, Maria] Carlos III Hlth Inst, Madrid, Spain, [Gavrila, Diana] Murcia Govt, Hlth & Consumers Dept, Murcia, Spain, [Basora, Josep] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Reus, Spain, [Mayora, Eduardo] Andalusia Hlth Serv, Diabet Strategy, Seville, Spain, [Franch, Josep] Catalan Inst Hlth, Primary Care Ctr Raval Sud, Barcelona, Spain, [Franch, Josep] Catalan Inst Hlth, Primary Hlth Care Res Unit, Inst Jordi Gol, Barcelona, Spain, [Franch, Josep] Consortium Biomed Res Diabet & Associated Metab D, Madrid, Spain, [Mata, Manel] Primary Care Ctr La Mina, Barcelona, Spain, [Mata, Manel] Catalan Inst Hlth, Inst Jordi Gol, Primary Hlth Care Res Unit, Barcelona, Spain, [Castell, Conxa] Govt Catalonia, Publ Hlth Agcy, Barcelona, Spain, [Frances, Albert] Hosp del Mar, Dept Urol, Barcelona, Spain, [Grau, Maria] Univ Barcelona, Barcelona, Spain, MARATO TV3, Institute de Salud Carlos III-Fondo Europeo de Desarrollo Regional-European Regions Development Funds, Agency for Management of University and Research Grants, Consortium for Biomedical Research in Epidemiology and Public Health, Consortium for Biomedical Research in Obesity and Nutrition, and Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional-European Regions Development Fund FEDER
Subjects: Blood Glucose, Male, Complications, Endocrinology, Diabetes and Metabolism, Disease, 030204 cardiovascular system & hematology, Cohort Studies, 0302 clinical medicine, Risk Factors, Cause of Death, Neoplasms, Cause of death, education.field_of_study, Diabetis, Hazard ratio, Diabetes, Metaanalysis, Middle Aged, Cardiovascular Diseases, Female, Risk assessment, Cohort study, Adult, medicine.medical_specialty, Coronary-heart-disease, Population, 030209 endocrinology & metabolism, Sistema cardiovascular -- Malalties -- Mortalitat, Risk Assessment, Càncer -- Mortalitat, 03 medical and health sciences, Life Expectancy, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Mortality, education, Aged, Advanced and Specialized Nursing, business.industry, Mellitus, Hazards, All-cause, Cardiovascular risk, medicine.disease, Myocardial-infarction, Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Multivariate Analysis, Life expectancy, business, Follow-Up Studies
Abstract: OBJECTIVE: Diabetes is a common cause of shortened life expectancy. We aimed to assess the association between diabetes and cause-specific death. RESEARCH DESIGN AND METHODS: We used the pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35-79 years old. Diabetes status was self-reported or defined as glycemia >125 mg/dL at baseline. Vital status and causes of death were ascertained by medical records review and linkage with the official death registry. The hazard ratios and cumulative mortality function were assessed with two approaches, with and without competing risks: proportional subdistribution hazard (PSH) and cause-specific hazard (CSH), respectively. Multivariate analyses were fitted for cardiovascular, cancer, and noncardiovascular noncancer deaths. RESULTS: We included 55,292 individuals (15.6% with diabetes and overall mortality of 9.1%). The adjusted hazard ratios showed that diabetes increased mortality risk: 1) cardiovascular death, CSH = 2.03 (95% CI 1.63-2.52) and PSH = 1.99 (1.60-2.49) in men; and CSH = 2.28 (1.75-2.97) and PSH = 2.23 (1.70-2.91) in women; 2) cancer death, CSH = 1.37 (1.13-1.67) and PSH = 1.35 (1.10-1.65) in men; and CSH = 1.68 (1.29-2.20) and PSH = 1.66 (1.25-2.19) in women; and 3) noncardiovascular noncancer death, CSH = 1.53 (1.23-1.91) and PSH = 1.50 (1.20-1.89) in men; and CSH = 1.89 (1.43-2.48) and PSH = 1.84 (1.39-2.45) in women. In all instances, the cumulative mortality function was significantly higher in individuals with diabetes. CONCLUSIONS: Diabetes is associated with premature death from cardiovascular disease, cancer, and noncardiovascular noncancer causes. The use of CSH and PSH provides a comprehensive view of mortality dynamics in a population with diabetes. This work was supported by MARATO TV3 (081630), Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional–European Regions Development Funds (Red de Investigación Cardiovascular RD12/0042 [Programa HERACLES], Red RedIAPP RD12/0005, RD06/0018, PI081327, and PI1101801), Agency for Management of University and Research Grants (2014 SGR 240), Consortium for Biomedical Research in Epidemiology and Public Health, and Consortium for Biomedical Research in Obesity and Nutrition. M.G. was supported by the Instituto de Salud Carlos III– Fondo Europeo de Desarrollo Regional–European Regions Development Fund FEDER (FIS CP12/ 03287).
Published: 2016

49. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort

Author: María José Sánchez, Jennifer Ose, Antonia Trichopoulou, J. Ramón Quirós, Marc J. Gunter, Xavier Castellsagué, Carlotta Sacerdote, Inger T. Gram, H B As Bueno-de-Mesquita, Johanna Ekström, Ruth C. Travis, Joakim Dillner, Carmen Navarro, Silvia de Sanjosé, Annika Idahl, Renée T. Fortner, Domenico Palli, Noémie Travier, Amalia Mattiello, David Lindquist, Annika Steffen, Elisabete Weiderpass, Christian Munk, Kay-Tee Khaw, Aurelio Barricarte, Elio Riboli, Michael Pawlita, Petra H.M. Peeters, Valeria Pala, Eiliv Lund, Philippos Orfanos, Sabina Rinaldi, F. Xavier Bosch, Pagona Lagiou, Kim Overvad, Nerea Larrañaga, N. Margall, Sylvie Mesrine, Massimo Tommasino, Silvia Franceschi, Silvia Polidoro, Melissa A. Merritt, Tim Waterboer, Giovanna Masala, Agnès Fournier, Rosario Tumino, Esther Roura, Anne Tjønneland, Françoise Clavel-Chapelon, University Medical Center Utrecht, Imperial College Trust, [Roura,E, de Sanjosé,S, Bosch,FX, Castellsagué,X] Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain. [Roura,E, Sánchez,MJ, Navarro,C, Barricarte,A, Larrañaga,N, Castellsagué,X] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Travier,N] Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain. [Waterboer,T, Pawlita,M] Division of Molecular Diagnostics of Oncogenic Infections (F020), Research Program Infection, Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.[Pala,V] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Weiderpass, Dillner,J] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Weiderpass,E, Gram,IT, Lund,E] Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway. [Weiderpass,E] Department of Research, Cancer Registry of Norway, Oslo, Norway. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland. [Margall,N] Microbiology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain. [Dillner,J] Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. [Tjønneland,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Munk,C] Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. [Palli,D, Masala,G] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute–ISPO, Florence, Italy. [Khaw,K] School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom. [Overvad,K] Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. [Clavel-Chapelon,F, Mesrine,S, Fournier,A] Inserm, Centre for research in Epidemiology and Population Health (CESP), Nutrition, Hormones and Women’s Health team, Villejuif, France. Université Paris Sud, Villejuif, France.Institut Gustave Roussy, Villejuif, France. [Fortne,RT, Ose,J] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Steffen,A] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Orfanos,P] Hellenic Health Foundation, Athens, Greece. [Lagiou,P, Orfanos,P] Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Lagiou,P] Department of Epidemiology, Harvard School of Public Health, Boston, United States of America. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic—M.P. Arezzo' Hospital, Ragusa, Italy. [Sacerdote,C] Unit of Cancer Epidemiology, University of Turin, Turin, Italy. Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy. [Polidoro,S] Human Genetics Foundation (HuGeF), Turin, Italy. [Mattiello,A] Dipartimento Di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy. [Peeters,PH] MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, United Kingdom. Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.[Bueno-de-Mesquita,HB, Merritt,MA, Gunter,MJ, Riboli,E] Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom. [Bueno-de-Mesquita,HB] Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.[Quirós,JR] Public Health Directorate, Asturias, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Navarro,C] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. [Barricarte,A] Navarra Public Health Institute, Pamplona, Spain. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Larrañaga,N] Public Health Division of Gipuzkoa, BIODonostia Research Institute, Basque Health Department, Bilbao, Spain. [Ekström,J] BBMRI.se Service Center for Southern Sweden, Lund University, Medicon Village, Lund, Sweden. [Lindquist,D] Department of Radiation Sciences, Umeå University, Umeå, Sweden. [Idahl,A] Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden. [Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. [Rinaldi,S, Tommasino,M, Franceschi,S] International Agency for Research on Cancer, Lyon, France., Funding: The work was partially supported by grants from the Instituto de Salud Carlos III (Spanish Government) (grants FIS PI08/1308, PI13/00053, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056, RD12/0036/0018, and CIBERESP) and from the Agència de Gestió d’Ajuts Universitaris i de Recerca – Generalitat de Catalunya (Catalonian Government) (grants AGAUR 2005SGR00695, 2009SGR939 and 2009SGR126, 2014SGR1077, 2014SGR2016). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Health Research Fund (FIS) of the Spanish Ministry of Health (Exp P10710130), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), Navarra and the Catalan Institute of Oncology, La Caixa (BM 06-130), RTICC-RD06/10091 (Spain), Danish Cancer Society (Denmark), Ligue contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Italian Association for Research on Cancer (AIRC) and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF) and Statistics Netherlands (The Netherlands), Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skåne and Västerbotten (Sweden), Cancer Research UK, Medical Research Council (United Kingdom), and Norwegian Research Council, Norwegian Cancer Society, University of Tromso (Norway).
Subjects: Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma in Situ::Cervical Intraepithelial Neoplasia [Medical Subject Headings], Oncology, Replacement therapy, Pathology and Laboratory Medicine, Antibodies, Viral, Biochemistry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Pregnancy, Prospective Studies, lcsh:Science, Gonadal Steroid Hormones, education.field_of_study, Hormonal Therapy, Contraceptives, Humanos, Anticonceptivos, 030220 oncology & carcinogenesis, Cohort, Carcinoma, Squamous Cell, Cohort studies, Science & Technology - Other Topics, Intreaepithelial neoplasia, Human, Cohort study, Oral, Human Papillomavirus Infection, medicine.medical_specialty, Càncer de coll uterí, Sexually Transmitted Diseases, Estudios retrospectivos, 03 medical and health sciences, Drug Therapy, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [Medical Subject Headings], Neoplasias del cuello uterino, Humans, education, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Parity [Medical Subject Headings], Aged, Pharmacology, Gynecology, Cancer och onkologi, Science & Technology, Herpes Genitalis, Genitourinary Infections, Herpesvirus 2, lcsh:R, Case-control study, Biology and Life Sciences, Estrogens, medicine.disease, Hormones, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Cancer and Oncology, Case-Control Studies, Cervical cancer, Medical Devices and Equipment, lcsh:Q, Intrauterine Devices, 0301 basic medicine, Glutathione-S-transferase, Viral Diseases, Human papillomavirus infection, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Herpesvirus 2, Human, lcsh:Medicine, Uterine Cervical Neoplasms, Chlamydia trachomatis, Cervical Cancer, Cohort Studies, Cervix cancer, Paridad, Medicine and Health Sciences, Viral, Non-U.S. Gov't, Prospective cohort study, Papillomaviridae, Reproductive History, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Reproductive Control Agents::Contraceptive Agents [Medical Subject Headings], Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings], Multidisciplinary, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Pharmaceutics, Research Support, Non-U.S. Gov't, Femenino, Drugs, Estudios de Casos y Controles, Middle Aged, humanities, Multidisciplinary Sciences, Infectious Diseases, Serology, Research Design, Hormonal therapy, Female, Research Article, Biotechnology, Adult, Risk, Papillomaviruses, Embarazo, General Science & Technology, Hormone Replacement Therapy, Urology, Population, Individual data, Research Support, Research and Analysis Methods, Cervical intraepithelial neoplasia, Antibodies, Contraceptives, Oral, Hormonal, Young Adult, Collaborative reanalysis, Internal medicine, Oral-contraceptives, MD Multidisciplinary, Journal Article, medicine, Multicentric case-control, Cervical Intraepithelial Neoplasia, Neoplasia Intraepitelial Cervical, Papil·lomavirus, Reproductive factors, Hormonal, business.industry, Carcinoma, Papillomavirus Infections, Cancers and Neoplasms, Chlamydia Infections, Uterine Cervical Dysplasia, Squamous Cell, Organisms::Viruses::DNA Viruses::Papillomaviridae [Medical Subject Headings], business, Gynecological Tumors, Follow-Up Studies
Abstract: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Health Research Fund (FIS) of the Spanish Ministry of Health (Exp P10710130) In addition to HPV, high parity and hormonal contraceptives have been associated with cervical cancer (CC). However, most of the evidence comes from retrospective case-control studies. The aim of this study is to prospectively evaluate associations between hormonal factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC). We followed a cohort of 308,036 women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a questionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS cases were reported. In a nested case-control study, the sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivariate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). The cohort analysis showed that number of full-term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS and ICC (HR = 1.6 and HR = 1.8 respectively for ≥15 years versus never use). Ever use of menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%CI: 0.4-0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices (IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all cases and HPV seropositive controls yielded similar results, revealing a significant inverse association with IUD for combined CIN3/CIS and ICC (OR = 0.7). Even though HPV is the necessary cause of CC, our results suggest that several hormonal factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.
Published: 2016

50. The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study

Author: Pilar Amiano, Maria Jesus Michelena-Echeveste, Nuria Aragonés, Victor Moreno, Inés Gómez-Acebo, Manolis Kogevinas, Camilo Palazuelos, Gemma Castaño-Vinyals, Marcela Guevara, Ignasi Tusquets, Luis Ortega Valin, Trinidad Dierssen-Sotos, Virginia Lope, Marina Pollán, Antonio Camacho, Rosana Peiró-Pérez, M. Henar Alonso, Beatriz Pérez-Gómez, Aurelio Barricarte, Rafael Marcos-Gragera, Antonio José Molina de la Torre, Montse Muñoz, Adonina Tardón, Javier Llorca, Universidad de Cantabria, [Gomez-Acebo, Ines] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Dierssen-Sotos, Trinidad] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Perez-Gomez, Beatriz] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Lope, Virginia] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Henar Alonso, M.] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Moreno, Victor] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Amiano, Pilar] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Tardon, Adonina] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Peiro-Perez, Rosana] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Guevara, Marcela] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Castano-Vinyals, Gemma] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Aragones, Nuria] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Kogevinas, Manolis] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Pollan, Marina] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Llorca, Javier] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Gomez-Acebo, Ines] Univ Cantabria, IDIVAL, Santander, Spain, [Dierssen-Sotos, Trinidad] Univ Cantabria, IDIVAL, Santander, Spain, [Palazuelos, Camilo] Univ Cantabria, IDIVAL, Santander, Spain, [Llorca, Javier] Univ Cantabria, IDIVAL, Santander, Spain, [Perez-Gomez, Beatriz] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain, [Lope, Virginia] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain, [Aragones, Nuria] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain, [Pollan, Marina] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain, [Perez-Gomez, Beatriz] IIS Puerta Hierro IDIPHIM, Canc Epidemiol Res Grp, Oncol & Hematol Area, Madrid, Spain, [Lope, Virginia] IIS Puerta Hierro IDIPHIM, Canc Epidemiol Res Grp, Oncol & Hematol Area, Madrid, Spain, [Aragones, Nuria] IIS Puerta Hierro IDIPHIM, Canc Epidemiol Res Grp, Oncol & Hematol Area, Madrid, Spain, [Pollan, Marina] IIS Puerta Hierro IDIPHIM, Canc Epidemiol Res Grp, Oncol & Hematol Area, Madrid, Spain, [Tusquets, Ignasi] Hosp Mar, Serv Oncol Med, Barcelona, Spain, [Tusquets, Ignasi] Hosp Mar Med Res Inst, Canc Res Program IMIM, Barcelona, Spain, [Tusquets, Ignasi] Univ Autonoma Barcelona, Barcelona, Spain, [Henar Alonso, M.] Catalan Inst Oncol IDIBELL, Canc Prevent & Control Program, Barcelona, Spain, [Moreno, Victor] Catalan Inst Oncol IDIBELL, Canc Prevent & Control Program, Barcelona, Spain, [Henar Alonso, M.] Univ Barcelona, Barcelona, Spain, [Moreno, Victor] Univ Barcelona, Barcelona, Spain, [Amiano, Pilar] Biodonostia Res Inst, Hlth Div Gipuzkoa, Guipuzkoa, Spain, [Jose Molina de la Torre, Antonio] Univ Leon, Dept Ciencias Biomed, Area Med Prevent & Salud Publ, Leon, Spain, [Jose Molina de la Torre, Antonio] Univ Leon, GIIGAS, Leon, Spain, [Guevara, Marcela] Univ Leon, GIIGAS, Leon, Spain, [Barricarte, Aurelio] Navarra Publ Hlth Inst, Pamplona, Spain, [Barricarte, Aurelio] Navarra Inst Hlth Res IdiSNA Pamplona, Pamplona, Spain, [Tardon, Adonina] Univ Oviedo, IUOPA, Oviedo, Spain, [Camacho, Antonio] Hosp Juan Ramon Jimenez, Andalusian Hlth Serv, Huelva, Spain, [Camacho, Antonio] Univ Huelva, Res Ctr Hlth & Environm CYSMA, Huelva, Spain, [Peiro-Perez, Rosana] Fdn FISABIO Salud Publ, Area Canc & Salud Publ, Valencia, Spain, [Marcos-Gragera, Rafael] Autonomous Govt Catalonia, Epidemiol Unit, Girona, Spain, [Marcos-Gragera, Rafael] Autonomous Govt Catalonia, Girona Canc Registry, Oncol Coordinat Plan, Dept Hlth, Girona, Spain, [Marcos-Gragera, Rafael] Catalan Inst Oncol, Descript Epidemiol, Genet & Canc Prevent Grp, Girona Biomed Res Inst IdIBGi, Girona, Spain, [Munoz, Montse] Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain, [Jesus Michelena-Echeveste, Maria] Onkol Oncol Inst Gipuzkoa, Guipuzkoa, Spain, [Ortega Valin, Luis] Complex Assist Univ Leon, Serv Pharm, Leon, Spain, [Guevara, Marcela] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain, [Castano-Vinyals, Gemma] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain, [Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain, [Castano-Vinyals, Gemma] Univ Pompeu Fabra UPF, Barcelona, Spain, [Kogevinas, Manolis] Univ Pompeu Fabra UPF, Barcelona, Spain, [Castano-Vinyals, Gemma] Hosp Mar Med Res Inst, IMIM, Barcelona, Spain, 'Accion Transversal del Cancer' project, Instituto de Salud Carlos III-FEDER, Fundacion Marques de Valdecilla, ICGC International Cancer Genome Consortium CLL (Spanish Ministerio de Economia y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII)), ICGC International Cancer Genome Consortium CLL (Spanish Ministerio de Economia y Competitividad (MINECO) through Red Tematica de Investigacion del Cancer (RTICC) del ISCIII), Junta de Castilla y Leon, Consejeria de Salud of the Junta de Andalucia, Conselleria de Sanitat of the Generalitat Valenciana, Recercaixa, Regional Government of the Basque Country, European Commission, Spanish Association Against Cancer (AECC) Scientific Foundation, Catalan Government DURSI grant, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Instituto de Salud Carlos III, Junta de Castilla y León (España), Regional Government of Andalusia (España), Generalitat Valenciana (España), Fundación La Caixa, Fundación Marqués de Valdecilla, Government of Catalonia (España), Basque Government (España), Unión Europea. Comisión Europea, and Universitat de Barcelona
Subjects: Oncologia, Physiology, Receptor, ErbB-2, Canals de calci, Cancer Treatment, lcsh:Medicine, Angiotensin-Converting Enzyme Inhibitors, Apoptosis, 030204 cardiovascular system & hematology, Overweight, Biochemistry, Ion Channels, Body Mass Index, 0302 clinical medicine, Breast cancer, Risk Factors, Antihipertensius, Breast Tumors, Medicine and Health Sciences, Odds Ratio, Breast -- Cancer, Data reporting, Stage (cooking), Diuretics, lcsh:Science, Aged, 80 and over, Calcium-channel blockers, Multidisciplinary, Pharmaceutics, Physics, Hormonal Therapy, Cohort, Drugs, Middle Aged, Calcium Channel Blockers, Electrophysiology, Antihypertensive Drugs, Oncology, 030220 oncology & carcinogenesis, Physical Sciences, Hypertension, Female, medicine.symptom, Research Article, Adult, medicine.medical_specialty, Adrenergic beta-Antagonists, Biophysics, Neurophysiology, Breast Neoplasms, Càncer de mama, 03 medical and health sciences, Angiotensin Receptor Antagonists, Drug Therapy, Internal medicine, Breast Cancer, medicine, Humans, Women, Mortality, Hormone therapy, Antihypertensive Agents, Aged, Pharmacology, Gynecology, business.industry, lcsh:R, Carcinoma, Case-control study, Cancers and Neoplasms, Biology and Life Sciences, Proteins, Cancer, Hypotensive agents, Odds ratio, medicine.disease, Hormones, Calcium channels, Spain, Case-Control Studies, Mama -- Càncer, lcsh:Q, Calcium Channels, business, Body mass index, Hormonoteràpia, Antihypertensives, Neuroscience
Abstract: Introduction The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. Methods In this case-control study, we report the antihypertensive drugs–breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women’s characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. Results The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. Conclusions In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women)., The study was partially funded by the "Accion Transversal del Cancer" project, approved by the Spanish Council of Ministers on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PI09/00773-Cantabria, PI09/01286-Leon, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219), by the Fundacion Marques de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economia y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Tematica de Investigacion del Cancer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y Leon (LE22A10-2), by the Consejeria de Salud of the Junta de Andalucia (2009-S0143), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation and by the Catalan Government DURSI grant 2009SGR1489.
Published: 2016

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

313 results on '"Barricarte,A"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources